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For decades, research has been focussed on finding a way to produce artificial blood 
as a resolution for the insufficient amount of blood components provided by donation 
and to provide a more transportable alternative with a longer shelf life. Red blood 
cells (RBCs) are the most common cell type in blood and are responsible for oxygen 
transport throughout the human body. It is therefore extremely important to find an 
alternative oxygen carrier whether these are tissue engineered RBCs or a chemically 
defined oxygen delivery system 
 
The study conducted for this thesis was part of a larger project called Redontap, and 
was aimed to develop a bioreactor for the manufacture of RBCs. During this research 
to produce RBCs from adult stem cells in vitro, the main goal was to upscale 
haematopoietic and erythroid cultures. Understanding the biological signals and their 
temporal magnitude involved in the division, maturation and migration of the CD34+ 
haematopoietic stem cells (HSCs) and their differentiated progeny would allow for a 
controlled continuous production of mature blood cells. The differentiation of HSCs 
into different blood cell types occurs within different bone marrow niches and so 
mimicry of the erythrocyte niche is likely to result in maximisation of the rate of red 
blood cell development.  
 
Published research provides evidence that peripheral blood mononuclear cells 
(PBMCs), including CD34- cells, will be advantageous for erythroid maturation. For 
this thesis, CD34+ cells were expanded within a population of PBMCs on a stromal 
layer to recreate a niche-like environment. This approach was also utilised with 
umbilical cord blood isolated MNCs (UBMCs) to compare HSC expansion potential 
and subsequently efficiency in erythroid maturation was analysed. Whereas the cell 
output was limited, differentiated cells proved positive for a range of RBC surface 
markers and haemoglobin content.  
 
As part of the aim for upscaling cell culture by translating static cultures to 
bioreactor processes, bioreactors with volumes varying between 250mL-3L were 
analysed for cell retention and viability to achieve high cell densities whilst 
refreshing culture medium, monitoring culture parameters (e.g. pH, dissolved 
oxygen), and introducing an hypoxia environment for mimicking the in vivo stem 
cell niche. In general, this research was focussed on improving dynamic culture 
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The need to provide safe and functional auxiliary blood is a constant pressure for healthcare 
providers. It is essential for people undergoing particular medical treatments (i.e. heart 
surgery, organ transplant, and blood disorders) in order to maintain life, it is also essential in 
critical care and trauma to save lives. Currently, blood is provided by means of donation to 
blood banks. Often blood is not required in its whole form and therefore it has added value 
for use in multiple applications and is separated into different components (i.e. red blood 
cells, platelets, and plasma) to make more per unit of donated blood. Even this separated 
products approach is still not providing sufficient to keep up with the needs in medical 
treatments.  
 
For decades, research has been focussed on attempting to produce artificial blood to find a 
resolution for the insufficient amount of blood components provided by donation and to 
provide a more transportable alternative with a longer shelf life. Red blood cells (RBCs) are 
the most common cell type in blood and are responsible for oxygen transport throughout the 
human body. It is therefore an extremely important quest to find an alternative oxygen 
carrier whether these are tissue engineered RBCs or a chemically defined oxygen delivery 
system. In the first scenario, these cells need to be a copy of healthy RBCs and in the 
development of the latter product it is essential to create a high quality product with a good 
shelf life under convenient storage conditions, as well as an excellent oxygen binding and 
release affinity. This chapter will cover a wide range of techniques to supply RBCs into the 
human body as an alternative for traditional blood transfusion. 
 
 
1.1.1 The oxygen carrier protein: haemoglobin 
Many research groups focus on novel methods to administer haemoglobin (Hb) into humans 
as this abundant RBC protein is of paramount importance for the supply of oxygen to tissues 
of the body [1]. The foremost important property of erythrocytes is critical in situations of 
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anaemia due to e.g. significant blood loss [2-4]. One major aspect of this globally 
widespread research is the ex vivo creation of artificial RBCs; but we will also address 
oxygen carrier systems designed for in vivo studies [5].  
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1.2 The need for tissue engineering RBCs 
There is an increased need for donated RBCs, and although 92% of all RBC units that meet 
release criteria find a recipient, blood-banking is not tailored for massive supply and for rare 
blood-group units under extraordinary circumstances [6, 7]. Also, in transfusion medicine 
there are physical risks for the patient, arising from allogeneic transfusion and from issues 
regarding the storage of tissues. Currently, the major therapeutic option for oxygenating 
tissue is transfusion [8]. These issues may be overcome by engineering artificial red cells as 
an alternative solution for supplying oxygen capacity to the patient. 
 
One of the greatest potentials for transfusion medicine can be found in the developing world 
where blood is scarce and hazardous. The blood products, if available, are often untested and 
inadequately processed, stored and transported [9]. A safe and affordable RBC substitute 
could have a major impact on the lives of transfusion patients. 
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1.3 Current issues in transfusion medicine 
A number of issues arise when it comes to transfusion of blood products into patients.  The 
main risks for the patient are allergic reaction, anaphylaxis, fluid overload, transfusion-
related acute lung injury (TRALI), haemolytic transfusion reaction, bacterially contaminated 
blood, viral contaminated blood, variant Creutzfeld-Jacob disease (vCJD), and transfusion-
associated graft-vs-host disease (GvHD) [10, 11]. A number of these risks are usually mild 
(allergic reaction) and very rare (bacterial infection, GvHD), the number of incidents for 
other risks has greatly reduced since the mid-1980s (viral infection). Introduction of pre-
transfusion blood testing and risk analysis of donor behaviour contributed to this reduction of 
viral infection, but disease transmission may still occur during the time after infection when 
the donor is infectious but screening tests are negative. 
 
Other risks on this list, such as TRALI, anaphylaxis, and haemolytic transfusion reaction 
compose greater, possible life threatening, danger to the patient. The haemolytic transfusion 
reaction, where immune antibodies in the recipient plasma interact with the surface antigens 
on donor RBCs, is the one of most serious of complications and may either be immediate or 
delayed after transfusion. These antibodies develop after a patient’s exposure to RBCs 
expressing antigens they lack, ultimately destroying the transfused RBCs. Some haemolytic 
transfusion reaction result from plasma containing blood components and generally these 
transfusion reactions happen within two weeks [8, 11]. In general, the risks of non-infectious 
complications are generally well-recognised and amendable to technologic solutions. A more 
critical concern is whether the ageing of RBCs stored in plastic containers, as part of 
allogeneic transfusion,  affects the morbidity and mortality of the patient [7, 12]. Koch et al 
found that for patients undergoing cardiac surgery, a significant increased risk of 
postoperative complications was associated when patients received RBCs that had been 
stored for more than 2 weeks, including the reduction of short-term and long-term survival 
[13].  
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The storage, processing and screening, of blood is the main task of blood banks and with 
current guidelines RBCs may be stored up to 42 days at refrigerated temperatures [7, 12, 14]. 
During this period, the cells undergo ‘storage lesion’; a process where the morphology, 
biochemistry and structure of the RBCs deteriorate [9], ultimately affecting the cell function 
after administering to the recipient. Haemolysis is the most severe occurrence of storage 
lesion; the rupture of the RBCs which results in free suspended Hb and the loss of 
membrane-bound Hb in microvesicles could impose great risk to the recipient [15]. There is 
a need for prospective studies, with a large cohort of subjects, to analyse the effects of longer 
term RBC storage for transfused patients [14]. As part of quality control, both the Food and 
Drug Administration (FDA) and the Council of Europe have implemented a haemolysis 
standard for the licensing of RBC storage. A mean haemolysis of less than 1% and 0.8%, 
respectively, is the standard with the proviso of the ‘95/95 rule’ where 95% of the units meet 
the standard and this is evidenced with a 95% statistical certainty [7, 15].  
 
For each transfusion, the recipient’s blood needs to be matched with the donated blood to 
prevent haemolytic transfusion reactions. The pre-transfusion compatibility testing is crucial 
and ABO and Rh D are the two antigens to be tested first to find a match. Other antigens are 
not routinely checked but in special circumstances these may be added to the analysis to 
improve the match; for example when patients have had a transfusion before. The routine for 
analysis is electronic as well as immediate spin/antiglobin crossmatching of recipient and 
donor blood and takes about 30 minutes. It is common practice that when an emergency 
arises, with insufficient time to perform a cross match, group O cells may be given to the 
patient [8]. The highest risk of complications is the mismatching of donated blood with the 
recipient blood and is in most cases avoidable [8, 11]. In general, immunologic 
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1.4. Acellular oxygen carriers 
 
1.4.1 Haemoglobin-based oxygen carriers (HBOCs) 
Cell-free Hb causes problems (e.g. toxicity, vasoconstriction [16, 17]) and therefore it needs 
a certain degree of modification before it can be used in humans [17, 18]. A decade ago, 
Winslow reviewed the history of blood substitute research and overlooked the current 
progress on Hb solutions (chemically and genetically modified Hb), increasing oxygen 
affinity of Hb and the design of safe and effective solutions by increased viscosity and 
oncotic pressure [18]. At that time it became clear that there was no consensus on clinical 
applications but it was believed that the first successful products could be used in elective 
surgery and trauma to maintain tissue oxygenation [5, 18]. Since then a few products based 
on Hb-conjugated molecules have been tested during clinical trials. The benefit of using this 
type of oxygen-carriers is the universal compatibility with all blood groups, it is disease free 
(highly preferable in areas with high risk of HIV/AIDS transmission), and it has a long shelf 
life compared to blood products [5, 19]. One of these synthetic blood substitutes was 
PolyHeme, a glutaraldehyde polymerised stroma-free human Hb product, produced by 
Northfield Laboratories [20]. It reached Phase III clinical trials but the FDA decided that the 
risks outweighed the benefits and the product was rejected [21].  
 
Another product which had slightly more success is a derivative of HemoPure (HBOC-201) 
and was produced by Biopure. This HBOC-201 acellular Hb product is a glutaraldehyde-
crosslinked bovine Hb for intentional use in humans but after extensive testing in pigs and 
humans, Biopure decided that due to the adverse events no further clinical trials were 
warranted [20]. The Biopure-developed product Oxyglobin (HBOC-301) was approved by 
the FDA and the EC for veterinary use in the USA and EU [22-25]. This evidences that 
finding an acellular oxygen carrier system is extremely challenging but by continuing 
development the results so far could be a step forward in creating an all important HBOC 
therapy for humans.  
Chapter 1 - Introduction 
8 
 
It is important to remember that a potential clinical product of this kind will not have the 
same function as donated blood upon administering to patients as continued doses might 
induce toxic effects. 
 
 
1.4.2 Perfluorocarbon oxygen carriers 
Another category of chemically defined products, aiming for oxygen delivery in humans, is 
perfluorocarbon (PFC) based [26]. Typical for this product is the absence of Hb [27] and the 
relatively small size of emulsified particles (~0.2 µm) when compared with erythrocytes (~7-
9 µm) [26, 28]. PFCs are synthetic fluorinated hydrocarbons and in emulsion able to dissolve 
(no binding) large quantities of oxygen proportional to the inspired oxygen and once entered 
into the blood stream capable of oxygenating local tissues. As PFCs are chemically and 
biologically inert, they are not metabolised but are initially taken up by the 
reticuloendothelial system, secreted back into the blood, and transported to the lung where 
they are excreted via exhalation  [5, 26, 29].  
 
To date there have been First and Second Generation PFC emulsions developed and tested. 
The first product that has been fully approved by the FDA for phase III clinical trial was 
called Fluosol-DA, developed in Japan and contributed to oxygen delivery under higher 
oxygen tensions. This product belonged to the First Generation PFC emulsions and 5 years 
after it was approved in 1989 it was withdrawn due to its limited success, complexity of use, 
and side effects (e.g. anaphylaxis, pulmonary hyperinflation) [5, 26, 30]. In 2010, Castro and 
Briceno reviewed a range of PFC-based oxygen carrier products and their trials. They 
included Second Generation PFC emulsions and defined the improvements compared to First 
Generations PFC emulsions: Second Generation emulsions have a significantly higher PFC 
content compared with First Generation emulsions, Second Generation products use natural 
phospholipids instead of the water-soluble emulsifier F-68, and Second Generation products 
can be stored without freezing [30, 31]. This generation of products have been tested in 
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various applications and some still ongoing (pre)clinical studies relating to brain injury, 
haemorrhage shock, ischemia, and cardiac surgery. Despite improvements in properties over 
first generation products, some second generation products still suffer from unwanted side 
effects. Therefore these clinical trials have been suspended and abandoned altogether or 
require more extensive studying before trails could be resumed [30]. There are overall more 
positive outcomes to discuss which demonstrates that this field is rapidly developing to 
facilitate the demand for oxygen delivering systems. Oxycyte (Oxygen Biotherapeurtics) is 
available on the market and there are still ongoing clinical trials (Phase II) for patients with 
traumatic brain injury [26, 32].  
 
Positive improvements in the field of acellular blood substitutes are of the utmost importance 
to maintain the momentum of finding an alternative for blood transfusion. An essential part 
of this process is furthering the understanding of mechanisms upon administering these 
products to animal and human models and how to interpret the result to modify the acellular 
blood substitutes to develop a suitable option when current practice of blood transfusions is 
not possible.  
  





1.4.3 Dendrimers and micelles oxygen carriers 
Other acellular blood substitutes that are under investigation are dendrimers, biodegradable 
micelles and lipid vesicles. Twyman et al reported in 2006 and in 2012 the progression of the 
porphyrin-pyridine complex encapsulated by hyperbranched polymers (3,5-diacetoxybenzoic 
acid) as heme protein models. The Fe(II) phorphyrin is the active unit on Hb, responsible for 
reversible binding of oxygen. By developing this dendrimer they have shown potential for 
biomimetic models for use in oxygen storage and delivery [33, 34]. 
 
One type of HBOC is Hb conjugated with micelles as is described by Li et al. They reported 
the use of a triblock amphiphilic copolymer PML (PEG-b-PMPC-b-PLA). After conjugating 
with Hb the micelles could bind and release oxygen reversibly with the outer Polyethylene 
glycol (PEG) segments protecting the Hb from being attacked by the immunological system. 
PEG can also stabilise the particles in the aqueous medium of blood and prolong the 
systemic circulation of micelles [19]. The use of PEG in this type of micelle is described in 
 
 
Fig. 1.1. Overview of artificial oxygen carriers (Li et al 2011) 
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the literature [35] as is its use in HBOC lipid vesicles to improve the circulation time [36-
38].  
 
From the current literature we can conclude that major progress has been achieved but also 
that a stable product, highly suitable for the blood transfusion market, has not been 
established yet.  
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1.5 Cellular oxygen carriers 
 
1.5.1 Principles of in vitro generation of RBCs 
A completely different concept, but with the shared goal of finding an oxygen delivery 
system, is research into a cellular blood substitute. For more than half a century this research 
attempted to understand the stem cell responsible for the blood cell lineages. The 
haematopoietic stem cell (HSC) is studied extensively as is the role of erythropoietin (EPO) 
in the differentiation of HSCs into erythrocytes. The current status is that RBCs have been 
cultured in vitro for many years and these RBCs have been successfully tested in animal 
models. However, limitations lie within the number of RBCs that can be cultured from one 
unit of blood and the associated costs of these expensive cultures. 
 
Migliaccio et al reviewed the history of ex-vivo expansion of RBCs and the principles of 
massive red cell amplification in vitro. By culturing stem cells in the presence of the 
essential cytokines stem cell factor (SCF) and EPO [39], unilineage production of 
erythroblasts can be achieved. This breakthrough, in combination with initial culture of cells 
in expansion media and subsequently in maturation media, achieves optimal in vitro 
erythroid expansion [40]. Many researchers have published their data on various approaches 
to tissue engineering RBCs [41-50]. The general consensus for producing RBCs in vitro is a 
pre-culture of HSC for erythroid progenitor cells with a subsequent generation of high 
numbers of erythroblasts followed by a erythroid maturation phase in the presence of a 
feeder layer to facilitate enucleation [51]. Importantly, maturation without a feeder layer has 
also been reported now [52] and this development is essential if tissue engineered RBCs is to 
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1.5.2 A clinical trial 
To date, only one study reported on the transfusion of cultured red blood cells (cRBCs) into 
humans: Giarratana et al. achieved this major step as reported in 2011. They successfully 
injected 1x1010 cultured enucleated cells (68% enucleation rate during culture), generated 
from autologous peripheral blood HSCs, into a healthy volunteer. The lifespan of these Cr51-
labeled cells was 94-100% over the first 5 days and ~50% after 26 days. Together with the 
positive results from extensive testing cRBC characteristics, this data shows the feasibility of 
human cRBCs for clinical applications [53].  
 
The fact that after decades of research just one clinical trial has been reported does not mean 
we are not getting closer to more trials in humans. However we note that the culture of high 
numbers of erythrocytes is still an enormous challenge. In order to create several blood units 
for transfusion thousands of litres of media are needed, let alone the vast space required to 
establish and maintain these cultures [54]. In the human clinical trial mentioned above they 
isolated stem cells from peripheral blood (PB) which have inferior biological properties for 
erythroid maturation compared to HSCs isolated from cord blood [55, 56]. Other origins of 
cells which have been used for erythroid maturation are adult bone marrow (BM) [56], 
embryonic stem cells (ESCs) [47] and induced pluripotent stem cells (iPSCs) [57].  
 
 
1.5.3 Tissue engineering RBCs 
HSCs from the various sources have been analysed for their biological properties and 
potential for various applications. The high yield and high expansion potential of cells 
isolated from cord blood and BM make these excellent sources for erythroid maturation [45, 
58]. Most HSCs and progenitor cells in humans express the CD34 antigen while being 
CD38- [58]. However, some reports state that CD38 is indefinite for the erythroid potential 
and that HSCs can be referred to as CD34+; a heterogeneous cell population of which only a 
small fraction are actually HSCs [54]. This heterogeneity is even further demonstrated by 
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data that suggest that the erythroid expansion potential of CD34- outweighs the contribution 
of CD34+ cells [41] and that CD3+/CD14+ depletion from mononuclear cells (MNCs) before 
expansion of this mixed cell population improves the CD34+ cell yields [59]. Most research 
still uses highly purified CD34+ populations, isolated from donated human tissue, for 
erythroid maturation. Cord blood isolated CD34+ cells generate on average 10x times more 
erythroblasts (Figure 1.2) than CD34+ cells isolated from adult blood [60]. These cells are 
considered adult stem cells. For all cell populations containing HSCs it is well documented 
what conditions are required for tissue engineering RBCs. The various stages of 
erythropoiesis are characterised by distinctive cell types, from the self renewal of the stem 





1.5.4 The use of pluripotent stem cells 
For the tissue engineering of RBCs, research has mainly focussed on the use of adult human 
stem cells (e.g. HSCs isolated from PB, BM, and umbilical cord blood (UCB)). A possible 
other cell source for this research could be induced pluripotent stem cells (iPSCs). Although 
there can be subtle differences, ESCs and iPSCs are both pluripotent stem cells. These cells 
have been extensively studied for erythropoiesis in mice but essential is the ongoing research 
of basic science studies and translational studies with human cells. These studies are 
 
 
Fig. 1.2. A schematic overview of erythropoiesis (Hattangadi et al 2011) – Distinctive cell types 
in each step of erythropoiesis with corresponding growth factors and cell division rate in one 
differentiation method 
Chapter 1 - Introduction 
15 
 
essential before haematopoietic derivatives of PSCs can be used for clinical trials. A difficult 
challenge is possibly the differentiation of PSCs into cells with an adult phenotype without 
any adverse effects [61]. 
  
Compared to erythroid maturation from adult stem cells, erythropoiesis from iPSCs brings 
extra possibilities but also extra concerns. Possible pre-existing genetic mutations in somatic 
cells are still a major concern for the production and further use of iPSCs but access to 
somatic cells are near unlimited which, theoretically, could give access to the manufacture of 
unrestricted numbers of RBCs. There is limited availability of adult HSCs which currently 
restricts cell therapy; iPSCs could overcome this hurdle. A recent review regarding the use of 
iPSCs for safe cell therapy showed the work that has been focussed on creating and selecting 
the appropriate iPSC cell lines that are not tumorigenic or show teratoma formation in vivo. 
This provides evidence that progress has been made but safety concerns must be assuaged by 
thorough long-term validation of iPSC(-derived) cells: tumorigenicity, genetic and 
epigenetic status, and in vitro and in vivo differentiation capability for various clinical 
applications [62].  
 
Up to now, published data have shown the generation of erythroid progenitors by using 
hESC on a murine fetal liver-derived stromal feeder layer where the Hb content gradually 
changed over time from mostly Hb-ε to almost 100% adult type Hb-β [63]. Most research 
show similar data but when iPSC-derived HSCs are used in a xeno-free erythroid 
environment the challenge remains one of quantity and quality (i.e. adult phenotype) of these 
differentiated erythrocytes [64, 65]. The full potential of these promising iPSC derived 
erythroid maturation conditions in vitro has yet to be achieved. 
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1.6 The HSC environment 
The micro-environment of the stem cell is crucial for its fate. This environment includes 
medium composition, paracrine signalling, mechanical stress, and metabolic activity. Ideally 
the parameters of this environment would recreate the widely discussed stem cell niche to 
develop derived daughter HSCs into RBCs, comparable with the in vivo unrivalled 
expansion rates to produce cells of exceptional quality. 
 
When targeting for clinical use, media for tissue engineering RBCs needs to be in 
compliance with good manufacturing practice (GMP) and it is essential that no xenogeneic 
components should be used (e.g. serum, feeder layers). Several companies have defined 
specialised serum-free medium for HSC expansion and basic medium for erythroid 
maturation. Examples are StemSpan (Stem Cell Technologies), Stemline (Sigma-Aldrich),  
Haematopoietic Progentior Cell Expansion Medium DFX (PromoCell), and StemPro®-34 
(Invitrogen) with or without an accompanying cytokine mix. Some research groups have 
defined their own medium based on a formula with either Iscove’s Modified Dulbecco’s 
Medium (IMDM), Alpha Modification Minimal Essential Medium (αMEM), or Dulbecco’s 
Modified Eagle Medium (DMEM) [40]. Common ingredients of non commercial basic 
medium are transferrin, insulin, bovine serum albumin (BSA), ferrous sulphate, ferric nitrate, 
thioglycerol, glucose, myo-inositol, and glutamine. 
 
Much research has been focussed on the crucial factors for the culture of HSCs to maximise 
erythroid expansion and terminal differentiation. For expansion SCF, flt3-ligand (Flt3-L), 
thrombopoietin (TPO) are commonly used but also interleukin-3 (IL-3), interleukin-6 (IL-6) 
and granulocyte colony-stimulating factor (G-CSF) are mentioned for use in various cocktail 
compositions [66, 67].  
 
For erythroid differentiation, EPO is the utmost important factor and is used in all various 
stages of the maturation process. It is widely known that this cytokine is used in synergy 
Chapter 1 - Introduction 
17 
 
with a cocktail of SCF, IL-3, insulin-like growth factor-1 (IGF-1), dexamethasone, 
hydrocortisone, and/or cholesterol-rich lipids. During the three phases of this culture 
(erythroid expansion, maturation, terminal differentiation) the cocktail recipe usually 
changes [2, 42, 45, 53]. 
 
Erythroid cultures benefit from feeder layers as a surrogate for the cellular in vivo 
microenvironment and this was regarded as essential for quite a time. More recently, data 
has been published on the terminal differentiation of HSCs that proved successful without a 
supportive cell layer. The expansion fold rate without was higher (~37,000) than with a 
feeder layer (~29,000) but enucleation rate was ~68% and ~90% respectively [42, 53] whilst 
another study obtained a majority of erythroblast and observed no reticuloctyes or 
erythrocytes after 21 days of culture [68]. Of importance is the efficiency of enucleation in 
each of these cases and the result will have widespread potential of translating this 
redesigned culture into the clinic. Although there are reports of unsupported terminal 
differentiation, it has not been widely published yet for all common cell sources (e.g. PB, 
cord blood). If research groups will be able to succeed, this will most likely have a major 




1.6.1 3D (dynamic) cultures 
A closed system that would generate cultured RBCs (cRBCs) from stem cells throughout all 
the various stages of erythroid maturation would be ideal. This would imply continuous 
refreshment of medium, change of medium composition at essential stages of the culture, 
and high density cell packaging to create artificial blood units with the sole function of 
oxygen transport. The high demanding culture conditions for the production of ex vivo 
erythrocytes does not make the translation from a static to a dynamic environment 
straightforward. For over 20 years, small scale 3D cultures have been setup to analyse 
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haematopoietic and erythroid cell growth [69-71]. Despite various attempts, no all-inclusive, 
large-scale dynamic systems have yet been successfully created for the manufacture of RBCs 
[72]. Most current studies involve small-volume closed-systems such as gas-permeable bags, 
stirred flasks, flatbed perfusion bioreactors and 3D scaffolds [73]. 
 
A novel method to expand HSCs and differentiate erythroid committed cells is the automated 
suspension bioreactor with online monitoring and control. This system can detect different 
cell responses and act accordingly regarding O2 tension and seeding density, but it is merely 
a very valuable small-scale tool for studying HSC bioprocessing rather than a system for 
gaining high quantity (and quality) cell output [74]. Another tool for studying erythrocyte 
production is an 800 mL 3D hollow fibre capillary membrane-based bioreactor scaled-down 
to a capacity of 2-8 mL. For these miniature compartments the same perfusion unit 
(containing pump units, pressure control, heating chamber with automated temperature 
control, and gas mixing unit) was used as for the 800 mL bioreactor compartment. The 
hydrophilic medium perfusion capillary membranes were fabricated from microporous 
polyethersulphone with a molecular weight cut-off (MWCO) of ~500,000 Dalton. Static 
preculture of CD34+ cells was still required but this pioneering device is a step forward to a 
possible large scale bioreactor for erythroid cultures as successful harvesting of cells with 
mature RBC characteristics was achieved [75]. More studies utilised hollow fibres, with a 
similar MWCO to retain medium supplements such as cytokines within the capillaries 
preventing dilution in the bulk medium, although this is not a common type bioreactor [72].  
 
The use of scaffolds has also been among a method to establish 3D cultures for effectively 
expanding HSCs and haematopoietic progenitor cells (HPCs). The main purpose is a 
sustainable culture of HSC although up-scaling of 3D scaffold cultures might prove difficult. 
The rationale for introducing scaffolds is based on evidence that the co-culture of 
haematopoietic cells with stromal cells is useful for proliferation, as well as a recreation of a 
stem cell niche. Various scaffolds have been mentioned in the literature, for example highly 
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porous poly(D,L-lactide-co-glycolide) (PLGA) and polyurethane scaffolds coated with 
collagen type I cultured with UCB MNCs (UBMCs) to facilitate cytokine-free HSC 
expansion. Collagen-coated polyurethane scaffolds were advantageous for support and cell 
expansion (54 fold after 28 days) and this was supported by positive Wright-Giemsa 
staining. Other research mentioned 3D collagen gels either with or without embedded 
mesenchymal stem cells (MSCs) as a model for the haematopoietic niche. Analysis showed 
that the presence of BM MSCs (BMSCs) in the gel significantly enhanced the number of 
primitive CD34+/CD38- HPCs when compared to more conventional suspension cultures. 
Recently, data was published on entrapped cryopreserved BM cells in a porous polyvinyl 
fluoride 3D scaffold to influence HPC expansion [76-78].  
 
All the above-mentioned 3D scaffolds benefit in their specific way the expansion of 
haematopoietic cells for potential erythroid maturation. While these systems are excellent 
research tools for improving expansion conditions, as are the stated small volume 
bioreactors, the establishment of potential clinical applications will need characteristics 
improved over those currently available. These characteristics are preferable and ultimately 
Good Clinical Practise focussed for prospective clinical approval with systems that can 
either be continuous or fed-batch processes with more emphasis on elevated production of 
erythroid differentiated cells [79]. 
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1.7 Comparison of artificial RBCs 
For clinical use, cRBCs need to mimic RBCs in every possible way. After establishing 
cultures to produce cRBCs more emphasise has shifted to compare size, shape, Hb content, 
and volume of both RBC sources. Research should aim for uniformity in a range of tests to 
check the validity of the ex vivo manufactured RBCs, comparable to current practise for 
blood tests. After global implementation the production process can be validated by testing 
the cRBCs for approval in transfusions. 
 
 
1.7.1 Native RBCs vs cultured RBCs 
Table 1.1 provides a brief summary of cRBC characteristics and the comparison with RBC 
characteristics from isolated PB. All cRBCs contain a degree of fetal Hb, the cell size is up 
to ~40% larger and the total Hb content can be found in a similar range as isolated RBCs 
(27-33 picograms). The information provided by Giarratana et al (2011) showed that with 
nearly identical RBCs it is possible to perform a blood transfusion. The in vivo life span of 
these cells is promising with a survival rate of 76±10% at day 14 and at day 26 this was 
51±12%, as measured by counting the 51Cr sodium chromate labelled cRBCs at various time 























1.7.2 The comparison between acellular and cellular oxygen carriers 
For the development of acellular oxygen carriers, the research is focussed on delivery 
systems containing Hb (HBOCs). The majority investigates cell-free Hb and Hb 
encapsulated in lipid vesicles or polymers. These are non-biological systems which use 
molecules to ‘carry’ Hb. No cell culture is involved and these chemically produced HBOCs 
have a relatively long shelf life, are disease free and have a universal compatibility with all 
blood groups [5, 19]. So far, the side-effects of this product resulted in very restricted use of 
HBOCs. Improved product design to eliminate these detrimental effects may results in 
reconsideration of HBOC for healthcare use [80].  
 
On the other side of the line, researchers aim to use biological oxygen carriers which are in 
vitro produced cells containing intracellular synthesised Hb. This system, which does not 
have the above-mentioned advantages of the acellular platform, aims to manufacture cRBCs 
which should be identical to native RBCs. This system has potential to become a tailor-made 
 Cell Source RBCs (%) Size (µm) MCV (fL) MCH (pg) Hb type (%) Blood type Literature 
Adult RBCs PB 100 8 ~90-93 27-33 >95 Hb-A - [C, D] 
Cultured 
RBCs 




CB-CD34+ 82±4 9 113±3 33±2 63±13 Hb-F n.d. [A] 















Table 1.1. The characteristics of cultured RBCs compared to RBCs isolated from PB. The characteristics of the 
cultured RBCs can be found in a similar range except for the content of the various Hb’s which is highly 
variable. Not all studies report on the blood type but a few state similar blood types as the donor. Important to 
note is that the cRBCs used in the human clinical trial are 11 µm in diameter and contain ~88% Hb-β 
(Giarratana et al., 2011) 
MCV: Mean Cell Volume, MCH: Mean Cell Haemoglobin, µm: micrometer, fL: femtolitre, pg: pictogram, n.d.: no data, CB; cord blood, 
PB; peripheral blood. Literature: [A]: Giarratana et al., 2005; [B]: Baek et al., 2008; [C]: Timmins et al., 2011; [D]: Hess, 2010; [E]: 
Giarratana et al., 2011 
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cell therapy which could be more patient friendly than chemically defined HBOCs and this 
might benefit the patient’s recovery. The risk for the cellular platform is the chance of 
exposure to diseases during culture and therefore, among other regulations, GMP is 
paramount. The success of this product depends on the ability to safely manufacture 
clinically relevant numbers of cRBCs at a sustainable cost either as an alternative for current 
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1.8 In vivo animal studies 
Most in vivo testing of cRBCs have been done in animals (mice) after extensively comparing 
the characteristics of these cells with isolated erythrocytes; so far only one human clinical 
trial using autologous cells has been performed [53]. Table 1 showed that cRBCs are similar 
but not exactly the same in size and content to PB isolated RBCs. A mice study was 
performed with ~3x106 10-day old erythroid differentiated cells and post injection cell 
expansion was observed with cells located in the BM, liver, lung and spleen undergoing 
terminal maturation. Four days in vivo, an overall 96-fold amplification of the human 
erythroid cells was detected [46]. Other data also suggested that after the transfusion of 
reticuloctyes/immature erythrocytes into mice these cells fully mature in vivo [42]. These 
results indicate that cRBC will only need in vitro stimulation to a certain level before the 
body will finish this process of terminal differentiation. This minimum level of erythroid 
stimulation in vitro is essential to ensure that cRBCs produced for transfusion are ready for 
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1.9 Crucial challenges for the engineering of oxygen carriers 
Researchers have made tremendous progress in the field of creating artificial RBCs, however 
there are still challenges to be faced to make this story a success. There are key issues, in 
terms of technical challenges, which will determine the success of engineering solutions. A 
requirement for potential products involves abiding by the regulation of governing bodies 
which allow for safe human therapies. This regulation demands thorough (clinical) testing of 
engineered oxygen carriers and guards patient safety. 
 
When it comes to regulation of administering oxygen carriers, there will always be safety 
concerns for products that might have been exposed to xenogeneic substances during cell 
culture. Xenogeneic-free cell culture is crucial and the development of suitable complete 
humanised media for the ex vivo maturation of RBCs is essential. Other safety concerns 
involve possible exposure to infectious agents and neoplastic transformation during product 
manufacture and are prevented by appropriate GMP procedures. Cell products require 
evaluation by cytogenetic and genotoxicity assays (in compliance with FDA guidelines) and 
these products need to be treated as any transfusion product relating to risks for infection, 
incompatibility, and antigenicity [60]. 
 
Current regulation provides the guidance for finding a suitable oxygen carrier and is of 
paramount importance for patient health protection. Researchers need to overcome the 
technical hurdles in order to provide a solution for artificial oxygen carriers. One of the main 
challenges for a cellular platform for transfusion remains the requirement of a great number 
of cells which may be tackled by enhanced culture techniques. However, CD34+ cells from 
the same donor generate a similar number of erythroblasts in culture repeated over time, 
whereas there is great variability in culture production from different donors [60].  
 
Erythroblasts from autologous cells could be a potential cell therapy with a relatively long 
term therapeutic effect but for transfusion of immediate oxygen carrying capacity, in case of 
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emergency, only enucleated artificial red cells could provide an alternative to transfusion of 
RBCs [60]. Efficient enucleation and separation of extruded nuclei is a major obstacle in 
cRBC culture protocols. First reports which showed a high enucleation efficiency rate used 
co-cultures but researchers have now achieved high enucleation efficiency without the use of 
feeder layers for low-density cultures. High-density cultures are essential and therefore high 
enucleation efficiency rates still need improving in order to achieve successful manufacture 
of cRBCs  [61]. 
 
Human ESCs and iPSCs may have potential as a source for ex vivo expansion of 
erythroblasts for a cell-therapy product as RBCs do not have a nucleus. However, it is 
believed that this research might be more beneficial for important developmental biology 
issues than it will for generating erythroblasts ex vivo for transfusion [60].  
 
A critical issue is the acceptance of oxygen carriers by the recipient’s body. So far, the 
majority of developed and tested acellular platforms did not reach the clinic mainly because 
of their adverse effect profile. An in depth analysis by Silverman and Weiskopf stated that 
all HBOCs tested to date caused vasoconstriction and elevation in blood pressure [20]. 
Therefore, targeted chemical modification of HBOC, to eliminate vasoconstriction, might be 
the key to success for certain second-generation products [80]. For the cellular oxygen 
variant (e.g. cRBCs) the situation is somewhat different. As a potential cell therapy, the 
antigen profile of the graft should be identical as possible to that of the host’s to minimise 
the effects of inflammation and any other undesirable physical response. During the reported 
clinical trial with autologous cells there were no noticeable differences in antigen expression 
between the native RBCs and cRBCs, including the ABO and Rh antigens [53]. It was not 
reported what effect the injection of 1x1010 cRBCs had on the human subject. This is 
interesting data, however the administration of such a cell number is a factor of 250 smaller 
than that in a regular blood unit and this might evoke a different immune response. For that 
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reason, more in-depth analysis is required into the effect of real life quantities of cRBCs on 
transfusion subjects. 
 
As stated, there are a number of barriers that need to be overcome in order for artificial 
oxygen carriers to become an acclaimed treatment. The quality and the quantity need to be 
sufficient for an alternative therapy in transfusion. When the quality of a potential product is 
perfect, sufficient product needs to be available in order to become reliable for treatment. 
With products available in the veterinary sector for acellular products it is shown that this 
can be done cost effectively. For cellular products, which require high numbers of cells, 
manufacturing requires large volumes of expensive media and this includes the costs of 
GMP [60]. This creates a tremendous financial challenge to make it sustainable when 
compared with current transfusion practice. 
 
 
1.9.1 Potential clinical applications in the short term 
It is evident that despite the reality of manufacturing cRBCs, this practise has not reached the 
clinic due to many hurdles. The use of artificial cellular oxygen carriers as a sustainable 
transfusion therapy might happen in the future, but tissue engineered RBCs might have other 
benefits at the present time. With relatively easy access to HSCs and available protocols for 
erythroid maturation, the in vitro production of RBCs allows for precise control of the 
various stages of the erythroid progenitor cells to select cells for other applications. Two 
areas which could benefit from this research are drug discovery and drug delivery [40]. Over 
the past few years, researchers have started to use erythroid progenitor cells for drug 
discovery including identification of the toxicity mechanism of the B19 parvovirus [81], 
screening for compounds that induce γ-globin production [82], and susceptibility of 
erythroblasts to malaria infection [83]. This stage-specific control of erythroid progenitor 
cells grants better opportunities to analyse the susceptibility of cells, including rare blood 
types, for various diseases than is the case with isolated cells. 
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RBCs have been reviewed as a vehicle for intravascular drug delivery with strategies 
involving encapsulation into cells and coupling drug molecules to the cell surface [84]. 
Human isolated RBCs for a drug delivery system is a novel and promising technique but will 
also evoke the same issues as occurs in current transfusion practise. Ex vivo manufactured 
RBCs for drug delivery systems might overcome these issues as these cells have a potential 
to be tailored to the patient’s, possibly rare, antigen profile, minimising an immune response. 
All developmental progress made in the field to develop therapies involving cRBCs will 









Over the past decades tremendous research has been performed to bring us to the stage 
where we are now. The first data of a human clinical trial with in vitro produced erythrocytes 
is hugely important. On the route to full clinical use of cultured RBCs, more in vivo 
experiments with humans are paramount to establish a robust argument for this method as an 
alternative to current blood transfusion. In the mean time, cRBCs could have their use in the 
development of drug discovery and drug delivery, indicating applications beyond 
transfusion.  
 
Controlling the antigenic profile of cRBCs and the use of non-autlogous cells are essential 
pieces of this complex jigsaw. Critically, upon administration of these cells the recipient’s 
immune system should not reject the oxygen carriers including minimal inflammatory 
response. Ideally, the developed product should reduce the risks for the patient when 
compared to current transfusion products. It is also vital to develop a device that is ultimately 
capable of producing at least multiple units of RBCs from a select number of HSCs in a 
clinically safe manner. Despite major progress, there are still major challenges to overcome 
in manufacturing cRBCs including the increase of enucleation efficiency and complete 
allogeneic culture conditions.  
 
As with any medical treatment regulation from governing bodies is required to safeguard 
quality control for patient’s safety. A degree of uniformity in this market will be required if 
tissue engineered RBCs for transfusion becomes common practise in order to avoid 
discrepancy between the use and quality of cellular products. A potentially successful 
outcome will produce a rationale for widespread clinical use if production costs can compete 
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1.11 The research project 
In the previous paragraphs the wider scope of producing artificial RBCs has been described. 
The title of this particular research study was officially formulated as “Continuous 
proliferation and simultaneous maturation of HSCs into RBCs”. This is a tissue engineering 
approach to produce RBCs from adult stem cells in vitro. 
 
The research was part of a larger project involving European research groups and a company 
(Applikon Biotechnology, Delft (NL)) which produces bioreactors for cell culture. The 
overall aim of this project was the bioreactor development for the manufacture of RBCs. 
During this project, intensive contact was maintained with all research partners and in 
particular with Applikon Biotechnology. The work done in chapter 5 was performed in 
partnership with Applikon. Experiments were performed in the laboratory located in 
Liverpool, using equipment provided by Applikon, and data was fed back to the company 
located in Delft (NL) in order to improve and optimise the bioreactors for cell culture. 
 
During this project, the research was divided in three research topics: 
i. Haematopoietic Cell Culture (Chapter 3) 
ii. Manufacture of Red Blood Cells (Chapter 4) 
iii. Development of the Bioreactor (Chapter 5) 
 
The first topic, described in chapter 3, involved the long term culture of HSCs isolated from 
PB and UCB. This chapter reports on the efficiency of HSC isolation and subsequent 
proliferation of these stem cells including the progress made by including MNCs for HSC 
expansion. Chapter 4 shows how this research is continued by differentiating the expanded 
cells, including MNCs, into RBCs. The research described in chapter 5 was aimed at the 
upscaling of successful erythroid maturation cultures. This chapter contains results, obtained 
after analysis of bioreactors, including the culture parameters and cell viability. Together 
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these chapters provide a process for upscaling cell culture with the overall aim of producing 
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2.1 Culture media 
 
2.1.1 Medium for haematopoietic stem cell expansion 
A selection of media was used for the expansion of HSCs: 
I-Medium: 
ISCOVE incomplete medium (BioChrom AG, T0046) supplemented with 5mM glucose 
(Sigma-Aldrich, G7021), 0.4mM myo-inositol (Sigma-Aldrich, I7508), 2mM glutamine 
(Invitrogen, 25030-024), 10% (v/v) fetal calf serum (FCS) (BioWhittaker, DE14-701FH), 
1% (v/v) penicillin/streptomycin (Pen/Strep) (Sigma-Aldrich, P4458), and 50 ng/mL SCF, 
TPO, and Flt3-L. 
I-Medium [Serum Free]: 
ISCOVE incomplete medium (BioChrom AG, T0046) supplemented with 5mM glucose 
(Sigma-Aldrich, G7021), 0.4mM myo-inositol (Sigma-Aldrich, I7508), 2mM glutamine 
(Invitrogen, 25030-024), 2.5 mg/mL BSA (Sigma-Aldrich, A3912), 50 µg/mL holo-
transferrin (Sigma-Aldrich, I6634), 25 µM β-mercaptoethanol, 10 µM Fe(II)SO4, 1% (v/v) 
Pen/Strep (Sigma-Aldrich, P4458), and 50 ng/mL SCF, TPO, and Flt3-L. 
P-Medium [Serum Free]: 
HPC Expansion Medium DFX (PromoCell, C-28021) supplemented with cytokine mix E for 
HPC-expansion Medium DFX (PromoCell, C39891). 
D-Medium [Serum Free]: 
IMDM with GlutaMAXTM (Gibco, 31980), 1.6x10-4 1-thioglycerol (Sigma-Aldrich, M6145), 
120 µg/mL holo-transferrin (Sigma-Aldrich, I6634), 10 µg/mL insulin Sigma-Aldrich, 
T0665), 1% (v/v) Pen/Strep (Sigma-Aldrich, P0906), and 10 mg/mL BSA (Sigma-Aldrich, 
A3912) as described as a basic medium by Douay et al (2009) [86], supplemented with 50 
ng/mL SCF, TPO, and Flt3-L. 
S-Medium [Serum Free]: 
StemLine® II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, S0192) 
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2.1.2 Basic medium for erythroid maturation (Douay and Giarratana, 2009) [86] 
The basic medium that was used for erythroid maturation was IMDM with GlutaMAXTM 
(Gibco, 31980) containing 1.6x10-4 M 1-thioglycerol (Sigma-Aldrich, M6145), 120 µg/mL 
holo-transferrin (Sigma-Aldrich, I6634), 10 µg/mL insulin (Sigma-Aldrich, T0665), 1% 
(v/v) Pen/Strep (Sigma-Aldrich, P0906), and 10 mg/mL BSA (Sigma-Aldrich, A3912). 
 
 
2.1.3 Cytokines for HSC expansion and erythroid maturation 
Human-SCF (Stem Cell Factor):  
-(R&D Systems, 255-SC-050) and  (Miltenyi Biotec, 130-093-992) 
Human-EPO (Erythropoietin):  
-(R&D Systems, 287-TC)  
Human-IL-3 (Interleukin-3):  
-(R&D Systems, 203-IL/CF)  
Human-TPO (Thrombopoietin):  
-(Miltenyi Biotec, 130-094-013) and (Gibco, PHC9514) 
Human-Flt3-L (Flt3-Ligand):  
-(Miltenyi Biotec, 130-093-855) 
Human-G-CSF (Granulocyte Colony-Stimulating Factor):  
-(Miltenyi, 130-096-346) 
 
2.1.4 Medium for the human lymphoblast cell line U937 
U937 cells were either cultured in low glucose DMEM (Gibco, 21885) supplemented with 
5% FCS (Gibco, 10099-141) and 1% Pen/Strep (Sigma, P4458)  
and 
RPMI 1640 medium (Gibco, 21875) supplemented with 5% FCS (Gibco, 10099-141) and 
1% Pen/Strep (Sigma, P4458). 
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2.1.5 Medium for primary cultures and dental pulp stem cells (DPSCs) 




2.1.6 Medium for mesenchymal stem cell expansion 
Mesenchymal Stem Cell Growth Medium (MSCGM™) (Lonza, PT-3001) contains 
Mesenchymal Stem Cell Basal Medium and a MSCGM™ SingleQuots® Kit. 
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2.2 Cell isolation 
 
2.2.1 Purification of MNCs from peripheral blood 
Samples of 30mL PB were isolated from healthy donors and 0.6 mL of heparin (Multiparin, 
74301/5) were added per sample to prevent coagulation.  Each blood sample was mixed with 
20 mL 1mM EDTA (Gibco, 15575) in Phosphate Buffered Saline (PBS) (Sigma-Aldrich, 
D1408) (4°C), up to a total volume of 50 mL. LeucosepTM 50 mL tubes (Greiner Bio-One, 
227290), preloaded with 15 mL histopaque (Sigma-Aldrich, 1077), were filled with 25 mL 
of mixed blood and centrifuged at 2000 rotations per minute (rpm) for 20 min at 20°C, no 
brakes. Buffy coats from the same donor were pooled in a 50mL tube, washed with up to 
50mL of 1mM EDTA in PBS (4°C) and centrifuged at 1700rpm for 10 min at 4°C.  Obtained 
cell pellets were washed with 50 mL of 1mM EDTA in PBS (4°C) and centrifuged at 
1500rpm for 10 min at 4°C. Supernatant was discarded and MNCs were either resuspended 
in medium, 300 µL buffer or freezing buffer, depending on application. 
 
 
2.2.2 Enrichment of CD34+ cells using MACS® technology 
Purified MNCs were resuspended in 300 µL magnetic-activated cell sorting (MACS®) buffer 
(kept cold on ice), containing 2mM EDTA and 1% BSA in PBS, in a 15mL falcon tube and 
100 µL FcR blocking reagent (Miltenyi Biotec, 130-046-702) was added well mixed.  Next, 
100 µL CD34 MicroBeads (Miltenyi Biotec, 130-046-702) were added to the cell suspension 
and mixed well, followed by a 30 minute incubation time at 4°C while slowly rotating on a 
Spiramix 5 Roller Mixer (Denley).  After incubation the cells were washed with MACS® 
buffer and centrifuged at 1500rpm for 5 min. The cell pellet was resuspended in 500 µL 
MACS® buffer, ready for magnetic separation.  
 
For magnetic separation, a MS column (Miltenyi Biotec, 130-042-201) was placed in the 
magnetic field of a MiniMACS® Separator (Miltenyi Biotec, 130-042-102). The column was 
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rinsed with 500 µL MACS® buffer before the cell suspension was added, followed by 1 mL 
MACS® buffer. The column was rinsed four times with 500 µL MACS® buffer. Next, a new 
MS column was placed in the MACS® separator and prepared as stated above. Cells from the 
first column were eluted into a second MS column using 1mL MACS® buffer and plunger. A 
second column with cell suspension was washed three times with 500 µL MACS® buffer. 




2.2.3 Isolation of MSCs from human bone marrow  
Samples of BM (5-20mL) were collected from human donors by standard surgical 
procedures. Each sample was diluted 1:1 (v/v) with 1mM EDTA in PBS (4°C), put through a 
100 µm cell strainer to remove any bone debris, and transferred to a 50mL LeucosepTM tube, 
preloaded with 15mL Histopaque and subsequently centrifuged at 2000rpm for 20 min at 
20°C, no brakes. Buffy coats were transferred to a 50mL tube, washed with up to 50mL of 
1mM EDTA in PBS (4°C) and centrifuged at 1700rpm for 10 min at 4°C. Obtained cell 
pellets were washed with 50 mL of 1mM EDTA in PBS (4°C) and centrifuged at 1500rpm 
for 10 min at 4°C. The supernatant was discarded and MNCs were either prepared for culture 
or resuspended in 300 µL MACS® buffer or freezing buffer, depending on application. 
 
For culture, each cell pellet was resuspended in 5 mL primary culture medium and 
transferred to a 25 cm2 tissue-culture treated flaks (BD Falcon, 353136) to allow cell 
adherence. Medium was refreshed weekly until the flasks was 70-90% confluent. Cells were 
harvested for subculture in MSC medium and analysed for MSC phenotype using 
Fluorescent Activated Cell Sorting (FACS) using appropriate antibodies (CD90, CD105, 
CD29, CD73, CD34, and CD45). 
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2.2.4 Isolation of MSCs from human adipose tissue 
Adipose tissues (5-20mL) were collected from human donors by standard surgical 
procedures. On arrival, tissue was washed in a 100mL container with lid, filled with 30-50 
mL PBS containing 2% Pen/Strep (Sigma-Aldrich, P4458) by shaking vigorously for 10 
seconds. PBS was removed and the washing procedure was repeated until the culture 
medium was clear. 
 
To digest adipose tissue and harvest the MSCs, tissue was cut in 2 mm2 pieces using 22mm 
blades (Swann-Morton, 22-0208),  placed in a 50ml tube and subsequently digested  by 10% 
collagenease (Sigma-Aldrich, C2674) in DMEM (Gibco, 31966) containing 2% Pen/Strep, 
incubated overnight at 37°C whilst slowly rotating on a Spiramix 5 Roller Mixer (Denley).  
Collagenase activity was stopped by adding 10% FCS (BioWhittaker, DE14-701FH) and 
collagenase-digested tissue was transferred to a 50 mL tube through a 100 µm cell strainer 
(BD Falcon, 352360) to obtain a cell suspension free of undigested tissue.  
 
Cell suspension was centrifuged at 1500rpm for 5 min and supernatant was removed. To 
remove erythrocytes, the cell pellet was resuspended in Red Blood Cell Lysing Buffer 
(Sigma-Aldrich, R7757) for 5 minutes at RT followed by a washing step with 20 mL of PBS. 
After centrifugation, cells were resuspended in 10 mL of primary culture medium, 
transferred to a 50 mL tube through a 40 µm cell strainer (BD Falcon, 352340) and 
subsequently the cell suspension was transferred to a 75 cm2 tissue-culture treated flaks (BD 
Falcon, 353136) to allow cell adherence. Medium was refreshed weekly until the flask was 
70-90% confluent. Cells were harvested for subculture in MSC medium and analysed for 
MSC phenotype with FACS using appropriate antibodies (CD90, CD105, CD29, CD73, 
CD34, CD45). 
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2.3 Cell culture 
 
2.3.1 Culture of HSCs and MNCs 
CD34+ cells were isolated from MNCs from PB or UCB. The CD34+ cells were cultured as a 
liquid cell culture in 24 and 48 well plates using media for haematopoietic cell expansion 
either without or with a stromal layer. The stromal cells were either harvested from BM or 
adipose tissue and cultured on a tissue culture (TC) treated surface prior to culture. For 
subculture, attached cells were detached using a cell scraper (Greiner Bio-one, 541070), the 
cell suspension transferred to a falcon tube, and the culture surface was washed thoroughly 
to harvest all the cells. The obtained cell suspension was transferred to a falcon tube, and 
cells were centrifuged at 1500rpm for 5 minutes, resuspended in appropriate medium, 
subcultured in wells or a flask depending on the application, and stored in a 37°C incubator 
with 5% CO2 infusion. 
 
 
2.3.2 Erythroid maturation (Douay and Giarratana, 2009) [86] 
Either MNCs or CD34+ cells, isolated from either PB or UCB were used for differentiation 
towards the erythroid lineage. In general, erythroid culture is divided into three different 
phases: 
Phase I (Day 0-8): During this phase of erythroid culture, complete IMDM (Douay 
and Giarratana, 2009) [86] was supplemented with the following additions with the 
following final concentrations: 100 ng/mL SCF, 5 ng/mL IL-3, 3 IU/mL EPO,  10-6 M 
Hydrocortisone (Sigma-Aldrich, H2270). 
Phase II (Day 8-11): For phase two, complete IMDM (Douay and Giarratana, 2009) 
[86] was supplemented with 3 IU/mL EPO only. Maturing cells were cultured on a stroma of 
MSCs and resuspended at ~5x106 cells/mL. 
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Phase III (From Day 11): For phase three only complete IMDM (Douay and 
Giarratana, 2009) [86] was used. Maturing cells were cultured on a stroma of MSCs to allow 
elimination of nuclei, which are engulfed by the stromal layer. 
 
For better preservation of maturating erythroid cells during phase II and III, human AB 
serum (Sigma, H4522) could be added to the medium up to a final concentration of 5%. 
During this phase of culture, non-adherent cells were removed gently to obtain a greater 
percentage of enucleated cells. 
 
 
2.3.3 Culture of U937 cells 
Cells were seeded in suspension either in a T75 flask (BD Falcon, 353136), a T225 flask 
(BD Falcon, 353139), a 250 mL bioreactor (Applikon), or in a 3 L bioreactor (Applikon) at a 
cell density of 2-5 x 105 cells/mL. When cultured in flasks, cells were reseeded once a cell 
density of 1-2 x 106 cells/mL was reached. 
 
 
2.3.4 Subculture of adherent cells 
When cells were 70-90% confluent culture medium was removed from the TC treated flask 
(BD Falcon), cells were washed with PBS and Trypsin-EDTA solution (Sigma-Aldrich, 
T4174) was introduced to the flask and incubated for 5-10 min at 37°C to allow cells to 
detach. Following detachment, trypsin was neutralised by adding medium containing 10% 
FCS, the cell suspension transferred to a 10 mL falcon tube (BD Falcon, 352096) and 
centrifuged at 1500rpm for 5 min. The supernatant was discarded and the cell pellet was 
resuspended in appropriate medium. Aliquots of cell suspension were transferred to flasks 
containing medium and stored in a 37°C incubator with 5% CO2 infusion. Medium was 
refreshed every 7 days. When required a haemocytometer in conjunction with an inverted 
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light microscopy was used for cell counting. Images of cells were obtained using an inverted 
light microscope in conjunction with the software platform Axiovision (Zeiss, UK). 
 
 
2.3.5 Inhibition of cell expansion for stromal cells 
To inhibit stromal cell expansion, after reaching confluence, mitomycin C (Sigma, M4287) 
was added to the culture medium to avoid over confluence cultures. First, the powdered 
stock of 2 mg was dissolved in 4mL of dH2O to obtain a stock solution of 1 mg/mL. Next, 
either 4 µL of mitomycin C solution was added per 1 mL of cell culture medium, filter 
sterilised, and incubated at 37°C for 3-4 hours, or 1 µL of mitomycin C solution was added 
per 1 mL of cell culture medium, filter sterilised, and incubated at 37°C for 24 hours. After 
inhibition, medium was discarded and cells were washed with PBS before appropriate 
medium with either MNCs or CD34+ cells was added to the culture. 
 
  
Chapter 2 – Materials and Methods 
41 
 
2.4 Freezing and thawing of cells 
Freezing of cells: 
Freezing media were prepared with Medium A (100% FCS) at room temperature and 
Medium B (FCS with 40% DMSO (Sigma, D2650)) at 4°C. Cryovials (Simport, T311-2) 
were put on ice. Cells were resuspended in 1mL of Medium A, then 1 mL of Medium B was 
added slowly whilst swirling gently until the two media were at a 50:50 ratio. Promptly the 
cell suspension was aliquoted in the cryovials; 1 mL suspension per vial. Cryovials were 
placed in a Mr Frosty at -80°C for 24 hours before storage in liquid LN2. 
 
Thawing of cells: 
The vial with frozen cells was thawed in a water bath at 37 °C by gently moving until a small 
ice crystal is left. The cell suspension was then transferred to a 50 mL conical tube and 1 mL 
of cold appropriate medium containing 2% FCS was added drop-wise to the conical tube 
whilst swirling gently. After three minutes, 2 mL of the thawing medium containing 2% FCS 
was added slowly to the cell suspension whilst swirling gently and after another three 
minutes this process was repeated with 4 mL of thawing medium; this is the same volume as 
the cell suspension in the conical tube. The procedure was repeated every three minutes, 
whilst swirling gently, until the final volume reached 32 mL. Next, the tube was centrifuged 
at 250g for 10 minutes at room temperature, the supernatant removed and the cell pellet was 
resuspended in 20mL of thawing medium and centrifuged at 200g for 8 minutes at room 
temperature. The supernatant was removed and the cell pellet resuspended in appropriate 
medium at 0.5 x 106 cells/mL. A cell count was performed using the viability assay trypan 
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2.5 Bioreactor culture methods 
 
2.5.1 Cell culture using bioreactors 
Various bioreactors were used for culturing U937 cells and UBMCs. The bioreactors have 
working volumes ranging from 50mL-3L. The bioreactors were provided by Applikon 
Biotechnology (Delft, The Netherlands). The bioreactors were connected to My-Control 
Units (Applikon) to control and monitor parameters using the My-Control user-interface (UI) 
and BioXpert Lite software (Version 1 and 2) for Windows. 
 
 
2.5.2 Bioreactor equipment 
The bioreactor equipment consisted of: 3L bioreactor vessel, 2L bioreactor vessel, 2x 250 
mL bioreactor vessel, 2x My-Control Unit, 2x dissolved oxygen (DO) sensor (6mm), 2x pH 
sensor (6mm), DO sensor (10mm), pH sensor (10mm), 6x cable for connecting sensors with 
My-Control Unit, 2x heating blanket for 250 mL bioreactor, 1x heating blanket for 2L/3L 
vessel, 2x thermometer for My-Control Units, 2x stirrer for 250 mL vessel, 1x stirrer for 
2L/3L vessel + motor, 2x (porous) sparger for 250 mL vessel, 2x (porous) sparger for 2L/3L 
vessel, acoustic cell separation device for 2L and 3L vessel; BioSep, tubing (Cole-Parmer), 
peristaltic pumps (Masterflex), air filters (Sartorius), medium bottles (Duran), gas tubing for 
CO2, air, and N2 supply, gas pressure regulators, rotameter, medium sample systems, 
BioXpert Lite software for recording parameters (i.e. stirrer speed, temperature, DO, pH). 
My-Control Unit: UI for controlling (and calibrating) the pH, DO, temperature, rotation 
speed of stirrer, and the addition speed of medium. 
 






2.5.3 Cleaning the bioreactor 
Before use, all parts to be exposed to the cell suspension were rinsed with dH2O and 70% 
ethanol before allowing to air dry. After use all exposed surfaces, including tubing, were 
cleaned using Virkon (SLS, CLE1556) and 0.1 M NaOH (Sigma, S8045) solution, rinsed 
with dH2O and 70% ethanol before the equipment was air dried. pH sensors were stored in 
appropriate storage solution before reuse.  
 
 
2.5.4 Preparing the bioreactor for culture 
The pH sensor was calibrated using the UI of the My-Control Unit using a 2-step calibration 
method that was temperature dependent. Next, the pH sensor was cleaned with dH2O and 
fixed in the head plate of the bioreactor as was the DO sensor. To facilitate heat exchange 
during autoclaving, 10mL dH2O were added to the vessel. All other relevant tubing (e.g. air 
supply, medium addition, air exchange filter) were connected to the various head plate inputs 
and all remaining connections were sealed off from atmospheric conditions to maintain 
sterile conditions after autoclaving. The bioreactor, with all connected tubing and vessels, 
was autoclaved and was set aside to cool down overnight. The DO sensor, in either PBS or 
 
Fig. 2.1. UI of the My-Control unit (Screen print of the control system) 
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appropriate medium, was calibrated under sterile conditions using the UI of the My-Control 
Unit in the presence of air. 
 
The fully calibrated and sterilised bioreactor was placed in a laminar flow cabinet to allow 
addition of appropriate medium and cells under sterile conditions, via a head plate port, and 
afterwards the bioreactor was again sealed. Next, the bioreactor sensors were connected to 
the My-Control Unit, the stirrer was connected to the stirred motor, the heat blanket was 
placed around the bioreactor vessel, the thermometer was placed in the thermometer pocket, 
the oxygen/nitrogen/CO2 supply tubing including filter was connected to the My-Control 
Unit, the tubing for the alkali addition (pH control) was connected to a My-Control pump, 
and other tubing (e.g. medium addition) was connected to an external pump. Data was 
recorded using BioXpert Lite software for Windows (32bit). 
 
 
2.5.5 Controlling the dynamic culture 
Controlling of the bioreactor culture was performed by the My-Control Unit with pH and 
temperature respectively set at 7.4 and 37°C under standard conditions. DO was normally set 
at 20% and stirrer speed at 75, 100 or 150rpm. All changes in parameter readings were 
recorded with BioXpert Lite. 








Fig. 2.2. BioXpert Lite interface for monitoring the pH, temperature (Temp), DO, and the 
stirrer speed of the bioreactor (Screen print of the interface) 





2.6.1 Fluorescent Activated Cell Sorting (FACS) 
Phenotypic analysis of cells by means of cell antibody markers was performed using FACS. 
Cells were harvested from flasks and/or wells by trypsinisation of adherent cells or using a 
cell scraper for liquid cell suspensions. Cell suspensions were washed once with PBS, 
transferred to tubes and centrifuged at 1500rpm for 5 min. The resulting cell pellet was then 
resuspended in PBS and aliquots of cell suspensions (10-50 µL) were transferred into FACS 
tubes (BD Falcon, 352008). A FACS antibody (3 µL) was added to each cell suspension, 
incubated at 4°C for 30 minutes and 200-300 µL of sheath fluid added to each tube. Cells 
analysed for Hb-ß were first fixed using paraformaldehyde/sucrose and then permeabilised 
using the BD Cytofix/Cytoperm™ Kit (BD Biosciences, 554714) prior to incubation with 
the antibody. Cells were analysed using a FACsort flow cytometer (BD-Biosciences, UK) 
and CellQuest software (BD Biosciences, UK).  Non-specific fluorescence was determined 
using negative control samples. All FACS antibodies and isotype controls can be found in 
Table 2.1. Analysis of data was performed using WinMDI v2.9 for Windows (32bit). Typical 
graphs for analysis can be found in Figure 2.3. 
  

















Fig 2.3. Flow-Cytographs with the negative control (Isotype) and the antibody specific 
marker (Antigen) shown above and the subtraction (below) 
Isotype (-) Antigen (+) 
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Antigen Specification Reactivity Conjugate Isotype Supplier 
CD34 Mouse Human FITC IgG1 BD Biosciences 
CD29 Mouse Human PE-Cy5 IgG1 BD Biosciences 
CD71 Mouse Human PE IgG1 R&D Systems 
CD44 Mouse Human PE IgG1 BD Biosciences 
CD90 Mouse Human FITC IgG1 BD Biosciences 
CD105 Mouse Human FITC IgG1 BD Biosciences 
CD45 Mouse Human FITC IgG1 BD Biosciences 
CD235a Mouse Human PE IgG1 R&D Systems 
CD73 Mouse Human PE IgG1 BD Biosciences 
Hb-β Mouse Human FITC IgG1 Santa Cruz Biotechnology 
CD36 Rat Human FITC IgG2b R&D Systems 
CD45 Mouse Human PE-Cy5 IgG1 BD Biosciences 
CD133 Mouse Human PE IgG1 MACS® Miltenyi 
CD38 Mouse Human FITC IgG1 BD Biosciences 
CD117 Mouse Human PE IgG1 BD Biosciences 
Isotype Mouse Human FITC IgG1 R&D Systems 
Isotype Rat Human FITC IgG2b R&D Systems 
Isotype Mouse Human PE IgG1 BD Biosciences 
Isotype Mouse Human PE-Cy5 IgG1 BD Biosciences 
Table 2.1. FACS antibodies used in flow cytometric analysis 
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2.6.2 Real-Time Polymerase Chain Reaction (qRT-PCR) 
2.6.2.1 Primer design 
As previously stated we selected genes based on the literature (section 2). When an 
appropriate range of genes was selected, highly specific and efficient primers were designed 
in house using Beacon Designer 7.0 (Biosoft). The primers are listed in Table 2.2.  
 
 
2.6.2.2 RNA Isolation 
Prior to cellular RNA isolation the following solutions were prepared: 44mL of 100% 
ethanol were added to 6mL of buffer RPE and 10µL of 1M β-mercaptoethanol (Sigma-
Aldrich UK) were added to 1mL of buffer RLT.   
Isolated CD34+ UCB cells were transferred to an eppendorf tube and 350 µL buffer RLT 
were added and incubated for 5 minutes at RT to obtain cell lysate. The lysate was then 
transferred to a QIA shredder column and centrifuged at 16,000g for 2 minutes. 350 µL of 
70% ethanol were added to the tube with eluted liquid and a total of 700 µL were then 
transferred to an RNeasy Mini column placed in a 2 mL collection tube and centrifuged at 
12,000g for 15 seconds. Next, 700 µL of buffer RW1 were added to the column, centrifuged 
at 8,000g for 15 seconds and the flow through discarded. Then 500 µL of buffer RPE were 





Sense Primer Anti-Sense Primer Tm 
(°C) 
GAPDH NM_002049 TTG GTA TCG TGG AAG GAC GTA GAG GCA GGG ATG ATG 55.4 
CD34 M81104 TTC CAC TCG GTG CGT CTC CCC AGA AGG CAG CAA ACT C 59.9 
GATA2 M68891 TCA GAC GAC AAC CAC CAC TCT TGC TCT TCT TGG ACT TG 55.5 
HoxB4 NM_024015 AAA GCA AGA AGA AGG AAG AAA G CAG AGG AAA CAA GAC AGA TGG 52.7 
Hb-ß NM_000518 TTC ACT AG CAA CCT CAA ACA G CAC CAC CAA CTT CAT CCA C 53.7 
Tal1 NM_003189 GCC TGA GTT ATT GAG ATT GTC CTG AGG TGA GAG GAT TGC 53.4 
RunX1 BC136381 CCT CGT GCC TCC CTG AAC GTA TTG GTA GGA CTG ATC GTA GG 55.5 
EPO NM_000799 CTG ACA CTT TCC GCA AAC CAA GCA ATG TTG GTG AGG 55.1 
Table 2.2.  Primer details qRT-PCR 
Chapter 2 – Materials and Methods 
50 
 
discarded. This step was repeated again but instead centrifuged for 2 minutes and afterwards 
the RNeasy Mini column was placed in a new 2mL collection tube and centrifuged at 
16,000g for 1 minute. Finally to collect the isolated RNA the column was placed in a 1.5 mL 
RNase-free tube and 30 µL of UltraPure™ DNase/RNase-Free dH2O (Gibco, 10977) added 
to the column and centrifuged at 8,000g for 1 minute. RNA samples were stored at -80°C 
until required for further processing. All products were purchased from Qiagen (RNeasy 
Mini Kit) unless stated otherwise. 
 
2.6.2.3 Reverse Transcription 
A RT2 First Strand Kit (QiaGen, 330401) containing 5X gDNA Elimination Buffer (GE), 5X 
Reverse Transcription Buffer (BC3), RT Enzyme Mix 3 (RE3), Primer and External Control 
Mix (P2), and RNase-free H2O was used to synthesise cDNA from isolated RNA. A 
Genomic DNA Elimination Mixture was prepared by adding 8 µL RNA sample to 2 µL of 
GE buffer in a sterile PCR tube. Contents were mixed gently with a pipette followed by brief 
centrifugation and incubated at 42°C for 5 minutes. Next, tube was chilled on ice 
immediately after for one minute. Parallel, the RT cocktail was prepared by adding 4 µL 
BC3 Buffer, 1 µL P2 Mix, 2 µL RE3 Mix, and 3 µL H2O to a sterile PCR tube. First strand 
cDNA synthesis was executed by mixing 10 µL of RT cocktail gently with the 10 µL 
Genomic DNA Eliminiation Mixture, incubated at 42°C for exactly 15 minutes and 
immediately followed by incubation at 95°C for 5 minutes to terminate the reaction. The 
resulting cDNA was stored at -20°C until required for further processing. 
 
2.6.2.4 RT-PCR 
The synthesised cDNA was either diluted 10 or 100 fold with UltraPure™ DNase/RNase-
Free dH2O for subsequent RT-PCR reactions. Prior to RT-PCR reactions the following 
solutions were prepared. Stock Primer Mixes were prepared from 100 µL Sense Primer and 
100 µL of associated Anti-Sense Primer (Invitrogen) according to Table 2.3. Subsequently, a 
PCR Reagent Stock solution was created from 7.5 µL iQ SYBR Green Supermix (Bio-Rad, 
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170-8882), 4.5 µL UltraPure™ DNase/RNase-Free dH2O, and 1 µL Stock Primer Mix per 
well. All PCR reactions were carried out in iQ 96-Well PCR plates (Bio-Rad, 223-9441). 
 
Diluted cDNA was added to each well in triplicates of 2 µL and 13 µL of PCR Reagent 
Stock solution was added per well with cDNA to obtain a total working volume of 15 µL. 
Well content was gently mixed using a pipette whilst avoiding air bubbles. Negative controls 
were included for each Primer Stock Solution by replacing the cDNA with UltraPure™ 
DNase/RNase-Free dH2O, in triplicate. 
 
RT-PCR reactions were carried out using a Bio-Rad iCycler (Version 2.039) and the 
standard iCycler operating platform (Bio-Rad). The PCR profile included a 3 minute 95°C 
initialisation step followed by 40 cycles of a 2 two-step amplification programme: 30 
seconds at 95°C (denaturation) and 30 seconds at the optimum annealing and extension 
temperature for each specific primer (Table 2.2, Tm).  Threshold cycle (Ct) values were 
calculated when the fluorescence from SYBR Green binding to double stranded DNA 
entered its exponential phase during amplification. Subsequently, PCR products were 
subjected to melting curve analysis.  
 
Target Gene Sense Primer- nanomoles 
Sense Primer- 




Volume ( µL) 
GAPDH 18.0 180 24.3 243 
CD34 17.6 176 13.9 139 
GATA2 23.5 235 18.6 186 
HoxB4 11.8 118 13.0 130 
Hb-ß 17.8 178 21.6 216 
Tal1 21.4 214 21.2 212 
RunX1 20.6 206 21.7 217 
EPO 25.3 253 23.7 237 
Table 2.3. Lyophilised, in-house designed, primers dissolved in DNase/RNase free dH2O 





2.6.3.1 Preparation of a blood/cell smear 
Cell suspensions were diluted to appropriate cell densities for analysis (i.e. whole blood was 
diluted 1:2 in PBS). A drop of cell suspension (5-20µL) was placed near the edge of the 
glass slide. Another glass slide, the spreader, was used to create a smear by placing it at a 45° 
angle and backing into the drop of cell suspension so that the drops spread evenly along the 
edge before pushing the spreader across the slide to create the smear. The slide with smear 
was air dried before the staining procedure was started. 
 
2.6.3.2 Brilliant cresyl blue stain for reticuloctyes 
Brilliant cresyl blue (Fluka, Sigma-Aldrich) stock solution was diluted 1:80 to 1:100 with 
PBS. For a single test 20 µL blood or 20 µL cell suspension was added to 20 µL brilliant 
cresyl blue (BCB) solution in a tube. This solution was mixed thoroughly and a thin smear 
was prepared after 30 minutes of incubation at room temperature. For test in series, thin 
smears of BCB solution were prepared on microscope slides. Air-dried slides were stored up 
to 2-3 weeks. When used, a small drop of blood was quickly smeared over the stain layer and 
the still wet preparation was placed in a moist chamber for 5-10 minutes before air drying. 
Samples were observed using light microscopy (Zeiss). 
 
2.6.3.3 Methylene blue stain for observation of cell nucleus 
Glass slides with air dried cell smear were subjected to staining using a 0.05% solution of 
methylene blue in dH2O (Sigma-Aldrich). Samples were incubated with the stain for 5 
minutes at room temperature followed by rinsing in dH2O. Samples were air dried at room 
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2.6.3.4 Preparation of cells for scanning electron microscopy (SEM) 
Prior to cell seeding, cover slips (Sarstedt, 83.1840.002) were coated with Poly-L-Lysine 
(Sigma, P4832) for 5 minutes. The solution on the coverslip was discarded and cover slips 
were washed with PBS and air dried for 2 hours.  Cells (1x104-1x106) were seeded on the 
coated cover slips. Next, cells were fixed with 1% (w/w) gluteraldehyde (Sigma, G5882) in 
PBS for 1 hour, cells were washed 3 times for 5 minutes with PBS followed by 1 wash in 
deionised water.  Cells were then dehydrated using a graded ethanol series; 15%, 25%, 50%, 
50%, 70%, 2x 100% (v/v) ethanol for 10 minutes each. Cover slips were dried with 
hexamethyldisilazane (Fluka, 52620) for 3 minutes prior to mounting onto aluminium 
specimen stubs (Agar Scientific Ltd) using carbon double sided sticky tabs (Agar Scientific 
Ltc). Afterwards, these specimens were gold sputter coated (Emitech K575X Sputter Coater) 




Statistical analyses were carried out using independent sample T-tests using the software 
package Microsoft Excel. All used p-values were stated with the corresponding results 
(Chapter 3 and 4). All error bars shown were calculated using the ‘STDEV’ formula 
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3.1 Introduction  
The HSC is fundamental for the development of RBCs. HSCs can be found in various tissues 
throughout the human body. The most used sources are BM, UCB, PB [87]. Another source 
for HSCs are iPSCs which can be created from a range of adult terminally differentiated cells 
(e.g. fibroblasts).  
The use of pluripotent cells is more complicated for establishment of erythroid cultures and 
there are also a number of ethical issues to consider. In contrast, the ease of access and 
relatively low costs make the use of UCB, and particularly PB, more favourable as sources 
for potential scaled up erythroid differentiation.  
 
As described previously, HSCs are reported to possess CD34 receptors which, in turn, 
provide a potential method to distinguish these cells from other cells [88]. Therefore, CD34 
specific antigen can also be used in separating these cells from the rest of the cell population. 
The most common technique used for the isolation of HSC from blood is the utilisation of 
magnetic bead cell separation to target specific stem cells (i.e. those expressing CD34+) [88]. 
This method is described in Chapter 2 and Figure 3.1. and shows the principle of this cell 
separation system. In short, the technique utilises magnetic beads labelled with specific 









After mixing and incubating with a heterogeneous cell population, the mixture of beads and 
cell suspension is passed through a magnetic column where the magnetic beads and targeted 
 
Fig. 3.1. Magnetic Cell Separating Technique (Miltenyi Biotech) 
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cells are retained. After all non cell-bead conjugates have been washed through, the targeted 
cells will be eluted.  
 
This chapter focuses on the establishment of HSC cultures. The objectives were 1) to isolate 
the cells from PB and 2) to determine how to optimise the conditions in order to maintain 
these stem cells in culture for more than 7 days. 
 
The hypothesis of this chapter is: Can the long term culture of HSC be improved by 
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3.2 Suspension cell culture 
All cultures involving HSCs are suspension cell cultures. This means that the cells have no 
automatic impulse to adhere and spread onto the tissue culture-treated culture plastic. For 
example, Figure 3.2 shows the differences between cells in suspension and adherent cells. 
The advantage of suspension cell cultures over adherent cell cultures is based on the ease of 
scale up due to only volume, as opposed to surface, restrictions for the concentration of cells. 
In addition, easy cell subculture whereby the culture can be diluted to stimulate growth. 
 
During this study, for example, to setup an expansion culture with a T25 culture flask the 
working volume of 5 mL of medium requires an adherent cell culture of 2,000 cells/cm2 
whereas for a suspension cell culture at least 30,000 cells/mL are needed. This means that to 
initiate a culture 50,000 and 150,000 adherent or suspension cells will be required 
respectively. A number of cultures were performed in well plates (6, 12, 24 or 48 wells) and 





Fig. 3.2. Suspension Cell Culture vs. Adherent Cell Culture - The suspension culture with 
UCB isolated cells have a round morphology (left) whereas the MSCs in the adherent 
culture have a stretched, elongated morphology (right) 
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3.2.1 Isolation and culture of PB isolated CD34+ cells 
An essential step in this project was the acquisition of CD34+ cells (HSCs) isolated from 
human tissue. As described in Chapter 1, blood is an ideal source for HSCs as it is accessible 
and taking blood samples is common practice in clinical environments.  In the first set of 













Buffy coats were prepared from 30mL of blood and subsequently 4x107 MNCs were 
isolated. After applying the CD34 MicroBead magnetic separation approximately 3x104 cells 
were collected. Figure 3.3 illustrates the results of flow cytometry analysis which shows that 
of the cell population 82.6% expressed CD34 and 47.1% expressed the haematopoietic cell 
associated marker CD45 [89].  
 
When comparing the number of isolated CD34+ cells between two age groups a difference in 
isolation efficiency was found. Blood isolated from the age group younger than 30 years 
contained a higher proportion of CD34 positive cells than blood isolated from donors older 
than 30 years, normalised for the number of isolated MNCs (Figure 3.4).  
 
Fig. 3.3. The CD34+ purity of this cell population is 82.6% which can be derived 
from the graph on the right (top). The expression of CD45 is 47.1%, indicating a 






































Once successful isolation of PB-CD34+ cells was established, cultures with PB CD34+ 
isolated cells were setup with the aim of expanding HSCs. In each instance, between 30 and 
40mL of PB were isolated from healthy voluntary donors. Subsequently, MNCs and CD34+ 
cells were isolated as described in Chapter 2. Once cultures were either initiated for HSC 
expansion or erythroid maturation (described in Chapter 4), the isolated cells did not always 
expand at a rate consistent with that in the literature. Generally, the expansion potential was 
very low. Cultures with a cell density between 3x103 cells/mL and 104 cells/mL, the 
recommended cell density for UCB-CD34+ cultures, struggled to expand and remain viable 
for more than 2 days. Overall, the results obtained showed that the CD34+ cell isolation from 
small volumes of PB for culture, and therefore limited numbers of isolated PB MNCs 
(PBMCs) was restricted.  
 
To prevent early termination of PB-CD34+ cell cultures as a result of low cell densities in 
culture, a higher number of PBMCs was required initially. Therefore CD34+ cells were 
isolated from leukocyte cones which should contain more MNCs compared to 30-50mL PB.  
These cones, prepared by the National Health Service (NHS) contained 10mL of Buffy 
Coats and RBCs .These cones (NC24) were prepared daily by the NHS (United Kingdom) 
 
Fig. 3.4. Isolated cell number per donated mL of blood from donors 
younger and older than 30 years. Donors aged younger than 30 years 
























e) MNCs/mL CD34+ cells/mL
p<0.06
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with buffy coats pooled from a number of donors. Figure 3.5 shows a buffy coat cone with a 
volume of 10mL. In an aseptic environment the buffy coat was transferred to a leukocyte 
tube containing separation medium (Chapter 2). The procedure was similar to isolating 













With the current isolation method, a theoretical maximum of 1.3x108 MNCs could be used 
for isolation. Prior to CD34 magnetic cell separation approximately 6.5x107 viable PBMCs 
were isolated per leukocyte cone. With the selected separation technique no more than 6x104 
cells were isolated. After a 2 day culture period in commercially available serum-free 
medium, further described as P-medium (HPC expansion medium (PromoCell))  
supplemented with HPC Cytokine Mix E (PromoCell), all viable cells (1.8x104) were 
analysed by FACS. This HPC Cytokine Mix E contained the cytokines SCF, TPO, Flt3-L, 
and IL-3. Of the total isolated cell population, 88.4% of the cells were positive for CD34 
(Figure 3.6).  
  
 
Fig. 3.5. Leukocyte cone 
with a capacity for 10mL 
Buffy Coat 












This experiment was repeated and after a culture period of 14 days it was found that only 
1.5% of the cell population was CD34 positive (Figure 3.6). During this culture period  cells 
were counted at days 7 and 14 and 9x104 and 1.9x104 cells were found respectively. These 
data show that a HSC culture was not able to maintain a CD34 positive phenotype beyond 7-
14 days. Results in the literature depict a similar picture and long term culture of HSCs 
remains a challenge. The current results also showed that isolating CD34+ cells from PBMCs 





Fig. 3.6. In two experiments the CD34 expression after 2 days (left) and 14 days (right) of 
CD34+ isolated PBMCs from Leukocyte Cones. In the first experiment we harvested 1.8x104 
cells after two days (88.4% CD34+). In the second culture we harvested 1.9x104 cells after 
14 days (1.5% CD34+) 
Day 2            CD34: 88.4% Day 14   CD34: 1.5% 
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3.2.2 Isolation and culture of UCB isolated CD34+ cells 
Another source for HSCs is UCB. To study the expansion of HSCs isolated from UCB 
frozen aliquots of pre-isolated CD34+ cells from fresh blood (kindly provided by Stem Cell 
Biology Lab, University of Leipzig) were used. For the expansion of UCB-CD34+, 2.95x105 
cells were cultured in serum-free P-medium containing HPC Cytokine Mix E at 3x104 
cells/mL. After 10 days, 15.6x106 cells were harvested and subsequently analysed for the 
expression of CD34, CD44, and Hb-β using Flow Cytometry (Figure 3.7). The results show 
that the UCB-CD34+ cells retained their HSC phenotype after a 10 day culture in P- medium. 
At day 10, 7.8x106 cells were subcultured and after an additional 3 days of HSC expansion a 
total of 17.6x106 cells were then collected which were processed for freezing and stored in 









Two types of serum free media, other than P-medium, were tested for the expansion of 
HSCs. One type of medium is a chemically defined basic medium that is also used in the 
erythroid maturation of stem cells: D-medium. The other medium was the commercially 
available StemLine II HSC medium and will hereafter be described as S-medium. Both D-
medium and S-medium were tested during HSC culture in their basic form and when 
supplemented with SCF (100ng/mL) and IL-3 (5ng/mL).  
 
Fig. 3.7. After 10 days of Haematopoietic Progenitor Expansion of CD34+ cells isolated from 
UCB the cells maintained their primitive phenotype with a positive expression of CD34 (93.2%) 
and also  highly positive for the leukocyte marker CD44 (90.9%) while negative for the oxygen 
carrying molecule Hb-β (0.5%) 
CD34: 93.2% CD44: 90.9% Hb-β: 0.5% 















The cell number and cell viability were recorded for these culture conditions at day 0, day 4, 
and day 9 (Table 3.1). Both culture conditions containing cytokines SCF and IL-3 showed a 
high cell viability over 9 days (>95%). The cultures without cytokines did not possess any 
expansion potential. At day 4 the culture containing D-medium without cytokines showed a 
decrease in cell number and viability and after 9 days the cell viability dropped to below 
25%. The cell culture with S-medium, designed for HSC expansion, contained SCF and IL-3 
and showed an expansion of 13.1 fold compared to 2.6 fold for the cell culture with D-
medium containing cytokines. 
 
Over 90% of this HSC population used during this experiment was positive for CD34. Cells 
were cultured at 5x104 cells/mL. These results show that during a 9 day culture, the CD34 
expression decreased dramatically for both D-medium and S-medium lacking cytokines 
(Figure 3.8). The loss of CD34 phenotype for cells cultured in S-medium with SCF/IL-3 was 
less dramatic, but lower when compared to the expression on day 0. 
 
Fig. 3.8. After 9 days of culture the CD34+ expression 
dropped from 93.2% to below 6% for all conditions except for  


































) 9 Day culture period
UCB-CD34+ cells in various media




After establishment and analyses of cultures with UCB-CD34+ cells, the CD34 Magnetic 
Cell Separation method was used to isolate cells from frozen aliquots of UBMCs. This 
method is a standard method to isolate CD34+ cells and is widely used in the literature.  
HSCs isolated from UBMC have a higher expansion potential and a unit of UCB contains a 















Day 0 Day 4 Day 9 
Cell no. Viability Cell no. Viability Cell no. Viability
D-medium (w/o c.k.) 2.5x105 >95% 1.5x105 >80% 6x104 <25% 
D-medium + SCF/IL-3 2.5x105 >95% 3.2x105 >95% 6.5x105 >95% 
S-medium (w/o c.k.) 2.5x105 >95% 2.8x105 >95% 1.1x105 >70% 
S-medium + SCF/IL-3 2.5x105 >95% 1.02x106 >95% 3.28x106 >95% 
Table 3.1. The cell number and cell viability decreased for cultures without cytokines. The 
cell number increased dramatically for the condition with the better optimised HPC 
expansion medium (S-medium + SCF/IL-3). Cell viability remained high (>95%) for culture 
conditioned which contain SCF and IL-3 
 
 
Fig. 3.9. CD34 expression of cells isolated from UBMCs using MACS®. 
The number of CD34+ cells was ~1500 out of a total isolated 4.2x104 
(~3.6%) 
CD34: 3.6%  
Chapter 3 – Results: Haematopoietic Cell Culture 
65 
 
From 5.9x106 thawed UBMCs approximately 4.2x104 cells were isolated using the CD34 
magnetic cell separation method. Of these cells, ~1500 cells were CD34 positive; ~3.6% 
(Figure 3.9).  In a separate cell isolation experiment with a significantly higher number of 
thawed UBMCs (~15x107) approximately 1.9x105 cells were isolated. Analysis with flow 
cytometry showed that ~11.2% of these cells were CD34 positive after a culture period of 7 
days in P-medium with cytokines. After 10 days of culture the percentage of CD34+ cells in 
the population dropped to 3.7% (Figure 3.10). For flow cytometric analysis, 1x105 cells and 










It was observed that not all cultures with CD34+ isolated UBMCs maintained their 
phenotype throughout culture. To stimulate prolongation of CD34 positive phenotype, a 
supportive stromal cell layer of human MSCs was used. The MSCs were either isolated from 
BM, BMSCs, or adipose tissue: adipose MSCs (AMSCs). The medium used was defined 
especially for expansion of HSCs by the Stem Cell Biology Lab (University of Leipzig). 
This medium was named I-medium and during this set of experiments the medium contained 
FCS and cytokines (SCF, Flt3-L, and TPO). Due to insufficient cell numbers this setup could 
not be tested for P-medium.  
 
Morphological images of the co-cultures with UCB-CD34+ cells and either adipose or BM 
stromal cells are shown in the figures below (Figure 3.11-14). The total number of cells 
 
Fig. 3.10. The CD34 expression of CD34 isolated UBMCs decreases over time. 
Day 7              CD34: 11.2% Day 10   CD34: 3.7% 
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recorded in the culture without a stroma was lower than the number of cells cultured on a 
stroma after both 7 and 14 days. The UCB-CD34+ cells on an adipose stromal layer showed 
a round morphology and were distributed on the elongated stromal cells after 7 days of 
culture. During an additional 7 days of culture the cell number increased and the morphology 
remained similar. For the cells cultured on a BM stromal layer a range of cell sizes was 
observed and in some instances the cells were clustered together on day 7. The cell number 
was lower over the first 7 days of the culture and over the additional 7 days the cell 
expansion rate increased, resulting in a higher cell number when compared to the cultures on 
an adipose stromal layer. The cell cultures without a stromal cell layer were less viable at 

















Fig. 3.11. UCB-CD34+ cells cultured in I-medium on adipose isolated 
MSCs showed a round like morphology on the elongated stromal cells at 
day 7. Few cells were close to each other whereas other cells were more 
spread out on the stromal layer. On day 14 the cell density had increased 
compared to day 7. The cells had a round like morphology with a few 
cells now slightly bigger than the majority of the cell population. The 
cells are spread out on the stromal layer 
Day 7 – CD34+ cells on Adipose Stroma 
Day 14 – CD34+ cells on Adipose Stroma 


































Fig. 3.12. UCB-CD34+ cells cultured in I-medium on BM isolated MSCs 
showed a variation in morphologies and different sizes at day 7. Only a 
minority of the cells had a round-like morphology comparable to the 
healthy CD34+ cells from Figure 3.2. On day 14 the majority of the cells 
had a round-like morphology and an increased cell density can be 
observed 
Day 7 – CD34+ cells on BM Stroma 
Day 14 – CD34+ cells on BM Stroma 


































Fig. 3.13. UCB-CD34+ cells cultured in I-medium without a stromal cell 
layer at day 7 did not have a round like morphology for the majority of 
the cell population and a lot of cell debris could be found in the culture. 
At day 14 the number of viable cells has decreased to below 20% and a 
lot of cell debris could be observed, similar to day 7 
Day 7 – CD34+ cells, no Stroma 
Day 7 – CD34+ cells, no Stroma 



























Results obtained with flow cytometric analysis showed for a culture without a stromal layer 
the expression of CD34+ increased between days 7 and day 14 whereas for the BMSC and 
AMSC stromal layers the CD34+ expression decreased (Figure 3.15). During harvest of the 




Fig. 3.14. Morphology of UCB-CD34+ cells in I-medium – This overview shows the various 
stromal cells and the influence on CD34+ cell morphology. After 14 days, the cells on the 





Day 7 Day 14 
Day 7 Day 14 
Day 7 Day 14 
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plastic. When cultured on an AMSC stroma, the relative expression of CD34 increased 
between day 7 and day 21. Due to infections no data was obtained for the cultures with 
BMSC stroma and without a stroma on day 21. The population of cells cultured without a 
supportive stromal layer showed a higher CD34+ expression than the cells on a stromal layer 
but the cell morphology was different to CD34+ cells freshly isolated from MNCs. When 
compared to previous expansion cultures with UCB-CD34+ cells, the percentage of CD34+ 



















Fig. 3.15. The expression of the HSC phenotype marker CD34 on cells cultured with 
and without a supportive MSC stromal cell layer. Due to unexpected premature 
termination of cultures without a stromal layer and with a BMSC stromal layer no 































UCB-CD34+ cells in HSC expansion
Day 7 Day 14 Day 21
Chapter 3 – Results: Haematopoietic Cell Culture 
72 
 
3.3 Analysis of PB-CD34+ cell cultures 
After results were obtained with the various expansion options used for UCB-CD34+ cells, 
the expansion method for PB-CD34+ cells was optimised. The cells were cultured on a 
BMSC stroma in P-medium, I-medium, or D-medium, all cultures containing SCF, Flt3-L, 
and TPO (50 ng/mL). P-medium and D-medium were serum-free, I-medium contained FCS. 
 
The expression of CD34 was analysed with flow cytometry and the results in Figure 3.16 
shows that the percentage of cells expressing the HSC associated antibody decreased 
dramatically over 28 days. PB-CD34+ cells cultured in P-medium showed the lowest 
expression of CD34 between day 7 and day 28 (<20%).  Cells cultured in D-medium showed 
the highest expression at day 7 and over time this decreased the most quickly to ~10% 
positive expression. On day 21, PB isolated cells cultured in I-medium showed overall the 
highest expression of CD34+ (~20%) whereas this was over 50% at day 7 of culture. The 
initial CD34+ expression at day 0 of the culture could not be measured due to insufficient cell 













Fig 3.16. The CD34+ expression of cultured PB-CD34+ cells drops over a 21 day 
culture period. No data for I-medium on day 14 due to insufficient cell numbers for 
analysis. No data for I-medium and D-medium on day 28 due to unexpected 























PB-CD34+ cells in HPC expansion medium 






























The cell number recorded in D-medium was lower than recorded for the P-medium, but the 
fraction of CD34+ cells was higher for D-medium on day 7 (Figure 3.17). Due to insufficient 
cells, no flow cytometric analysis could be performed for cells cultured in I-medium on day 









Day 7 Day 14 
Day 7 Day 14 
Day 7 Day 14 
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RT-PCR was used to confirm a list of genomic markers expressed in isolated cells which 
were able to rapidly proliferate, and then able to differentiate into RBC progenitor cells 
(Chapter 4).  
 
The focus of the first stage of this research was the isolation of HSCs from UCB. The CD34+ 
cell population isolated from UCB was analysed for haematopoiesis-related genes, as stated 
in the literature, in order to create a genomic fingerprint. Genes with a significant role in the 
regulation of the fate of HSCs are members of the GATA, SCL/Tal-1 and RunX families as 
well as HOX-B4. The cell population was also tested for the characteristic HSC/erythroid 
markers CD34, Hb-ß, and EPO [89]. The expression of the preliminary set of genes linked to 
haematopoiesis is listed in Table 2.1 and the data is shown in Figure 3.18 and Table 3.2. 

















Fig. 3.18. List of genes in CD34+ UCB cell-derived MNCs, after isolation from UCB. 
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The preliminary genes list gives a summarisation of haematopoiesis-associated genes. The 
results showed positive expression of the genes in a CD34+ cell population isolated from 
UCB when compared to the positive control (i.e. GAPDH). A 1:10 working concentration of 
cDNA in dH2O had an advantage over a 1:100 concentration due to the lower Ct values 
















Concentration 1:10 Concentration 1:100 
Average Ct StDev Average Ct StDev 
GAPDH 21.4 0.2 25.1 0.2 
CD34 28.5 0.7 32.6 0.3 
GATA2 25.8 0.7 28.1 0.5 
HoxB4 24.7 0.3 28.7 1.1 
Hb-Beta 26.0 0.3 29.3 0.5 
Tal1 27.9 0.2 31.8 0.2 
RunX1 27.6 0.3 30.7 0.3 
EPO 26.0 0.2 29.6 1.0 
Table 3.2. Preliminary gene expression profile of 
haematopoiesis genes which are expressed in CD34+ UCB 
cell-derived MNCs. GAPDH is the housekeeping gene. 
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3.4 Expansion of CD34+ cells within a MNC population 
The obtained results showed that there were issues with establishing viable HSC expansion 
cultures with the aim of providing stem cells for the production of RBCs. Further 
optimisation was needed in order to create enhanced viable HSC expansion cultures. In the 
literature it can be found that Van Den Akker et al (2010) published data which suggested 
that the majority of in vitro erythroid expansion potential resides in CD34 negative cells; 
these cells significantly increased the erythroblast yield from PB  [41]. This principle was 
applied by incorporating MNC-CD34- cells for expansion cultures prior to their 
incorporation for erythroid differentiation studies. 
 
 
3.4.1 Expansion of CD34+ cells within PBMCs  
Expansion cultures with PBMCs were initiated to analyse a possible increase in the output of 
CD34+ cells and potential benefit for long term viability of HSCs. CD34+ cells within the 
isolated MNCs population were allowed to proliferate within a heterogeneous cell population 
which possibly mimics the more natural in vivo conditions. This approach also allowed PB-
CD34- cells to show potential for HSC expansion. Data was analysed using flow cytometry 
and the figures shown in Figure 3.19 and Figure 3.20 depict the typical flow cytometry 











Fig. 3.19. Two typical flow cytometry graphs of positive CD34 expression in 
PBMCs cultured on a BMSC stroma for 21 days (left) and without a stroma cell 
layer for 14 days (right) 












Three types of previously tested media and two types of stromal cells (BMSC and AMSC) 
were used to analyse the CD34+ profile of PBMCs over 21 days. I-medium contained FCS 
whereas P-medium and D-medium were serum free. On day 14, when PBMCs were 
harvested from the co-cultures, a small number of stromal cells were harvested as the stromal 
layer was disrupted. This could have had an effect on the percentage of CD34 expression 
within the analysed cell population cultured under the following conditions: AMSC/I-
Medium, BMSC/P-Medium, and BMSC/D-Medium. 
 
The results show the effect of culture conditions on the CD34 expression profiles and the 
variation in culture conditions. An overview with all combined profiles is shown in Figure 
3.21 with separate detailed profiles in Figures 3.22, 3.23, and 3.24. During the first few days 
of culture a high number of cells died in the first few days. Afterwards, the expansion rate 
increased resulting in a higher number of cells. 
 
The CD34 expression profiles were different for each of the media types used (Figure 3.21). 
To study the results in more detail, expansion profiles were separated for each medium type 
(Figures 3.22, 3.23, and 3.24). Data obtained from cultures in I-medium showed that a 
combination of I-medium and a stromal cell layer elevated the CD34+ expression over 30% 
after 21 days. This was the highest expression amongst all culture conditions. The culture 
 
Fig. 3.20. Two typical flow cytometry graphs of negative CD34 expression in 
PBMCs cultured on an AMSC stroma for 14 days (left) and without a stroma cell 
layer for 21 days (right) 
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without a stromal layer reached its peak at day 14 after which the expression dropped. For all 
conditions, the sharpest rise in CD34 expression was recorded during the first 7 days of 
culture. 
 
Data obtained from cultures containing an AMSC stromal layer showed that the CD34+ 
expression was lower than expected, but could be linked to the harvest of not only the 
PBMCs but also a number of stromal cells. After 21 days the highest level of CD34 






Fig. 3.21. A complete profile overview. The results showed that PBMCs cultured either in I-
medium or on a BMSC stromal layer contained the highest percentage of CD34+ cells. (I=I-




































































Fig. 3.22. Percentage of CD34+ cells within their native PBMC population, cultured 




























Fig. 3.23. Percentage of CD34+ cells within their native PBMC population, cultured 




























Fig. 3.24. Percentage of CD34+ cells within their native PBMC population, cultured in 
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The results for PBMCs cultured in P-medium were different from the results obtained for I-
medium. The relatively low expression of CD34 for PBMCs isolated from the BMSC 
stromal layer on day 14 could be linked to the harvest of a number of stromal cells as the 
stromal layer was severely disrupted after isolation of suspension cells (data not shown). 
There are similarities in the expression pattern for all culture conditions with P-Medium in 
this experiment. For the initial days of culture the expression was ~5% or lower after which 
the expression rapidly increased to 15-20% during the next 7 days. The maximum positive 
expression reached was just over 20% (BMSC stromal layer) after 21 days. 
 
The PBMCs cultured in D-Medium showed a CD34 expression profile that was not as 
elevated when compared to the profile for two other medium types. The culture profile for 
the BMSC stromal layer only showed a relatively high expression for CD34 after 21 days 
when compared to the expression profiles for P-medium. During the 21 day period in D-
Medium, a positive expression for CD34 was 10% and 5% respectively for PBMCs cultured 
on an AMSC stromal layer and cultured without a stromal layer. During the harvest of 




3.4.2 Expansion of CD34+ cells within UBMCs  
The experiments with the PBMCs for HSC expansion potential showed that the BMSC 
stromal layer had the most promising results. Together with the data obtained from cultures 
using I-medium this resulted in the use of a BMSC stromal layer and I-medium in order to 
analyse the HSC expansion potential of UBMCs. The conditions under which these cells 
were cultured were (A) serum free I-Medium without cytokines with a stromal layer, (B) 
serum free I-Medium containing cytokines SCF/Flt3-L/TPO without a stromal layer, and (C) 
serum free I-medium without cytokines or stromal layer. To stimulate improved adherence 
of the BMSC stromal cells, to prevent premature detachment, the tissue cultured treated 
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plastic was coated with 0.3% gelatine. Subsequently the BMSCs were cultured for 72 hours 
before becoming confluent. Proliferation of BMSCs was inhibited by incubation with 
Mitomycin C overnight.  
 
The UBMCs were cultured at 3x104 cells/mL and cells were exposed to serum-free ‘I-
medium’ either with or without cytokines. The cell numbers were monitored to obtain 
additional quantitative data in order to draw reliable conclusions regarding the increase in the 
number of CD34+ cells. The previous experiments showed that a period of 21 days and 
shorter might not have shown the full potential of MNC long term cultures for HSC 
expansion. Over a period of 28 days, cells were analysed using a haemocytometer and flow 
cytometry (Figures 3.25 – 3.29). Due to low cell numbers, cells were analysed for two 
antibody markers only (CD34 and CD45). The latter antibody is associated, in combination 
with CD34, as a HPC marker [90]. CD45 was only applied to cell samples isolated from 
















Fig. 3.25. An overview of the cell numbers for UBMCs in HSC expansion (n=3, error bars 
represent StDev). [w/ stroma w/o c.k. = with a BMSC stromal layer/without cytokines] - 
[w/o stroma w/ c.k = without a stromal cell layer/with cytokines (SCF/TPO/Flt3-L)] - [w/o 


















UBMCs in HSC expansion
w/ stroma w/o c.k.
w/o stroma w/ c.k.
w/o stroma w/o c.k.

















For all three culture conditions at least 75% of the cells did not survive the first 7 days. With 
either a stromal cell layer or cytokines available, the number of UBMCs increased over the 
next 14 to 21 days. The culture without a supportive cell layer and no cytokines was a non-
viable cell culture condition. The UBMCs supported by a BMSC cell layer hardly 
proliferated during the first two weeks of culture (~35x103 cells on day 15) before the cell 
number increased dramatically to ~160x103 cells. In comparison, the cell numbers for a 
culture with cytokines SCF, Flt3-L, and TPO were ~100x103 cells (day 15) and ~60x103 
(day 28) cells. The relative expression of CD34 during all culture conditions increased over 
the first 7 days when most of the cells died. The relative number of cells with a CD34+ 
phenotype decreased over the subsequent 21 days. The cells cultured on a stromal cell layer 
showed the overall highest expression throughout the entire culture period; ~20% at day 7 
(~10% at day 28). The highest CD34+ expression for cultures with cytokines was ~10% at 
day 7 (~3% at day 28) whereas this was ~13% for the cultures without cytokines and without 
a supportive cell layer (0% at day 28). 
 
Fig. 3.26. The relative positive expression of CD34 within each culture condition for up to 
28 days (n=3, error bars represent StDev).  [w/ stroma w/o c.k. = with a BMSC stromal 
layer/without cytokines] - [w/o stroma w/ c.k = without a stromal cell layer/with cytokines 
























Expression of CD34 on UBMCs
w/ stroma w/o c.k.
w/o stroma w/ c.k.
w/o stroma w/o c.k.
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The result depicted in Figure 3.27 shows information about absolute number of CD34 
positive HSCs present in the culture. The number of CD34+ cells remained stable (~3x103 
cells) throughout the culture condition with cytokines for 28 days. For the culture condition 
without a BMSC stromal layer/without cytokines the number of cells expressing CD34 
decreased to ~0.2x103 (day 10) and ~0.1x103 (day 15). The condition where the number of 
CD34+ cells did increase contained a stromal cell layer. During the first 14 days the increase 
was slow (up to ~5x103 cells) whereas the increase was more prominent in the last 14 days 
















The percentage of cells with a CD45 phenotype cultured on a BMSC stromal layer dropped 
from 100% to ~30% within 10 days. For UMBCs in medium with cytokines the percentage 
of CD45+ cells dropped to ~20%. During the next 18 days of culture, both cell populations 
reached an expression lower than 20% for cells with a CD45 phenotype. 
 
 
Fig. 3.27. The absolute number of cells expressing the CD34 marker over a 28 day culture 
period (n=3, error bars represent StDev). [w/ stroma w/o c.k. = with a BMSC stromal  
layer/without cytokines]- [w/o stroma w/ c.k = without a stromal cell layer/with cytokines 
(SCF/TPO/Flt3-L)] - [w/o stroma w/o c.k. = without a stromal cell layer/without cytokines] 

















Expansion profile of CD34+ cells
w/ stroma w/o c.k. (CD34)
w/o stroma w/ c.k. (CD34)
w/o stroma w/o c.k. (CD34)
































Fig. 3.28. The relative positive expression of CD45 within each culture condition for up to 
28 days (n=3, error bars represent StDev). [w/ stroma w/o c.k. = with a BMSC stromal  
























Expression of CD45 on UBMCs
w/ stroma w/o c.k.
w/o stroma w/ c.k.
 
Fig. 3.29. The absolute number of cells expressing the CD45 marker in direct comparison 
with the total cell number in the culture (n=3, error bars represent StDev). [w/ stroma w/o 
c.k. = with a BMSC stromal layer/without cytokines] - [w/o stroma w/ c.k = without a 
stromal cell layer/with cytokines (SCF/TPO/Flt3-L)] - [(CD45) = Number of CD45 positive 

















Number of CD45+ cells
w/ stroma w/o c.k. (CD45)
w/ stroma w/o c.k. (Total)
w/o stroma w/ c.k. (CD45)
w/o stroma w/ c.k. (Total)
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The number of cells, overall and CD45 positive cells, decreased during the first 15 days of 
culture before increasing during the last two weeks of culture. At day 28, a total of ~160x103 
cells including ~30x103 CD45+ cells were counted for the culture containing a stromal cell 
layer. For the UBMCs cultured with cytokines present in the medium, the overall cell 
number fluctuated whereas the number of CD45+ cells decreased during the first 10 days of 































During the first 7 days of culture cell viability was relatively high for the UBMCs cultured 
without a stromal layer/cytokines (top images Figure 3.30). For the remaining three weeks of 
culture slightly bigger cells were observed when compared to days 1 and 3. More cell debris 
was present in the culture after day 10. At day 28, only a few viable cells were observed, the 






Fig. 3.30. An overview of UBMCs cultured without a stromal layer and without cytokines - 
Day 1 and 3, Day 7 and 10, Day 15 and 28 (left to right, top to bottom) 
Day 1 Day 3
Day 7 Day 10
Day 15 Day 28 



































Fig. 3.31. An overview of UBMCs cultured on a BMSC stromal layer - Day 1 and 3, Day 7 
and 10, Day 15 and 28, Day 28 and 28 (left to right, top to bottom) 
Day 1 Day 3
Day 7 Day 10 
Day 15 Day 28
Day 28 Day 28 
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For UBMCs cultured on a BMSC stromal layer, the cell number dropped during the first 
days of culture and this was reflected by the images shown in Figure 3.31. Few round shaped 
cells were observed on the elongated cells of the stromal layer. On day 15, an increase in cell 
number was observed. The three images representing the cultures on day 28 show various 
sections of the cultures with a high number of cells at the centre of the well and a less 
populated at the edge of the well. 
 
When cells were cultured without a stromal layer in medium containing cytokines, cells with 
a round like morphology were observed (Figure 3.32). For this culture, there were fewer 
cells present on day 15 compared to the culture with the stromal layer. Cell debris was 
observed and in addition, the cells were smaller. On day 28, a higher number of cells was 
observed. These cells were smaller in size compared to the other culture conditions and cell 








































Fig. 3.32. An overview of UBMCs cultured without a stroma and with cytokines - Day 1 and 
3, Day 7 and 10, Day 15 and 15, Day 28 and 28 (left to right, top to bottom) 
Day 1 Day 3
Day 7 Day 10
Day 15 Day 15
Day 28 Day 28 
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The previous results showed that a BMSC stromal layer had a positive influence on the 
expansion of CD34 positive cells. In the following experiment cytokines were added to 
standard serum free I-medium where in one culture condition a BMSC stomal layer was 
present (w/ stroma) and in a second culture condition the stromal layer was not present (w/o 
stroma. This is different from previous experiments were either a stromal layer or cytokines 
were present. The results (Figure 3.33) showed that over 7 days, the expression of CD34 
increased the most when the UBMCs were cultured in the presence of a BMSC stromal layer 
(30%). Table 3.3 shows that this percentage represented a total of ~440x103 CD34 positive 
cells. In the culture condition without an additional stromal cell layer the positive expression 




















Fig. 3.33. The relative positive expression of CD34 within each culture condition. The 
culture medium contained the cytokines SCF/TPO/Flt3-L. The UBMCs were cultured 
either with or without a BMSC stromal layer (n=3, error bars represent StDev). 
[w/ stroma w/ c.k = [with a BMSC stromal layer/with cytokines (SCF/TPO/Flt3-L)] - 

























UBMCs in HSC expansion: 
I-medium
w/ stroma w/ c.k.
w/o stroma w/ c.k.
p<0.01
Cell Number (#) CD34+ (%) CD34+ (#) 
Day 0: after isolation 300*103 1.7 ~5.1*103 
Day 7: with BMSC stromal layer / 
            with cytokines 1,410*10
3 30.9 ~440*103 
Day 7: without BMSCstromal layer /    
            with cytokines 
90*103 18.2 ~16*103 
Table 3.3. The absolute number of total cells and CD34+ cells from the UBMCs culture for 
HSC expansion 
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The total number of cells obtained with the culture containing a BMSC stromal layer and 
medium containing cytokines was ~50 times higher than the cell number obtained at day 7 of 
a previous experiment with only a BMSC stromal layer to support the UBMCs for HSC 
expansion (Figure 3.25). In both the previous and current experiment the total number of 
cells for the culture condition containing only cytokines was 25x103 cells and 90x103 (~3.5 
times higher). The UBMCs were cultured at the same cell density. 
 
In an optimised repeat of this experiment with 6x103 cells/mL, instead of 3x103 cells/mL in a 
previous experiment, the percentage of positive CD34 expression was similar for the 
condition with medium containing cytokines and with a stromal layer, but the number of 
CD34+ cells was more than twice as high. The efficiency for the culture condition containing 
cytokines only (without stromal layer) was not as high as in the previous experiment: 

















Fig. 3.34. Expansion of CD34+ cells within a population of UBMCs. For condition ‘A’ the 
percentage of CD34+ cells rose from ~3% (day 0) to ~30%, for ‘B’ ~23%, and for ‘C’ ~8% at 










A: w/ stroma w/ c.k. 
(299,667)
B: w/ stroma w/o c.k. 
(51,667)
C: w/o stroma w / c.k. 
(96,667)

















(..) shows total cell number at day 7:  day 0 = 300,000 UBMCs)









HSCs were isolated from PB with purity rates over 80%. Expansion potential was minimal 
(< 7 days) with low numbers of CD34+ cells: < 105 CD34+ cells from ~7x107 PBMCs. 
Thawed UCB-CD34+ cells were successfully expanded for over 10 days whereas CD34+ 
cells isolated from thawed UBMCs showed low purity rates and expansion potential was 
minimal. 
 
To improve prolonged cultures from fresh PB isolated cells and from thawed UCB isolated 
cells, CD34+ cells were cultured in an environment including a stromal cell layer and MNCs. 
A number of cell populations in a variety of HSC expansion conditions contained over 30% 
CD34+ cells up to 21 days. The culture condition with the highest expansion fold of CD34+ 
cells, over 7 days, (~85x fold) contained UBMCs in I-medium including cytokines on a 
BMSC stromal layer. 
 
The results obtained led to the optimisation of the stem cell environment to stimulate 
expansion output of CD34 positive cells. These data were subsequently used to create an 
environment to promote and sustain the differentiation of these CD34+ HSCs into RBCs 








The establishment of HSC expansion for the first time in this laboratory was paramount for 
increasing the cell input during erythroid maturation. Therefore the question for this research 
topic was formulated as ‘How to establish and optimise in vitro HSC expansion as a 
sufficient source of cells for the manufacturing RBCs?’. 
 
The main challenge was to isolate and expand CD34+ cells with their short-lived phenotype, 
compared to other cell types (e.g. MSCs, dental pulp stem cells (DPSCs)), which maintain 
long-term expansion cultures. 
 
For the proliferation of HSCs a source of these CD34+ cells was needed and both PB and 
UCB were either available directly or via research partners. These two sources were 
analysed for their CD34+ isolation potential in this project. The stem cells were either 
isolated from fresh PB or frozen aliquots of UBMCs. The magnetic bead cell separation 
technique to isolate CD34+ cells from fresh PB showed high efficiency rates with >80% of 
the cells showing positive for CD34. This technique is commonly used with comparable 
efficiency rates [91-93].  However, the number of CD34+ isolated cells was too low (~104 
cells from ~107 MNCs) to initiate larger scale expansion cultures. These numbers 
corresponds with figures stated in the literature but usually higher quantities of MNCs were 
obtained in those studies: ~108 MNCs from >250mL of blood [41].  
 
In this project only 30-50mL of blood could be obtained per patient, which was restrictive 
for HSC isolation. An alternative cell source for PBMCs was buffy coat preparations 
provided by the NHS in a 10mL leukocyte cone. These cones contained a concentrated cell 
volume with the aim to obtain higher numbers of PBMCs for CD34+ isolation. Due to the 
time intervals allowed for processing and travel of this tissue, only ~6x107 viable MNCs 
were present and subsequently ~6x104 cells were isolated utilising the CD34 magnetic bead 
separation technique. Although this cell population proved highly positive for CD34 after 
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several days of HSC expansion, only 104 viable cells could be obtained. Overall, these 
results together with the low number of MNCs and quality of the provided buffy coat 
resulted in the decision not to use these cells as a prime source in this project.  
 
With limited quantities of PB available and low harvest rates from PBMCs, it was decided 
that UBMCs would be obtained from fellow research groups (i.e. project partners). UCB-
CD34+ were analysed for HSC expansion potential under various conditions to determine the 
optimal culture environment. All experimental setups aimed to generate as many progenitor 
cells as possible, eventually to be used for erythroid maturation.  
 
UCB is known for containing a higher percentage of HSCs and a higher expansion potential 
of stem cells when compared to PB [56]. Due to the various geographical locations of 
collaboration research centres, UBMCs were aliquoted and processed for freezing on site, 
shipped frozen, stored in LN2 and thawed upon use in this laboratory (described in Chapter 
2). The thawing protocols used were supplied by the same research centres. The aliquoted 
UBMCs were single donor instead of pooled donor aliquots, and therefore the quality varied 
between UBMC aliquots.  
 
The thawed UCB-CD34+ cells proved successful for HSC expansion for up to 10 days in 
commercially available medium (P-medium) with a 50x expansion fold over 10 days. This 
chemically defined medium, free of animal and human-derived components except Human 
Serum Albumin, required the addition of a commercially defined cytokine mix containing 
SCF, TPO, Flt3-L, and IL-3 for increased HSC expansion potential. Chemically-defined 
media without xenogeneic components and preferably allogeneic components is important 
for eventual use in human cell therapies [64, 94]. 
 
For all cell sources a culture density of 3x104 cells/mL was used for HSC expansion. P-
medium was also used for the expansion of PB-CD34+ cells isolated from buffy coats. In 
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comparison, after 14 days of expansion these PB-CD34+ cells did not express an HSC 
phenotype (Figure 3.6) whereas the population UCB-CD34+ was still considered positive for 
CD34+ after 10 days of culture (Figure 3.7). This data with this degree of expansion potential 
of UCB cells matched published data [95].  
 
 
3.6.1 Media for HSC expansion 
P-medium stimulated expansion of fresh PB-CD34+ and thawed UCB-CD34+ cells with rates 
similar to those found in the literature. UCB-CD34+ cells were also used to analyse 
expansion, while aiming to maintain the CD34+ phenotype, with basic medium tailored for 
erythroid maturation (D-medium) and HSC expansion (S-medium) supplemented with and 
without cytokines used in HSC expansion: SCF and IL-3. Whereas the D-medium was 
expected not to maintain the CD34+ phenotype, it was hypothesised that the S-medium 
containing SCF/IL-3 would positively influence expansion of CD34+ cells. This proved 
correct with this S-medium option resulting in a positive expression of ~24% whereas the 
results of the other three media options were regarded negatively with an expression lower 
than 6% (Figure 3.8). The expansion fold and viability were highest for S-medium (SCF/IL-
3) however, the overall result being not as positive as hypothesised for HSC expansion and 
inferior in comparison to complete P-Medium. This could be the result of a different 
cytokine cocktail or due to a difference in the basal formulation of these two commercially 
available media. D-medium contained BSA whereas both P-medium and S-medium 
contained human serum albumin.  
 
The research group in Leipzig, who specialised in HSC research, recommended the use of I-
medium; optimised for HSC expansion and could either be used with FCS or BSA. The use 
of the cytokines SCF, TPO, and Flt3-L was advised for optimal HSC expansion with I-
medium. The basic component of I-medium, IMDM, is widely used for the expansion of 
HSCs [55, 71, 96]. A range of cytokine concentrations is used in the literature and the 
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concentration used in this study was based on results provided by our research partners and 
published data [76, 96-98]. There was limited access to CD34+ cells during this stage of the 
project which denied direct comparison of I-medium and P-medium for HSC expansion. 
 
 
3.6.2 Isolation and culture of UCB-CD34+ cells 
The access to frozen aliquots of UCB-CD34+ was restricted but the availability of frozen 
aliquots of UBMCs was ample for studying HSC expansion. Established protocols were used 
for thawing aliquoted UBMCs and subsequent CD34+ magnetic cell separation. Cell 
separation was unsuccessful with extremely low CD34+ positive expression of isolated cells. 
Insufficient availability of cell numbers allowed either in post-isolation cell analysis but not 
expansion, or expansion without post-isolation cell analysis. Complete P-medium was used 
for cell proliferation but due to low cell numbers available for culture expansion of thawed 
and isolated UCB-CD34+, expansion fold rates were minimal over a 10 day culture period.  
Published studies generally do not state whether fresh CB, frozen CB, or frozen UBMCs 
have been used. Researchers analysed various thawing methods demonstrating that a certain 
percentage of cell death is unavoidable within the first 48 hours after thawing [99, 100]. This 
was also observed for thawed aliquots, when UBMCs were used for either cell separation or 
cell culture. 
 
In general, the cell cultures with magnetic bead isolated UCB-CD34+ cells struggled to fully 
revive and expand after thawing. With the aim of solving this issue, the literature was 
analysed to optimise culture conditions for these cells. Previous studies reported on the 
support of UCB-CD34+ cells by co-culture with MSCs to stimulate maintenance of HSCs 
over a prolonged period [48, 98]. In this project, these published methods were utilised: 
AMSCs and BMSCs were used in the co-culture to support prolonged HSCs expansion with 
FCS-containing complete I-medium. The use of an AMSC supportive layer indicates an 
advantage for cell expansion by maintaining cell morphology over 14 days with ~49% of the 
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population being positive for CD34 after 14 days. The BMSCs supported a higher cell 
expansion of UCB-CD34+ over 14 days and around 44% of the population showed CD34+ 
after 2 weeks. These results indicate a positive contribution of a stromal cell layer when 
compared to a non-co-culture over a prolonged period when fewer cells and a large quantity 
of cell debris were observed. In addition, the co-culture results are in keeping with data from 
the literature for the maintenance of the HSCs [48]. 
 
3.6.3 Culture conditions of PB-CD34+ cells 
The PB-CD34+ isolated cells were cultured on a BMSC supportive cell layer to stimulate 
prolonged maintenance of HSCs as performed with UCB-CD34+ cells. Whereas there was 
sufficient cell expansion with P-medium and D-medium, cell expansion was negligible in I-
medium. However, the expression of CD34 was either lower than 40% (day 14) and 30% 
(day 21) for a number of culture conditions, or expression was barely detectable (Figure 
3.16). Overall, both the expansion fold rate and percentage of CD34 cells were low for all 
culture conditions. AMSCs were used in a similar setup to UCB-CD34+ previously discussed 
but due to low cell numbers this was done in series rather than in a parallel setup. However, 
these results led to a change of focus to use MNCs for HSC expansion and so PB-CD34+ 
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3.6.4 PBMCs and UBMCs in HSC expansion conditions 
With the ongoing challenge to culture sufficient CD34+ cells over a prolonged period the 
project started the utilisation of MNCs for HSC expansion. The literature showed evidence 
of stimulation of CD34- PBMCs towards erythroid maturation [41]. The approach used for 
expanding UCB-CD34+ cells was applied for the HSC expansion of MNCs; three types of 
media and stromal layers were analysed for optimal expansion potential.  
 
In the first instance, PBMCs on a BMSC stromal layer cultured in I-medium containing 
cytokines showed the most promising results with a positive CD34 expression increasing 
from ~0% at day 0 to over 30% (day 14 and 21). The culture conditions having an AMSC 
stromal layer or no stromal layer, both containing the same cytokine cocktail, only showed a 
positive CD34 expression of ~20% or lower over 21 days. This culture environment with I-
medium and a BMSC stromal layer was used to study the expansion of MNCs in more detail. 
 
The UBMCs, all single donor, showed a drop in cell number during the first 3 to 7 days of 
culture as MNCs also contained non haematopoietic sensitive cells being exposed to a HSC 
optimised culture environment (Figure 3.25). This initial drop in cell viability was regarded 
as normal as comparable data was published [41]. The culture condition with only a stromal 
layer showed a higher increase in viable cells compared to medium with only cytokines, 
indicating that the stromal cells are important for cell viability and expansion. The number of 
CD34+ cells increased during the first 7 days of culture and over 28 days a fold expansion of 
~7 was recorded which was lower than the 52 fold increase for UCB-CD34+ cells during a 
10 day culture in P-medium.  
 
UBMCs cultured at 3x104 cells/mL in the presence of cytokines (no stromal layer) resulted 
in a minimal expansion of CD34+ cells. When the cell density was increased to 6x104 
cells/mL, the expansion was negative (Figure 3.34). This could indicate that insufficient 
cytokines were available to fully stimulate the UBMCs, resulting in non-optimal culture 
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conditions. The highest expansion fold obtained for CD34+ cells was ~85x for UBMCs 
supported by a BMSC stromal layer and cytokines, which is comparable to the values stated 
in the literature [101]. This was the ‘richest support’ for UBMCs in HSC expansion in terms 
of access to biological stimuli and at the same time this environment provided the best 
outcome for the proliferation of CD34+ cells from MNCs. 
 
As the BMSCs and AMSCs were harvested from a range of donors, differences were 
observed in the expansion rates of these MSCs from different donors. Some donors only 
produced cells with a very low expansion rate. During this project only MSCs were used 
with a normal expansion rate, but other possible differences between donors of MSCs were 
not investigated. This donor variability was also applicable to the single donor UBMCs and 
PBMCs used. Preferably, pooled donor MNCs should be used to minimise individual donor 
variability but due to the source of these cells the pooling of cells was not possible. 
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4.1 Introduction  
RBCs are produced in the human body and for decades scientists have focussed on 
translating this process into the laboratory. The ex vivo manufacture of RBCs has been 
achieved from HSCs [42]. Now, the focal point has shifted towards the optimisation of these 
cultures as part of a mission to find an alternative method for blood transfusion. As discussed 
in Chapter 1, at the current time, the supply of blood products is insufficient to keep up with 
the needs for medical treatments. Therefore, production and implementation of artificial 
blood products should, in turn, resolve the issues associated with conventional blood 
donation.  
 
A key challenge is the creation of sufficient numbers of RBCs from a single HSC and the 
target is now to scale up the expansion of RBCs. In current blood transfusion practice the 
volume of a unit of blood is approximately 500mL, and contains ~2500 billion RBCs [102]. 
Therefore, in theory it is possible to produce a few units of RBCs ex vivo from one unit of 
UCB, but there are practical restrictions. For example, the manufacture of 1 unit of RBCs, 
with a working cell density of 5x106 cells/mL, requires a culture surface the size of at least 
two tennis fields and ~40 litres of media (worth over $8000,-) [54]. In addition, upscaling 
from 2D culture flasks to 3D cultures in bioreactors is of paramount importance to achieve a 
higher cell density in order to reduce surface culture and medium volume. Other 
improvements can be achieved by creating a higher number of erythroid precursor cells 
during haematopoiesis (Chapter 3). Attempts to increase the output of RBCs will be 
described in this chapter.  
 
A number of studies have abandoned the supportive cell layer as part of the cell 
differentiation process [49, 53]. One reason for such an alteration includes the possible 
upscaling to dynamic 3D cultures where a second, adherent, cell line will prove difficult. 
Another argument for feeder free cultures is the complexity of establishing and maintaining 
co-cultures of mixed cell populations. Feeder free cultures for erythroid maturation (EM) 
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proved to be challenging in efficient enucleation and Hb synthesis in terminal maturated 
cells [49]. But optimising the concentration of cytokines and additional medium stimuli may 
fine tune these processes to culture RBCs of similar quality when a feeder layer is available 
[43, 103].  
 
The majority of research has focussed on the erythroid maturation of CD34+ HSCs which 
have been isolated from BM, PB, and UCB. For years a supportive stromal layer has been 
used during the erythroid maturation of HSCs [42] and during this research project this 
particular method was utilised as outlined in Chapter 2. Here, the starting cell density was 
104 cells/mL for phase I using IMDM medium (Invitrogen), named D-Medium during this 
project, containing 100 ng/mL SCF, 5 ng/mL IL-3, 5 U/mL EPO and 10-4 M hydrocortisone 
(Day 0-8). During phase II, day 8-11, the cell density was 104 (PB), 4x104 (UCB), or 6x104 
cells/cm2 on a confluent BMSC stromal layer (feeder layer) and D-medium was used 
containing 5 U/mL EPO. At day 11, the cells were washed to remove any residual EPO and 
transferred back to the cultures containing the stromal layer and D-medium. Cells were 
maintained up to an additional two weeks. 
 
The decision to use not only PB-CD34+ and UCB-CD34+ cells in this study, but also to 
include MNCs was based on data published by Van den Akker et al (2010) who compared 
CD34+ cells, CD34- cells, and PBMCs for erythroid maturation, in combination with the 
limited access to PB and UBMCs for the isolation of sufficient numbers of CD34+ cells.  
Van den Akker et al also reported on an alternative approach to boost the erythroblast yield 
from PB samples. They isolated CD34- cells and CD34+ cells from PBMCs and showed that 
the output for CD34- cells contained the most significantly number of early erythroid 
progenitors [41]. Another study reported on the depletion of CD3+ and/or CD14+ cells from 
UBMCs to stimulate the ex vivo expansion potential of CD34+ cells [59]. These studies 
showed that the CD34+ HSCs within the heterogeneous MNC population (UCB, PB) were 
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affected by surrounding cells and that the research area which includes CD34- MNCs for the 
manufacture of RBCs requires further in depth analysis.  
 
In short, the first aim of this study was to produce RBCs from PB and foremost UCB 
isolated cells.  The second aim, as outlined in this chapter, was to research methods that 
allowed for improving the expansion rate of these cells and subsequently advance the 
erythroid maturation rate. 
 
The hypothesis of this chapter is: Can the erythroid maturation be maximised by optimising 
the input of cells during the differentiation process? 
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4.2 Erythroid maturation of PB-CD34+ cells 
After successful isolation of CD34+ cells from PBMCs, including the expansion of these 
cells, we used this source of cells to introduce a culture to an environment for erythroid 
maturation and analyse cell behaviour. 4.92x107 PBMCs were used for the magnetic 
isolation of CD34+ cells. Approximately 1.5x105 cells were isolated and cultured at 3x103 
cells/mL in a 12 well plate containing (serum free) D-medium including EPO, SCF and IL-3. 
At the end of a 7 day culture period, phase I of erythroid maturation, a total of 1.6x105 cells 
were collected and transferred to wells containing a BMSC stromal layer and D-medium 
containing EPO. Figure 4.1 shows the cells on a stromal layer. A low cell number was 
observed during this second phase of erythroid maturation. Minimal cell proliferation in 



















Fig. 4.1. Morphology on day 9 of erythroid maturation; a co-culture of HSCs and BMSCs in EPO 
containing D-medium 
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4.3 Erythroid maturation of UCB-CD34+ cells 
Unsuccessful erythroid maturation of PB-CD34+ cells resulted in a process to optimise 
CD34+ expansion and differentiation methods. UBMCs were previously used for the 
optimisation of HSC cultures and in this experiment UCB-CD34+ cells were  analysed for 
their maturation into RBCs. UCB-CD34+ cells were thawed and ~3x105 cells were cultured 
at 3x104 cells/mL in D-medium containing SCF, EPO, and IL-3. When cells were 
subcultured at day 4, the cell density was increased to 6x104 cells/mL.  
 
At the start of the second phase of erythroid maturation (day 10), ~2x106 cells were collected 
and 5x105 of these cells were subcultured in a co-culture with confluent BMSCs at 5x104 
cells/mL in D-medium containing EPO. The remaining cells were analysed by flow 
cytometry for the surface markers CD34 (HSC marker [104]) and CD44 (found on HPC 
subpopulation of MNCs [105] and erythroid cells [4, 106]) in addition to the presence of Hb-
β (Figure 4.2). Surface molecule CD44 also participates in the adhesion of HSC to stromal 
cells [48, 107]. The cell population was 92.9% positive for CD34 whereas this was 82.8% 
positive for CD44. When the cells were analysed for Hb-β using a cell permeability kit and 
flow cytometry 90.9% of the cells showed a positive expression. 
 
Cell morphology was monitored during the third phase of the erythroid maturation culture. 
An overview of the culture at day 12 (Figure 4.3A) showed cells in suspension on top of a 
stromal cell layer (elongated, adherent cells). The cells in suspension varied in size with the 
biggest cells of a similar size as UCB isolated cells (Figure 1.3). The smallest cells had 
approximately half the diameter of the largest cells. The higher magnification image (Figure 
4.3B) provides a clear picture with the suspension cells on top of the stromal cell layer. At 
day 12, a pellet of these cells showed for the first time a red colour similar to a pellet of 
RBCs and this was maintained throughout the remaining culture period (data not shown). 
After 20 days of culture, an overview image (Figure 4.4A) showed a dense populated cell 
culture. During 20 days of differentiation, the majority of the cells changed morphology and 
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Fig. 4.2. After 10 days of erythroid maturation, day 
2 of phase II, the cell population was analysed for 








































Fig. 4.3. Morphology of UCB-CD34+ cells on a stromal cell layer after 12 days of 
erythroid maturation: overview (A) and higher magnification (B) 
(A) 
(B) 





























Fig. 4.4. Morphology of UCB-CD34+ cells on a stromal cell layer after 20 days of 
erythroid maturation: overview (A) and higher magnification (B) 
(A) 
(B) 
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At day 24, cells were examined after staining with the histology stain BCB as shown in 
Figure 4.5. This histological examination is a method to visualise erythrocyte generation by 
the presence of reticuloctyes. After staining with BCB, the reticular filaments should appear 
deep blue against a pale blue background. In this figure, cells marked with a black arrow 
have a dark pink colour and pale grey cells with a number of darker dots were marked with a 
red arrow. The cells with a black arrow were ~5-7µm in diameter whereas the red arrow 
marked cells were slightly larger in size. Larger cells (>20µm in diameter) with a purple-
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At days 18, 21, and 24 cells were analysed for three different antibodies using flow 
cytometry (CD34, CD44, and Hb-β). In this particular experiment, it was found that the 
CD34+ expression remained high during the initial 10 days of culture. After an additional 
culture period of 8 days (day 18) the percentage of cells containing the CD34+ marker stayed 
above 10%. After an additional 7 days of erythroid maturation of this cell population, an 
overall lowest percentage of positive CD34 expression was recorded: 11.7% at day 25 
(Figure 4.6A). This same graph showed how the expression of CD44, dropped when 
compared to previously collected data (Figure 4.2B). From ~80% positive at day 10, the 
percentage of cells with a CD44 antibody reached ~55% at day 18 and was ~15% after 21 
and 25 days (Figure 4.6A). 
 
During the same culture period as stated above, the highest percentage of cells containing 
this oxygen carrying molecule Hb-β was ~95% at day 25 (Figure 4.6A). There was an 
increase in cells containing Hb-β during the last week of culture with ~50% of the cell 
population on day 18 and ~80% on day 21. Figure 4.8B shows the change in marker 
expression between day 10 and day 25 of erythroid maturation. This graph shows clearly 
how the expression of CD34 and CD44 diminished whereas the percentage of cells 









































Fig. 4.6. Flow Cytometry graphs (A) and accompanying overview (B) of cell markers important in 

































Day 18-CD34: 12.9% Day 18-CD44: 53.2% Day 18-Hb-β: 48.9%
Day 21-CD34: 12.6% Day 21-CD44: 14.3% Day 21-Hb-β: 82.6% 
Day 25-CD34: 11.7% Day 25-CD44: 18.2% Day 25-Hb-β: 94.2% 
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4.4 Erythroid maturation of UBMCs 
In the previous chapter, HSC expansion of PBMCs and UBMCs including the growth of 
CD34+ cells with a heterogeneous population was documented. These results combined with 
data published [41] resulted in the use of UBMCs for the manufacture of RBCs. 
 
To analyse the erythroid potential of UCB-isolated MNCs, including a majority of CD34- 
cells, UBMCs were first expanded under different HSC expansion conditions before the cells 
were introduced to the three phases of erythroid maturation as described before [42] and 
used in previous experiments (Chapter 3).  
We defined three HSC culture conditions to pre-treat UBMCs from day -7 (start expansion) 
up to day 0 (start erythroid maturation): 
•  (A) = UBMCs on a MSC stroma using I-medium containing cytokines (50 ng/mL of 
SCF/TPO/Flt3-L); 
• (B) = UBMCs using I-medium containing cytokines (50 ng/mL of SCF/TPO/Flt3-
L); 
• (C) = UBMCs on a MSC stroma using I-medium without cytokines  
 
In the subsequent phase, during erythroid maturation, cells from conditions (A), (B), and (C) 
were used and compared with UBMCs without pre-culture treatment (D). All erythroid 
maturation cultures used D-medium containing 100 ng/mL SCF, 50 ng/mL IL-3 (A, B, and 
C) or 5 ng/mL IL-3 (D), 5 U/mL EPO and 10-4 M hydrocortisone for 8 days. Next, the cells 
were transferred to cultures containing a BMSC stromal layer and D-medium containing 5 
U/mL EPO. After 2 days the cells were washed to remove any residual EPO and placed back 
in to the cultures containing a BMSC stromal layer and D-medium without cytokines for up 
to 14 days. During this culture period the cell numbers and erythroid maturation markers 
were analysed. 
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For the first 7 days, pre-erythroid maturation at day 0, the cell number decreased for (B) and 
(C), but when UBMCs were cultured in medium containing cytokines and in the presence of 
a stromal layer the cell number increased 5 fold (Figure 4.7). At day 0, culture (A) contained 
~440x103 CD34+ cells (30.9%), culture (B) contained ~20x103 CD34+ cells (18.2%) and 
culture (D) contained ~13x103 CD34+ cells (4.4%). No cell count was performed for culture 
(C) due to insufficient cell numbers. For all cultures, the highest cell number during the 
erythroid maturation was recorded at day 15. At day 10, a high number of suspension cells 
adhered to the stromal layer and this explained the low recorded cell number for culture (C).  
 
Overall, the culture without any pre-HSC expansion (D) showed the highest cell number 
throughout the entire culture period and at day 24 a total of ~1.2x106 cells were harvested. 

















Fig. 4.7. Overview of viable cell numbers during initial expansion of UBMCs; day -7 – 0 
(A-C) and during erythroid maturation; day 0 – 24 (A-D). The bars represent data from 
condition D, the lines represent data from the conditions undergoing expansion and 




















Expansion and Maturation 
D: direct E.M.
A: w/ stroma w/ c.k.
B: w/o stroma w/ c.k.
C: w/ stroma w/o c.k.


























The cells depicted in Figure 4.8 show BCB-stained MNCs at day 9 of erythroid maturation. 






Fig. 4.8. Cells stained with BCB at day 9 of direct EM (Condition D) 


























At day 16, MNCs in erythroid maturation were stained with Methylene Blue to distinguish 
cells with a nucleus from enucleated cells (Figure 4.9). The nucleus appears dark blue 
against a pale coloured cytoplasm with this stain. Cells marked with a black arrow showed 
pale blue coloured cells with deeper blue filaments. These cells are approximately 10µm in 
diameter. Cells marked with a red arrow appeared to extrude the nucleus. 
 
 
Fig. 4.9. Cells stained with Methylene Blue at day 16 of direct EM 
(Condition D) 
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The cell marker profiles for all cultures (A-D) during erythroid maturation have been 
recorded with flow cytometry at day 15 and day 24 (Figure 4.10). These data have been set 
out against the same cell marker profile of untreated UBMCs (day 0). Cells from culture 
condition (A) at day 24 were only analysed for Hb-β due to insufficient cell numbers (Figure 
4.7). Data for day 15 and day 24 was compared using statistics (Chapter 2.6.4) and for all 
cell markers the p-value was calculated. 
 
At day 15 and day 24, between 1% and 6% of each cell population was positive for CD34 
(CD34: p<0.5). When CD45 and CD44 were analysed, it was observed that a high 
percentage of the UBMC population was positive (CD45: ~96% and CD44: ~99%). During 
erythroid maturation the expression of these markers decreased below 15% for CD45 at day 
15 and below 10% at day 24 (CD45: p<0.5). It was recorded that for each cell populations 
between 30% and 55% were positive for CD44 at day 15. At day 24, between 22% and 
~42% of the cells were positive (CD44: p<0.2). CD44 can be detected on the surface of 
many cells including those found within the haematopoietic cell lineages [108] and on red 
cell membrane [109]. The marker CD36 can be found on colony forming unit erythrocytes 
(CFU-E’s) and was used to detect cells that were in the intermediate stage between HSC and 
RBC. At day 15, a cell population of ~40% was positive for CD36 (D). The cell population 
with the lowest positive expression was observed in culture (B): ~18%. At day 24 of the 
culture period conditions (B) and (C) the recorded positive expression for CD36 was ~38% 
whereas this was ~24% for culture (D) (CD36: p=0.5). 
 
CD71 is a marker that can be found on erythroid precursors as reported by [42, 110]. On day 
15, more than 40% (A, B) and more than 80% (C, D) of the cell populations were positive 
for CD71. On day 24 the recorded expression was ~30% for (B) and (C) and the expression 
was ~50% for (D) (CD71: p<0.1). The expression for UBMCs was ~5% on day 0. 
Cell markers which are commonly associated with erythrocytes (RBC) are Glycophorin A 
(CD235a) and adult Hb-β [110]. The UBMC population at day 0 was 5% positive for 
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CD235a and ~45% positive for Hb-β. At day 15, a 95% (B, C, D) and 80% (A) positive cell 
population was recorded for CD235a. At day 24 this was ~95% for the cultures (B), (C), and 
(D) (CD235a: p<0.5). When the expression of Hb-β was analysed at day 15, a positive cell 
population of ~13% was recorded for all culture conditions (A, B, C, and D). At day 24, the 
flow cytometry results showed that ~75% of the cultures (B) and (C) were positive. For 
culture (A), ~40% of the cells contained Hb-β whereas this was 60% of the cells from culture 



















































Fig. 4.10. UBMCs were cultured for 7 days in HSC expansion medium prior to erythroid 
maturation under different conditions: (A) = ‘with stroma/with cytokines’; (B) = ‘without 
stroma/with cytokines’; (C) = ‘with stroma/without cytokines’. (D) = UBMCs which have not 
been cultured in HSC expansion medium prior to erythroid maturation. The red bar represents 
the marker profile of UBMCs after isolation whereas the other bars represent the conditions A-C 
at the day 15 (above) and day 24 (under) of the differentiation period. The green bar represents 
the marker profile for condition D. The horizontal axis shows the haematopoietic and erythroid 























Erythroid Maturation of UBMCs - Day 15
UBMCs - Day 0 A: w/ stroma w/ cytokines
B: w/o stroma w/ cytokines C: w/o stroma w/o cytokines























Erythroid Maturation of UBMCs - Day 24
UBMCs - Day 0 A: w/ stroma w/ cytokines
B: w/o stroma w/ cytokines C: w/o stroma w/o cytokines
D: direct Erythroid Maturation
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The erythroid maturation of UBMCs has been analysed in more detail during a period of 21 
days. The culture conditions were similar to the conditions as stated in the previous 
experiment including pre-treatment by HSC expansion of UBMCs in I-medium during 7 
days: condition (A), (B), and (C). No pre-treatment was applied to the cells of condition (D). 
After the pre-treatment of (A), (B), and (C), all culture conditions were introduced to 
erythroid maturation using D-medium. During phase I (Day 0-8) the medium was 
supplemented with 100 ng/mL SCF, 5 ng/mL IL-3, 5 U/mL EPO, and 10-4 M hydrocortisone. 
Phase II (day 8-12) and phase III (day 12-21) were treated similar as stated in a previous 
experiment (Chapter 4). Data recorded during this experiment was based on cell numbers 
and flow cytometric analysis (CD117, CD34, CD45, CD36, CD71, CD235a, Hb-β). 
 
The expansion of HSCs, a pre-treatment of UBMCs, over 7 days showed that the culture 
‘with stroma/with cytokines’ showed the most dramatic increase in CD34 positive cells:  
~1.3x104 cells (day -7) to  ~8.9x104 cells (day 0).   The total number of cells recorded at day 















Fig. 4.11. HSC expansion of UBMCs over 7 days to increase the number of CD34+ cells 
before the start of erythroid maturation (day 0). The horizontal axis shows the various 
culture conditions and the number in parentheses states the total cell number at day 0. 
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For the culture conditions ‘with stroma/without cytokines’ (C) and ‘without stroma/with 
cytokines’ (B), the number of CD34+ cells dropped from ~1.3x104 (day -7) to ~1.2x104 (C) 
and ~0.8x104 (B) respectively. The total number of cells was ~0.5x105 (C) and ~1x105 (B) 
after 7 days of HSC expansion respectively. The culture condition of UBMCS ‘without 
stroma/without cytokines’ was not viable over 7 days. Cell morphology was observed for the 
culture conditions (A), ( B), and (C) at the end of HSC expansion and for condition (D) at 





Fig. 4.12. Morphology of cells on day 0, prior to erythroid maturation (D) and after the 
HSC expansion treatment (A, B, C) 
(A) (B) 
(C) (D) 
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The results from flow cytometric analysis showed the pre-treated UBMCs (A, B, C) 
compared against the not pre-untreated UBMCs (D) during erythroid maturation (Figure 
4.13). For a range of cell markers, the expression on cells for pre-treated versus non pre-
treated cultures were similar: CD117 (12-16% versus, ~17%, CD34 (0-4% versus ~1%), 
CD45 (6-15% versus ~2%), CD36 (20-30% versus ~32%), and CD235a (90-97% versus 
~98%).  
 
When the three remaining markers were analysed (CD44, CD71, and Hb-β), it was observed 
that culture (D) showed a higher positive expression over all other culture conditions (A, B, 
C). At day 21, ~50% of the cell population in culture (D) was positive for CD44 whereas this 
was ~34% for (A) and ~22% for (B) and (C). For CD71, ~27% of the cell population was 
positive (B) and this was ~39% for (C), ~52% for (A), and ~59% for (D). From the cells in 
culture (B), ~46% contained Hb-β. For culture (A) and (C), ~73% of the cells contained Hb- 
β whereas this was ~82% of the cells for culture (D). 
 
  

































Fig. 4.13. The marker profile of cultures (A-D) after 21 days of erythroid maturation.  UBMCs 
were cultured for 7 days in HSC expansion conditions, (A) = ‘with stroma/with cytokines’; (B) = 
‘without stroma/ with cytokines’; (C) = ‘with stroma/ without cytokines’, prior to erythroid 
maturation. (D) = UBMCs which have not been cultured in HSC expansion medium prior to 
erythroid maturation. The red bar represents the marker profile of UBMCs after isolation 
whereas the other bars represent the conditions A-C at the end of the differentiation period. The 
green bar represents the marker profile for condition D at day 21. The horizontal axis shows the 
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A: w/ stroma w/ cytokines
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UBMCs after isolation - Day 0
A: w/ stroma w/ cytokines
B: w/ stroma w/o cytokines
C: w/o stroma w/ cytokines
E: Direct Erythroid Maturation
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An overview with the number of cells at various time points during the erythroid maturation 
showed which culture conditions had a steady growth of cell numbers and which culture 
conditions had a different growth pattern (Figure 4.14). The untreated UBMCs (D) and the 
pre-treated UBMCs on a stromal layer (C) have a similar growth curve and almost 4x106 
cells were harvested at day 21. The pre-treated UBMCs with only cytokines showed an 
increase in cell number over the first 8 days of erythroid maturation before maintaining a cell 
number of ~1.4x106 cells. The pre-treated UBMCs (A), ‘with stroma/with cytokines’, had a 
different growth curve with a dramatic increase in cell number over the first 8 days (6x106 




















Fig. 4.14. The fluctuation in cell number during 21 days of erythroid maturation. (A) = ‘with 
stroma/with cytokines’; (B) = ‘without stroma/with cytokines’; (C) = ‘with stroma/without 






















Cell numbers during erythroid maturation
D: no pre-treatment
A: w/ stroma w/ c.k.
B: w/o stroma w/ c.k.
C: w/ stroma w/o c.k.
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The cell pellets were analysed for each culture condition after two and three weeks of 
erythroid maturation (Figure 4.15). The cell pellets of (A), (B), and (C) had a light bright red 
colour after 14 days of culture. Culture (D) showed a slightly darker red colour after 12 days 
of culture whereas the cell pellet of UBMCs at day 0 was white (data not shown). After 21 
days of erythroid maturation the cell pellets of (A), (B), (C), and (D) were slightly larger 
when compared to previous time points. All cell pellets showed a darker red colour at day 




















Fig. 4.15. The cell pellets of each culture condition after approximately 2 weeks (top) and 3 
weeks (bottom). (A) = ‘with stroma/with cytokines’; (B) = ‘without stroma/with cytokines’; (C) = 
‘with stroma/without cytokines’; (D) = ‘without pre-treatment’ 
C Day 12 DDay 14 
Day 21 
A B
A B C D
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The previous experiments analysed the potential of UBMCs for erythroid maturation. During 
a subsequent experiment the UBMCs were separated into a CD34 negative cell population 
(CD34-) and a CD34 positive cell population (CD34+), using the magnetic bead cell isolation 
method. After cell separation, cells were transferred directly into medium for Phase I of 
erythroid maturation. Phase II (day 8) and Phase III (day 11) were executed subsequently as 
stated previously. For both cell populations, the cell numbers were recorded and cell pellets 
were observed. The CD34- cell population was analysed for a series of cell markers (CD34, 
CD45, CD36, CD71, CD235a) at days 0 and 17.  
 
The cell numbers showed that for the CD34+ cell population the increase between day 0 and 
day 23 is ~10 fold whereas this is ~45 fold between day 0 and day 17 (Figure 4.15). The 
culture started with ~4x103 cells and ~3.2x104 cells were harvested at the end of culture 
which is an increase in cell number (Figure 4.16). For the CD34- cell population, the increase 
is ~0.04 fold over 23 days and ~0.95 fold over 17 days. The overall cell number decreased 
during erythroid maturation from ~2.0x106 cells at day 0 to 7.0x105 cells at day 17. When 
cell pellets were observed at day 11, the pellet originating from CD34- cells was red whereas 
the pellet with cells originating from the CD34+ cells was white. At day 17 both cell pellets 
were bright red and at day 23 the pellets were red but smaller in size when compared to the 
cell pellets from day 17 (no data shown). 
 
When the cell cultures were analysed with an inverted light microscope the culture of CD34- 
cells showed a high quantity of dead cells and cell debris with a high number of cells 
attached to the stromal layer (day 17). For the cell cultures of CD34+ cells at day 17, there 
were only a small number of dead cells present and a high number of cells were attached to 
the stromal layer (data not shown). At day 23, the CD34- cell culture showed a large number 
of cells attached to the stromal cell layer. The cells were smaller in size compared to those in 
the CD34+ cell culture. 
  



























































































Day 0 = 1
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The data collected with flow cytometry showed the change in cell marker expression for 
CD34- cells cultured for 23 days under erythroid maturation conditions (Figure 4.17). The 
expression of CD34 stayed below 6% and the expression of CD45 dropped from ~97% to 
~3% over 17 days. A marker for the intermediate stage of erythroid maturation (CFU-E’s) in 
the differentiation process, CD36, showed an increase in expression resulting in a positive 
cell population of ~70%. One of the erythroid lineage markers, CD71, was found on ~84% 
of the cell population at day 17. The RBC surface marker CD235a was observed on ~92% of 











































Erythroid maturation of UBMC-CD34- cells (Day 17)
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This chapter focussed on the erythroid maturation of cells isolated from PB and UCB. The 
erythroid maturation of PB-CD34+ cells was challenging due to low cell numbers available 
from isolated PBMCs. Erythroid maturation of UCB-CD34+ cells was more successful with 
viable cells throughout the entire culture period. At the end of the maturation stage, cells 
contained Hb and showed similar cell morphology as immature RBCs. 
 
Differentiation of UBMCs proved successful too with relatively high cell numbers compared 
to UCB-CD34+ cells. Cell pellets after 21 days, red in colour, were similar to human isolated 
RBCs. At the end of the differentiation period, more than 80% of the cell population 
contained Hb-β and over 95% of the cells were positive for the red cell membrane antibody 
CD235a. Erythroid maturation of thawed UCB-CD34- cells showed promising results 
compared to CD34+ cells isolated from thawed UBMCs but needs further optimising when 
compared to differentiated UBMCs. In summary, Figure 4.19 shows the distinctive different 
antibody profiles for differentiated UBMCs at day 1 (black bars) and after 2 weeks (blue 














Fig. 4.19. Collection of erythroid maturation cell marker profiles. Cells in differentiation 
cultures for approximately 3 weeks showed lower expression of CD36 and CD71 compared to 
cells in differentiation for 2 weeks. Black/grey bars show data collected at day 0. Blue bars 
show data collected after 2 weeks and brown bars show data collected after 3 weeks. Data is a 

































At the start of the main project to differentiate stem cells into RBCs, this research focussed 
initially on CD34+ cell isolation from PB and UCB. As these cell sources are commonly used 
in the literature these were the point of interest for optimising the erythroid maturation 
culture conditions in this project. The use of PB-CD34+ and UCB-CD34+ cells proved 
challenging as shown by the results concerning the haematopoietic expansion of these cells 
(Chapter 3).  
 
The number of isolated PB-CD34+ cells, combined with their low proliferation rate, was 
insufficient to study erythroid maturation in depth. When comparing these data to published 
research the encountered issue appeared to be limited access to this cell source. Therefore the 
research focus shifted to the use of UCB-CD34+ cells which were supplied by project 
partners.  
 
The method used to differentiate HSCs into RBCs was based on a study by Giarratana et al 
(2005) where they published data describing the ex vivo generation of fully mature human 
RBCs from HSCs [42]. This research group was amongst the first groups to publish the 
successful generation of mature RBCs and also succeeded in testing ex vivo generated RBCs 
in a human during a clinical study [53]. Other studies published have used comparable 
methods to generate RBCs in vitro, with different success rates regarding the generation of 
fully mature RBCs [44, 45, 63, 111]. 
 
As the method in this highly cited publication proved successful [42], this technique was 
implemented for all the erythroid maturation cultures during this project. A human MSC 
stromal layer was introduced, as preferred over a murine stromal layer, during phase II and 
III. Giarratana et al mimicked the marrow microenvironment by application of cytokines and 
stromal cells and expansion folds up to 1.95x106 and 1.22x105 were achieved for cord blood  
and PB cells respectively, with functional reticulocytes and RBCs as a result [42]. 




When the same research group successfully attempted the transfusion of autologous cultured 
RBCs into a human, they expanded 106 PB-CD34+ cells into 3.7x1010 cells with an 
enucleation rate of 68% without the use of stromal cells [Giarratana et al, 2011]. This is an 
expansion fold of 2.5x104 for enucleated cells and these two studies demonstrate the effect of 
stromal cells on the enucleation efficiency. 
 
 
4.6.1 Erythroid maturation of UCB-CD34+ cells 
Section 4.3 shows the results of erythroid maturation with cell size decreasing over 24 days. 
The viable cells were analysed for the cell markers CD34 and CD44 and the Hb-β molecule. 
Whereas all markers were expressed at over 80% at day 10, the acquired data on day 18, 21, 
and 25 showed a different, but more expected story. The expression of CD34 decreased 
whereas the percentage of cells containing Hb-β increased to almost 95%.  
 
The CD44 marker decreased to below 20% over 25 days. CD44 is highly expressed on HPCs 
and facilitates cell-cell adhesion on MSCs [105]. The results shown in Figure 4.12 show that 
this surface protein is profoundly expressed on UMBCs and this matches published data 
[105]. In addition to this, a study by Chen et al (2009) showed a decrease in CD44 
expression during the cell transition stage from proerythroblast to orthochromatic 
erythroblast/reticuloctyes. They also showed a progressive decrease in CD44 expression with 
decreased cell size [106]. Histological analysis did not provide conclusive data about the 
erythroid maturation stage of differentiated stem cells, but it showed a decrease in cell size 
and cell enucleation. Pellets of these cells had a red colour after 12 days of maturation, 
comparable to published data [4]. 
 
The use of thawed UCB-CD34+ cells proved more successful for erythroid maturation when 
compared to the cells obtained with the CD34 magnetic cell separation of thawed UBMCs, 
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partly a result of the availability of larger cell numbers. These latter cells proved difficult to 
expand in an HSC culture environment due to insufficient cell numbers, as shown in Chapter 
3, and therefore the proposed subsequent erythroid maturation step proved difficult. The 
majority of studies do not state whether fresh MNCs, thawed blood, or thawed MNCs were 
used. It is believed that the recovery of cells from fresh blood is superior to the recovery of 
cells from cryopreserved blood and aliquoted MNCs but improvements have been made 
regarding the cryopreservation and recovery of these cells [99]. 
 
As a result of the limited supply of UCB-CD34+ cells, the variety in quality of supplied 
UBMCs, and the limited success of isolating CD34+ cells from thawed UBMCs, the focus 
shifted towards the utilisation of UBMCs for erythroid maturation and was based on a study 
by Van den Akker et al (2010) [42]. 
 
 
4.6.2 Erythroid maturation of UBMCs 
The UBMCs were expanded using three different haematopoietic culture conditions 
(condition (A), B), and (C)) prior to erythroid maturation and results were compared with 
directly erythroid-maturated UBMCs (condition (D)). For these experiments it was 
hypothesised that UBMCs under HSC expansion conditions would prove beneficial for the 
manufacture of RBCs when compared to non-HSC expanded UBMCs. 
 
The results showed that the increase in number of CD34+ cells during expansion of UBMCs 
did not necessarily resulted in a higher cell output during erythroid maturation (Figure 4.7). 
However, during the 7 day haematopoietic expansion culture a higher cell density with 6x104 
cells/mL (Figure 4.14) could be linked to a higher output of red cells when compared to a 
starting cell density of 3x104 cells/mL (Figure 4.7).  
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Histological analysis of cells during erythroid maturation (condition (D)) showed a number 
of cells without a nucleus (cell diameter < 10µm) at day 16. At the same time point a number 
of cells appeared to extrude the nucleus and nucleated cells were still present as well (Figure 
4.9). The enucleated cells showed similarities with data published by Giarratana et al (2005) 
[42], although the overall success rate appeared to be lower during this experiment. When 
these cells were analysed for the presence of haematopoietic and erythroid surface markers 
the data suggest that at day 15 the cells possessed the erythroid precursor marker CD71 and 
RBC marker CD235a. After 24 days of erythroid maturation, the same cell population 
showed higher levels of CD235a and Hb-β and lower levels of the erythroid precursors 
CD36 and CD71 indicating successful maturation (Figure 4.10). For confirmation of 
successful production of cRBC, an aliquot of the cultured cells was tested with hospital 
equipment used for analysing blood samples: UniCel DxH 800 (Beckman Coulter). Due to 
insufficient cell numbers this test could not be completed. 
 
Culture conditions (A), (B), and (C) were compared with condition (D) and flow cytometric 
data indicated that on day 24 all the all surface markers showed a high degree of similarity 
compared to their expression on day 15. However, the expression of Hb-β was comparable 
for the four culture conditions after 15 days of erythroid maturation but at day 24 the 
expression varied tremendously. Cells cultured in the presence of a stroma during pre-HSC 
expansion (condition (A) and (C)) showed the highest expression of Hb-β (~75%) whereas 
condition (B) only showed a positive expression of 40%. With high levels of CD235a 
(>90%) for condition (B) and (C) this indicates that cultured cells were in the final stage of 
erythroid maturation as the expression of CD71 had dropped during the final 9 days of 
culture. 
 
During the flow cytometric analysis of Hb, adult Hb-β was used and therefore only 
conclusions can be drawn regarding the adult Hb content of differentiated cells. As is shown 
by Giarratana et al (2005 and 2011) [42, 53], cultured RBCs contain a high percentage of 
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adult Hb (over 85%). During this research cells were not analysed for fetal Hb, but the 
literature showed that a minor fraction of the cultured RBCs contained this type of Hb 
(~10%). However, these cells originated from adult CD34+ stem cells (e.g. PB, BM) whereas 
cultured RBCs originating from neonatal stem cells (e.g. CB) mainly contained fetal Hb: 
~64% [42].  
 
To study the erythroid maturation further, this experiment was repeated with an extended 
culture Phase II: 4 days instead of 2 days. This resulted in a shorter culture Phase III: 9 days 
instead of 14 days. The duration of culture Phase I was still 8 days and the duration of the 
three Phases were now comparable to the described erythroid maturation method [42].  Not 
only could flow cytometric data now be obtained for culture condition (A), cell pellets were 
also analysed and showed a red colour from day 12 (condition (D)) and day 14 (condition 
(A), (B), and (C)) of erythroid maturation (Figure 4.15). The bright red colour indicates the 
presence of oxygen bound to the haem group of Hb (oxyhaemoglobin) [3].  
 
The surface marker profiles were of a similar pattern to thoseobtained during the previous 
experiment, with condition (A) having a comparable profile to data obtained for condition 
(D) at day 21 of erythroid maturation. The only major differences between condition (A) and 
(D) can be found in a lower expression of CD44 (~30% and ~50% respectively) and a lower 
cell number (~4x106 and ~1x106 respectively). Condition (C) showed a lower surface 
expression for most markers of the erythroid lineage, except CD235a, when compared to the 
profile of condition (D), but the cell number during erythroid maturation was similar. 
Condition (B) showed a lower surface expression for all markers of the erythroid lineage and 
the cell number was also lower when compared with condition (D) (Figure 4.14). 
 
These data indicated that direct erythroid maturation of UBMCs had a positive effect on the 
manufacture of RBCs, including higher cell numbers, when compared to pre-HSC expanded 
UBMCs. 
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This study also analysed the potential benefit of using UCB-CD34- cells for erythroid 
maturation in relation to published data about the benefit of using PB-CD34- cells to increase 
the erythroblast yield [41]. Similar differentiation methods were used as was previously 
stated and resulted in lower expansion for UCB-CD34- cells (0.04 fold). However, during 
differentiation the number of UCB-CD34+ cells increased 10 fold but this was still regarded 
as a low fold increase. The cell surface marker profile showed an indication of transition of 
UCB-CD34- cells into the erythroid cell lineage and cell pellets indicated the presence of Hb 
from day 11 (red coloured pellet). The small number of UCB-CD34+ cells only allowed for 
analysis of the cell pellet and from day 17 this was coloured red, indicating later erythroid 
maturation compared to UCB-CD34- cells.  
 
Overall, the erythroid maturation of pre-HSC-expanded UBMCs was not as successful as 
direct maturation of UBMCs (Figure 4.13) and results were different to data published by 
Van den Akker et al (2010). A possible explanation could be the difference in differentiation 
protocol including a different cytokine cocktail and absence of stromal layer. In this project, 
the differentiation of UBMCs was successful compared to the differentiation of CD34+ cells 
and CD34- cells but further characterisation of these ex vivo generated cells would be needed 
for full comparison analysis with published data. This would require higher cell numbers at 
the start of culture to obtain sufficient cells during the end stage of erythroid maturation. 
 
During the experiments described in chapter 4 the difference between non-haematopoietic 
stimulated and haematopoietic stimulated UBMCs for the differentiation towards the 
erythroid lineage was assessed. There was no clear indication that HSC expansion of 
UBMCs prior to erythroid maturation would benefit the manufacture of RBCs with the 
currently used method. The differentiation of UBMCs for the erythroid cell lineage would 
need further optimisation to increase cell output and this should allow for full cell 
characterisation with hospital accredited equipment for RBC analysis as well.  





Chapter 5  













5.1 Introduction  
Cell cultures in a 2D environment (e.g. flasks, wells plates) have been highly beneficial for 
cell expansion. It allows for a simplified approach to study cells, whether human or animal 
derived. This is ideal for basic research but it is restricted in terms of creating large numbers 
of cells. In contrast, use of bioreactors can create a dynamic 3D culture which in turn is 
paramount for upscaling and producing sufficient cell numbers. These bioreactors have been 
developed in various formats and sizes over the past decades. Large numbers are used in 
laboratories as part of cell culture development processes. 
 
Figure 5.1A shows a schematic overview of a bioreactor. The bioreactor shows the addition 
of medium to provide nutrients (fed) to the cell culture. This type of culture is called a fed-
batch process as the cell product is harvested batch wise at the end of the culture run. Figure 
5.1B shows a schematic overview of a bioreactor where the cell culture process is perfusion 
based. In this system nutrients are continuously refreshed but where the cells are also 
retained in the bioreactor to prevent loss of product. This system is more complex and this 













Fig. 5.1. A schematic overview of a fed-batch bioreactor (A). A schematic overview of a 
bioreactor with a perfusion system (B). 





In this project, commercially available bioreactors were used to develop, improve and create 
a system for the culture of HSCs. The aims were to expand the HSC population and 
subsequently differentiate these cells into RBCs. To setup a system capable of achieving this, 
bioreactors of various volumes were analysed and during the developmental stages a range 
of devices and adaptations (e.g. cell retention devices, cell sampling) were tested.  
Of particular interest is the BioSep, a cell retention device used in this research, and is part of 
the bioreactor perfusion system (Figure 5.1B). A cell retention device is an useful device to 
create high cell density cultures similar to those of red blood cells. This device will be tested 
thoroughly and compared to another cell retention device. The BioSep is an acoustic-cell 
separator where acoustic waves in the resonator chamber are used to separate the cells from 
the medium. The benefit of this system is the lack of moving mechanical parts and therefore 
the BioSep is less prone to fouling and mechanical failure. During separation in the resonator 
chamber, a part of the liquid is pumped through and removed as a cell-free perfusion flow. 
The other liquid part is returned to the bioreactor and contains the cells that have been 
retained in the chamber as a result of the acoustic standing waves.  
 
During this research, the human U937 suspension cell line was used as a model for rapid 
growing cells as HSCs and MNCs were limited in supply. These U937 cells allowed for 
extensive testing to create a bioreactor environment ready for the development of 
haematopoietic and erythroid cultures. Figure 5.2 shows a schematic overview of the 
bioreactor design, with an overview and explanation of each of the three different stages of 
the bioreactor.  This bioreactor design was the basis for this project. 
 
The hypothesis of this chapter is: Can the process of manufacturing red blood cells be 
upscaled to a bioreactor process by improving the culture environment for this type of 
culture? 
 











Fig. 5.2. A schematic design showing the three different stages of the bioreactor, which 
could potentially be used to produce red blood cells. Part (A) shows the initial stage where 
the haematopoietic stem cells divide on  slow rotating discs (grey bars); with the ‘mother’ 
cells adhering to the surface, whereas the ‘daughter’ cells go into the suspension culture 
before being transferred to the second stage of the bioreactor. Part (B) allows for the cells 
to differentiate towards the final stages of the erythroid lineage after which they are 
transferred to the third and last stage of the bioreactor. In this part (C), the erythroid cells 
are allowed to fully mature into fully functional red blood cells and an integrated perfusion 
system will ensure a high cell density product. 





5.2 Initial Bioreactor Tests 
In an approach to initiate bigger scale cultures for HSC expansion various sizes of 
bioreactors, a variety of other bioreactor equipment, was analysed. For this experiment a 2L 
bioreactor vessel, with a maximum working volume of 1500 mL, was used with an acoustic 
cell retention device (BioSep, 10L/day) attached. No stirrer device was used and there was 
no pH/DO control. The entire setup was placed in a closed room with an ambient 













The bioreactor contained 500 mL of DMEM medium and the Feed Vessel contained 800 mL 
of fresh DMEM medium. The Feed Vessel with medium contained ~9x106 MSCs (~11x103 
cells/mL) and was placed on a shaking device. After 1 day, ~1x106 cells were harvested from 
the bioreactor vessel. The Feed Vessel without medium contained ~4.3x105 cells (>95% 
alive). The Harvest Vessel was connected to the output of the BioSep and contained 900mL 
of medium and ~5x105 cells. Both the Bioreactor Vessel and the Harvest Vessel contained a 
large quantity of cell debris. From the cell number at the start of culture (~9x106), only 
~2x106 viable cells were detected at the end of culture (1 day). The BioSep Control Unit was 
set to Run for ‘5 minutes’, Stop for ‘10 seconds’, and Powered at ‘5 Watts’. 
 
Fig. 5.3. Setup 2L bioreactor and BioSepon top of the head plate. 





DPSCs were also used to test the bioreactor in a different setup, maintained in a closed room 
with an ambient temperature of 37 °C (Figure 5.4). The 2L bioreactor vessel with the BioSep 
(10L/day) mounted on the head plate contained ~750mL DMEM medium. The connected 
Feed/Harvest Vessel (one container) contained ~250 mL DMEM medium. The BioSep 














At day 0, ~100x106 cells were transferred to the Bioreactor Vessel under aseptic conditions 
and cells were cultured for 2 days. No stirrer device was used and no pH and no DO control 
was available. A layer of cells on the bottom of the bioreactor vessel was observed at day 2. 
At the end of the culture 5.4x107 alive cells and 2.6x107 dead cells were harvested from the 
Bioreactor Vessel (275mL). For the Feed/Harvest Vessel containing 750 mL medium, the 
cell count was 1.2x107 alive cells and ~5x106 dead cells. The pH of the medium in both the 
Bioreactor and Harvest Vessels was 8.5 (37 °C) at day 2 whereas a pH of ~7.4 was measured 
at the start of culture. 
 
 
Fig. 5.4. Continued testing of initial bioreactor cultures (including BioSep) 





The previous experiments with dynamic cultures (2L) showed that without precise control of 
the cell environment the cell viability was compromised. Therefore control of the bioreactor 
culture was required. To log data and control culture parameters (e.g. pH, dO2) a My-Control 
Unit and BioXpert software (Applikon Biotechnology, Delft, NL) was used as described in 
Chapter 2. A typical bioreactor culture used calibrated sensors. The pH sensor was calibrated 
pre-sterilisation as guided by the My-Control UI, using two solutions, one with a pH of 4 and 
the other pH of 7. The dissolved oxygen (DO) sensor was calibrated post-sterilisation, 
guided by the My-Control UI and used maximum air influx to adjust set point to 100% under 












































5.3 Small Scale Bioreactor 
A system with a 250 mL MiniBioreactor (working volume 200 mL) was tested. The pH was 
controlled by the addition of CO2 and an alkali solution. The DO concentration was 
controlled by the addition of air only (set point 50%). The temperature was maintained at 
37°C using a My-Control powered heating blanket. To allow for a homogeneous 
environment and cell distribution a marine impeller was used with a stirrer speed of 50rpm. 
As a control, a stirrer flask without sensors and without pH and DO control was used. For 
both vessels, the starting volume of medium was 50mL and at each subsequent day 50mL of 
medium was slowly added, up to a total volume of 200mL.  
 
In this experiment, a cell line for suspension cultures was used. The basic culture of this 
human lymphoblastic cell line, U937, was described in Chapter 2. Both vessels contained 
7x106 cells (140,000 cells/mL) at day 0. After 3 days of culture, the MiniBioreactor 
contained ~38x106 alive cells (~190,000 cells/mL). Over 95% of the total cell population 
was alive. The stirrer flask contained ~3.7x106 alive cells (~187,000 cells/mL) which was 













Fig. 5.6. Parameters recorded during a dynamic culture using a MiniBioreactor (250mL) 









































The sensor readings showed a stable temperature and pH range of 7.3-7.5 (Figure 5.6). The 
DO curve showed an initial steep rise before gradually decreasing to ~110% after 48 hours 
of culture. This concentration of DO was maintained for the next 24 hours. 
 
The cell viability and expansion rate of U937 cells was analysed in a controlled bioreactor 
and compared with cell cultures in an uncontrolled bioreactor and a static culture flask. This 
determined in what way the correct pH and oxygen levels would influence these cell 
parameters and what the possible shortcomings for the control of cell environment would be. 
It was hypothesised that an accurate controlled culture environment would stimulate cell 
growth. The sensors of the two identical bioreactors were calibrated as stated in Chapter 2. 
At day 0, both bioreactors and the culture flask contained 42 mL of medium and ~10x106 
cells (~2.4x105 cells/mL). The temperature was maintained at 37°C for all three culture 
vessels. Bioreactor ‘C1’ was controlled for both the pH and DO whereas bioreactor ‘M1’ 
was not controlled for these parameters. Both bioreactors had a set stirrer speed of 75rpm.  
 
The standard tissue culture flask was placed in a 5% CO2 and 37°C controlled, humidified 
incubator. The total culture period for all three vessels was 9 days with the addition of 50 mL 
fresh medium on days 1, 2, and 5. The cell viability was determined at the start and end of 
the culture period (Table 5.1). The Controlled Bioreactor (C1) showed 97.8% viability and 
~11.1x fold amplification of viable U937 cells. For the Monitored Bioreactor (M1) this was 
68.1% and a fold amplification of ~10.6x. The result for the static flask showed a cell 
viability of 57.2% and a fold amplification of 4.7x. 
 
After the cell suspension was removed from the glass bioreactor vessel, it was found that less 
than 0.05% of all cells adhered to the glass vessel wall of the controlled bioreactor (C1). This 
was ~0% for the monitored bioreactor (M1). 
 













The sensor registration profile showed the instability of the pH and the DO during the first 
48 hours of culture before dropping to 7.3 (pH) and 10% (DO) respectively after ~96 hours. 
The time points when medium was added can be confirmed from distinctive peaks in pH and 
DO registration profile: after 24 hours, 48 hours, and 120 hours (Figure 5.6). The 
temperature was stable at 37ºC throughout the cell culture, with a slight drop after 24 hours, 
















Fig. 5.7. The sensor registration profile (pH/DO/Temp) of the monitored MiniBioreactor 




































 Day 0 Day 9 
 Alive Cells (#) Alive Alive Cells (#) Alive Dead (#) 
Monitored 
Bioreactor 
10x10^6 >95% 106.5x10^6 68.1% 49.9x10^6
Controlled 
Bioreactor 
10x10^6 >95% 111x10^6 97.8% 2.5x10^6 
Static Flask 10x10^6 >95% 47x10^6 57.2% 35.2x10^6
Table 5.1. The U937 cell viability shown for all three culture vessels at day 0 and day 9 

















The sensor registration profile shows the instability of the pH during the first 48 hours of 
culture before it stabilised ~7.4 for the remainder of the culture. The timepoint of when 
medium was added could be observed from the peaks within the DO profile after 24, 48 and 
120 hours (Figure 5.8). Because the DO during this experiment was controlled by the 
addition of air only it was not possible for the bioreactor to lower the DO level to 50%. The 
temperature was stable at 37ºC with a minor drop (1ºC-3 ºC) when fresh medium (50mL) 










Fig. 5.8. The sensor registration profile (pH/DO/Temp) of the controlled MiniBioreactor 
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The box plots in Figure 5.9 show the difference for the pH and DO values and how these 
values were distributed for both the Monitored and the Controlled bioreactors. There was a 







Fig. 5.9. Box plot of the pH and DO values for the monitored (M1) and the controlled 
(C1) bioreactor shows the distribution of values over 9 days. Each box plot is divided 
in 4 quarters, each containing 25% of the recorded values with the mean as the value 






























5.4 Cell Retention 
To allow for a carefully orchestrated scale up culture using bioreactors, a multi-step culture 
protocol was implemented. During the first phase of this culture a static culture flask was 
used and a 3L capacity bioreactor was used during the third phase. The MiniBioreactor 
(250mL) was responsible for the second, and intermediate, phase to scale up to a dynamic 
culture. The DO was controlled by the addition of air and the pH was controlled with CO2 
















During the first phase of this scale up process, a T75 with 30 mL of medium was used to 
culture U937 cells for 3 days before transferring the cell suspension to the MiniBioreactor 
containing 210 mL of fresh medium. After a 4 day culture period ~280x106 cells (>95% 
alive) were harvested. During the third, and final, phase the cell suspension was transferred 
to the 3L Bioreactor containing 260 mL of fresh medium (Figure 5.10) under aseptic 
conditions.  
 
Fig. 5.10. An overview of bioreactors. A) Harvested cell suspension from the 
MiniBioreactor (B) next to fresh medium without any U937 cells. C) 3L 
bioreactor with a stirrer and BioSep (10L), thermo blanket open. D) My-
Control Unit and Bioreactor with pumps and medium/waste vessels 
A B 
C D 





The BioSep and a stirrer were connected to the 3L Bioreactor to allow for medium 
refreshment and a homogeneous distribution of nutrition and oxygen. The BioSep Control 
Unit was set to run for ‘10 minutes’, Stop for ‘3 seconds’, and Powered at ‘2 Watts’. 
Attached to the bioreactor was a ‘Feed’ vessel containing 2000 mL of fresh medium to be 
gradually added to the bioreactor over a 7 day period. At the end of the third phase, the 
bioreactor contained 1400 mL of medium containing ~1.4x109 alive and ~600x106 dead cells 
(~70% alive cells). Approximately 1300 mL medium was collected in the ‘waste vessel’ 













The sensor registration profiles were recorded for both bioreactors (Figures 5.11 and 5.12). 
The set point for DO was 50% and the pH was set at 7.4. Both graphs show a temperature 
registration of 37ºC for the entire culture period and the DO dropped to 50% (set point) after 
approximately 24 hours of culture. The full culture period was approximately 88 hours for 
the 3L Bioreactor. The registration profile for the MiniBioreactor showed a pH between 7.3 
and 7.5 during the first 76 hours before the pH dropped to 7.1 after 91 hours of culture. The 
pH for the 3L Bioreactor was 7.1 for the first few minutes whilst the culture was initiated 
 
Fig. 5.11. The sensor registration profile (pH/DO/Temp) of the controlled MiniBioreactor 
(250mL) containing U937 cells over a 4 day culture period (part 1). Stirrer speed was set at 
















































before it reached a stable 7.3 for 128 hours. The pH then rose to 7.5 for the remainder of the 














The BioSep was compared with another cell retention device to analyse cell retention 
efficiency and cell viability. This device, a Spinfilter, was used in a similar Bioreactor as was 
used for the Biosep (Figure 5.13). To control the DO and the pH the addition of air (DO), 
and CO2 and an alkali solution (pH) was added. 80 mL of U937 cell suspension was added to 
the bioreactor which contained 300 mL fresh medium.  
 
The stirrer speed of the marine impeller, and Spinfilter, was set at 100rpm. At regular 
intervals fresh medium was added to the vessel and used medium was harvested via the 
Spinfilter to allow for optimal cell growth conditions. Fresh medium (~1750mL) in a 
separate vessel was available at the start of the culture. After ~120 hours of culture, all fresh 
medium was transferred to the bioreactor vessel. At day 6, the culture was terminated and all 
vessels were analysed for cell numbers, cell viability, and medium volume. 
  
 
Fig. 5.12. The sensor registration profile (pH/DO/Temp) of the controlled Bioreactor (3L) 
containing U937 cells over another 4 day culture period (part 2). Stirrer speed was set at 





























































The sensor registration profile (Figure 5.14) showed the influence of the addition of medium 
on the pH and DO during the first 120 hours of culture. Profile peaks were noticeable and 
only when fresh medium was no longer added at day 6, were the profile stable. The pH 
sensor registered a stable value of below 7.5 and a temperature of ~37ºC was registered 
throughout the entire culture. The DO was ~100% at the start of culture and decreased 
gradually during the first 96 hours before stabilising at 30% after 120 hours of culture. 
  
 
Figure 5.13. Spinfilter and impeller (left) and Spinfilter close up (right) 
















The cell numbers in Table 5.2 showed how many viable cells had been retained in the 
bioreactor vessel. Approximately 90% of all cells were retained when the spinfilter was used 









The cell data is depicted in Figure 5.15 and showed the difference in cell number between 
the bioreactor vessel and the harvest vessel and the increase in cell density over 6 days of 
culture. The total number of cells counted in the bioreactor vessel was 1.7x109 and this was 
Day 6 Bioreactor vessel with spinfilter Harvest vessel 
Medium Volume 837 mL 1315 mL 
Alive Cells ~1.5x109 ~0.084x109 
Cell Density (Alive) ~1.8x106 cells/mL ~0.06x106 cells/mL 
Cell Viability (Alive) 89.5% 46.4% 
Notes 
The viable cell population was 81.3% 
of all cells within this system. 
High amount of debris 
present. 
Table 5.2. Cell analysis of vessels used for the bioreactor with spinfilter 
 
Fig 5.14. Sensor registration profile (pH/DO/Temp) of the controlled Bioreactor (2L) with a 
spin filter containing U937 cells over a 6 day culture period. Stirrer speed was set at 100rpm, 








































~10 fold greater than the number obtained from the harvest vessel. The increase in cell 
density of viable cells in the bioreactor vessel was ~1x106 cells/mL compared to ~1.8x106 


























Fig. 5.15.  A) Cell viability graph for the Bioreactor with Spinfilter, and 

























































5.5 Upscaling and Cell Viability 
The previous experiments showed the improvement in the upscaling of cell cultures. Cell 
viabilities of more than 95% were achieved for the MiniBioreactor but the cell viability for 
the 2-3L bioreactors was only ~75%. Therefore the 2-3L bioreactor needed more research in 
optimising cell viability. A more careful upscaling could allow for a better controlled cell 
expansion resulting in higher cell viability.  
 
Another challenge during medium refreshment, with the use of a cell retention device, was to 
minimise the transfer of viable cells from the bioreactor vessel to the harvest vessel. The 
BioSep has advanced control settings and was therefore a suitable device for cell retention to 
optimise cell cultures. The BioSep Control Unit was set to Run for ’10 minutes’, Stop for ‘3 
seconds’ and Powered at ‘2 Watts’ as was recommended by the suppliers guide for a cell 













Fig. 5.16. Setup of a closed system with the MiniBioreactor in progress (right) and 
connected Bioreactor (3L) with BioSep (left) for the last stage of culture 





A MiniBioreactor and a connected 3L Bioreactor Vessel with BioSep and a My-Control Unit 
was used (Figure 5.16). At day 0, 50mL of cell suspension (6.5x105 cells/mL) was added to 
the MiniBioreactor and incrementally medium was added up to 200 mL over 3 days. Next, 
the cell suspension was pumped to the 3L Bioreactor Vessel containing 800 mL of medium; 
the total volume of cell suspension was 1000 mL. Fresh medium (1700 mL) was available in 
a connected vessel to supply fresh medium to the Bioreactor Vessel. The pH was controlled 
by the addition of CO2 and the DO level was controlled by the addition of air. 
 
The sensor registration profile showed the time points of medium addition to the 
MiniBioreactor after 8 hours, 24 hours, and 48 hours. The time point of medium additions 
can be observed by the slight rise in DO (5-10%) and pH (~0.1) and a minor drop in 
temperature (1-2ºC). The temperature recorded was stable at 37ºC and the pH was kept 
between 7.3 and 7.5. The DO dropped gradually from 100% to 20% over ~66 hours (Figure 
5.17A).  
 
The addition and harvest of medium for the 3L Bioreactor Vessel was more gradual and this 
was reflected in the sensor registration profile (Figure 5.17B). The pH was high (7.7) upon 
initial start-up but was stable between 7.3 and 7.5 for the remainder of the culture period. 
The temperature was low (~25ºC) at the start of the culture, but rose to 37ºC within 1 hour 
and remained stable until the end of the culture. The DO level dropped over a ~96 hour 
period to the setpoint of 20%; a slow decrease during the first 48 hours of culture and a rapid 
decrease during the last 30 hours of this ~96 hour culture period. For the remaining culture 








































Fig. 5.17. The sensor registration profile (pH/DO/Temp) of the MiniBioreactor (A) and 
the 3L Bioreactor with BioSep (B) filter containing U937 cells over respectively a ~2 
day and 6 day culture period. Stirrer speed was set at 75rpm, DO was set at 20%, and 













































































The cell number and viability is depicted in Figure 5.18 and shows the total number of cells 
at the end of the overall culture period and the increase in cell density during culture. 
Analysis of the 3L Bioreactor Vessel showed that 2.4x109 alive cells were harvested 
(~95.5% cell viability) and that ~2.5% of all the cells was transferred to the Medium Harvest 
Vessel during culture. The strategically controlled approach of scaling up a dynamic culture 
resulted in a steep increase in cell viability/mL while medium volume was expanded as well. 
The relatively low number of dead cells, compared with previous experiments confirmed the 























Fig. 5.18. A) Cell viability graph for the 3L Bioreactor with BioSep, and 
associated Medium Waste Vessel at the end of culture. B) Cell density graph 



















































In the previous experiments cell numbers were analysed at the start and end of a dynamic 
culture, not during culture. In order to gain better insight into cell expansion and viability 
continuous access to the culture was required. Therefore, access ports were designed and 
implemented into the MiniBioreactor to obtain cell samples using a 1 mL syringe (Figure 
5.19). One port was created with access to the bottom level of the vessel (I) and another port 
had access to the middle level of the vessel (II) as shown in the image. During system 
testing, the stirrer speed was set at 75rpm. The dynamic culture was not pH or DO 














The objective of the first tests was to obtain representative cell samples from the culture 
(Figure 5.20A) and in an additional test cell samples from high and low access ports in the 
MiniBioreactor were compared (Figure 5.20B). The obtained cell samples, 0.2mL in volume, 
were analysed using Trypan Blue to determine cell viability. A haemocytomer was used to 




Fig. 5.19. Manual cell sampling system for the MiniBioreactor in an aseptic environment 
with the ‘low’ (I) and ‘high’ (II) cell sample height marked 
II
I





The cell samples taken during the first stage were similar in number at set intervals. This 
similarity in cell number was also applicable to second stage testing. Graph ‘A’ shows the 
increase in viable cells over 24 hours. The steepness of the slope of dead cells indicated that 


























Fig. 5.20. A) Cell number and viability data as acquired by the Cell Sampling 
system in the MiniBioreactor. B) Comparison of cell numbers acquired via the 
‘low’ and ‘high’ cell sampling system after 24 hours (Student T-Test: p > 0.5, 
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Cell count - 'Low' vs 'High'
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p = 0.728 





When cell samples from the lower (I) and the higher (II) access ports were compared it was 
observed that the samples from each port contained similar numbers of cells and this 
correlation was confirmed by a Student T-Test. Therefore the hypothesis stating that 
acquiring cells from two different sample access ports heights results in a difference in cell 
number was rejected. 
 
The sensor registration profile showed a stable temperature of 37ºC. The pH recorded was 
8.5 during the first hour before it dropped to 7.5. Next, the pH decreased to 7.3 over 19 hours 
before it rose again to 7.5. During the last 4 hours of culture the pH dropped to ~7.4. In the 
same graph (Figure 5.21) the DO percentage was plotted. After an initial rise to ~110% DO 

















Fig. 5.21. The sensor registration profile (pH/DO/Temp) of the MiniBioreactor with a 
manual cell sampling system containing U937 cells over a 24hour period. Stirrer speed was 








































5.6 Addition of air, nitrogen and CO2 
During the previous experiments there was a long delay for the DO levels to drop from a 
high level to the desired setpoint (e.g. 20%). In order to gain accurate control of the DO 
level, a module was installed to the My-Control Unit to allow for the addition of nitrogen to 
the bioreactor. Nitrogen is an inert gas which is widely used to remove oxygen from cell 
environments [112]. The purpose was to achieve a controlled lower DO level in the medium. 














In another experiment of similar setup, the responsiveness of the DO levels was tested by the 
addition of air and nitrogen above the medium instead of addition from within the medium. 
The results showed that the level control was less accurate and lacked responsiveness as it 
took approximately 8 hours to adjust the DO level and in addition the fluctuation was higher 





Fig. 5.22. Improved control of DO levels within PBS by addition of air and nitrogen into 
the MiniBioreactor. The setpoints were changed during testing and were respectively 5%, 




















DO control - Addition to PBS

















An important aspect of this bioreactor is the addition of air, nitrogen, CO2 to control the pH 
and DO. The basic method is the addition of gases via a normal sparger, but this creates large 
air bubbles which could negatively affect the cell viability [113-115]. A commercial product 
(pore size: 15µm) was tested to produce smaller bubbles and is shown in Figure 5.24: This 
commercial porous sparger was screwed into the normal sparger. The bubbles released from 
each sparger were rated for bubble size and the results were listed in Table 5.3; a video of 
each sparger in use was created to observe and compare the bubbles. The flow rate of 
supplied air was 5 mL/min. 
 
The commercially available option was compared with a range of experimental spargers (e-
spargers). These e-spargers varied in ‘pore size’ (200µm, 300µm, 400µm, 500µm) and ‘Wall 
Depth’ (1mm, 1.5mm, 2mm). The Wall Depth is the length of the access hole (i.e. depth) 
into the sparger. All e-spargers with a 200µm pore size had the front side unfinished as can 
be observed from the images. All e-spargers did not contain a rubber gasket o-ring whereas 
the porous sparger contained this o-ring to seal the connection with the normal sparger port.  
The size of the bubbles were analysed for each sparger and were listed in Table 5.3. 
 
Fig. 5.23. Control of dO2 levels above the medium by addition of the inert N2 and air into 





















DO control - Addition above medium





The first series of e-spargers (1mm Wall) were tested and only the 300µm version produced 
smaller sized bubbles than the Applikon Porous Sparger. The 400µm and 500µm spargers 
showed no leakage but the bubbles were bigger in diameter than the bubbles produced by the 
commercially available sparger. The 200µm sparger did not produce any bubbles via the 














The second series of e-spargers (1.5mm Wall) were tested and the 300µm version produced 
the smallest sized bubbles of all tested spargers. All 1.5mm Wall spargers, except the 500µm 
version, showed a leak at the connection side. The 400µm and 500µm versions produced 
bubbles which were bigger than the commercially available porous version, but these 
bubbles were smaller than the bubbles produced by the standard sparger. The 200µm sparger 
did not produce any bubbles other than via a leak (Figure 5.26).  
 
The third series of e-spargers (2mm Wall) were tested and the 300µm version produced 
bubbles similar inside when compared to the 1mm Wall 300µm type sparger. All 2mm Wall 
spargers, except the 500µm version, showed a leak at the connection side. The 400µm 
 
 
Fig. 5.24. The standard sparger produced large size bubbles (top) whereas the Applikon 
Porous Sparger produced smaller sized bubbles (bottom)





version produced bubbles of similar size as the Applikon Porous Sparger and the 500µm 
version produced bubbles which were only slightly smaller in than those produced by the 
standard sparger. The 200µm sparger did not produce any bubbles other than via a leak 





























Fig. 5.25. Experimental porous spargers with a 1mm Wall and with various pore sizes: 
200µm, 300µm 400µm, 500µm (from top to bottom) 





































Fig. 5.26. Experimental porous spargers with a 1.5mm Wall and with various pore sizes: 
200µm, 300µm 400µm, 500µm (from top to bottom)




































Fig. 5.27. Experimental porous spargers with a 2mm Wall and with various pore sizes: 






Chapter 5 – Results: The development of the bioreactor 



















































































































































































































































































































































































































































































































































































































































5.7 Dynamic culture of UBMCs 
Previous experiments with the bioreactor established improved culture processes. Next, the 
MiniBioreactor was prepared for a culture with UBMCs to analyse cell viability and culture 
stability. The reactor was setup with a sample tube (Figure 5.19). The vessel contained 40mL 
of HSC expansion medium (I-Medium) and calibrated pH and DO sensors were placed in the 
head plate. The pH was CO2 and alkali controlled whereas the DO was only air controlled.  
A ‘Medium Feed Vessel’ contained 30mL of fresh I-medium and this medium was added 
gradually during the first week of culture. UBMC’s were thawed, washed, and resuspended 
in 5mL of medium. Cell count was performed including viability analysis using Trypan 
Blue. Cell suspension was added to the MiniBioreactor and culture was initiated. The cell 
density used corresponded with that used in static cultures. Cell samples (200µL) were taken 















During the dynamic culture the temperature (37ºC) remained stable whereas the pH 
fluctuated between 7.3 and 7.5 for the first 8 days of culture before stabilising at 7.45 for the 
 








































rest of the culture period. The recorded DO was ~120% for the first 24 hours of culture and 
rose to ~140% over the next 20 days (Figure 5.28). 
 
The graph with the viability of UMBCs shows how the viability rate dropped rapidly during 
the first 4 days of culture with almost no viable cells after 6 days (Figure 5.29). The number 
of dead cells is high when compared to the number of viable cells and dropped in a similar 
fashion as the number of viable cells. On day 8, a slight rise in cell number was recorded. At 
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A basic setup of a high volume (3L) bioreactor in a temperature controlled room (37ºC) was 
used to initiate dynamic cultures during this project and to determine requirements for 
successful cell expansion. Low cell viability indicated that improved control of the 
bioreactor was needed. Small scale cultures in a 250mL bioreactor were setup. Sensors were 
implemented and calibrated, a stirrer was added for distribution of nutrients to cells and data 
was logged over a prolonged period using specialised software (BioXpert Lite).  
 
High cell viabilities were obtained using U937 cells. Stable temperature (37ºC) and pH (7.4) 
were achieved throughout the cultures. Control of DO was improved by not only using air, 
but also introducing nitrogen to the culture in order to lower the DO level. 
 
The upscaling of cultures was tested by subsequently using a static culture, a MiniBioreactor 
(250mL), and a high volume Bioreactor (3L). Cell retention devices for the 3L Bioreactor 
were assessed as tools to refresh medium whilst maintaining cell retention in the bioreactor. 
Both the Spinfilter and the BioSep proved useful with the BioSep showing the most 
promising results and ease of handle. A range of porous spargers were tested to evaluate the 
means of introducing gases to the culture whilst minimising cell disturbance. A cell sample 
system was installed in the MiniBioreactor in order to analyse cell expansion and cell 
viability throughout the culture, under aseptic conditions. 
 
The MiniBioreactor proved valuable to initiate and study small scale dynamic cultures. This 
will aid as a tool to develop and improve a range of bioreactor cultures. The developmental 









The main aim of this project was to translate 2D haematopoietic and erythroid cultures to 3D 
bioreactor cultures. The upscaling of the cultures should result in a higher cell output, 
increasing the manufacture of RBCs. The 3D upscaling of cultures is widely applied in the 
literature to produce higher cell numbers than possible in a 2D environment. A range of 
bioreactors and 3D materials (e.g scaffolds) have been used to study and increase cell 
expansion [69, 75, 77, 78]. As the research into the expansion and erythroid maturation of 
HSCs occurred in parallel, the human suspension cell line ‘U937’ was used to study and 
optimise the bioreactor processes. After successful optimisation, the bioreactor would be 
used to study and manufacture the erythroid maturation of HSCs. 
 
During the early stages, adherent cells (e.g. MSCs) were used to analyse the parameters of 
the bioreactor under suboptimal conditions. During this initial phase it was established that 
all bioreactor models required pH and DO monitoring, a system for homogeneous 
distribution of cells and nutrients within the bioreactor, medium refreshment, temperature 
control, data recording, and cell sampling to allow for cell number and viability checks. As 
part of this analysis, feedback was provided to Applikon Biotechnology to provide required 
equipment, updates and advice in order to optimise 3D cell cultures and work together to 
improve culture conditions. 
 
MiniBioreactors (small scale bioreactors), with a working volume up to 200mL, were used to 
establish the minimal requirements to cultivate cells. The analysis of cell viability and cell 
numbers were the main methods to determine these culture conditions. The bioreactors with 
a maintained pH of ~7.4 showed high cell viability (>95%) up to 9 days (Figure 5.4 and 5.6) 
whereas the bioreactor without maintained pH (fluctuating between 7.2 and 8) showed a low 
cell viability of ~68% (Figure 5.9). The importance of controlled medium addition (150mL) 
over a time period of 9 days, to support increasing cell viability, resulted in a higher cell 
density when compared to addition of medium over 3 days.  





Another critical parameter was the fluctuation of DO during these and other bioreactor tests. 
As with the then current setup of the bioreactor control, only air and thus only upward DO 
control, was possible. To allow for downward DO control, an add-on was installed to allow 
for the addition of nitrogen, which should have resulted in lower controlled DO levels. It has 
been published that the human body represent low oxygen levels in the HSC niche, 
positioned in the BM, which stimulates erythropoiesis [116-118]. It was essential to 
precisely control the DO levels for creating culture conditions to stimulate HSC proliferation 
and subsequently the production of RBCs. 
 
Published data stated that it is possible to create low oxygen conditions (hypoxia) in a 
bioreactor [119] and that hypoxia increases the proportion of long-term-reconstituting HSCs 
during in vitro culture [120]. A recent review analysed the influence of hypoxia and 
hyperoxia for HSCs and the importance for the balance between quiescence, self-renewal 
and cell commitment [121]. This advocates precise DO control in a bioreactor aimed for 
HSC expansion and erythroid maturation. The implementation and optimisation of the 
addition of air and nitrogen for DO control will be discussed after ‘cell retention’ and 
‘upscaling and cell viability’ have been discussed. 
 
5.9.1 Cell retention and viability 
For cell retention two different devices were tested: an acoustic cell retention device 
(BioSep) and a spinfilter. Both the BioSep and the spinfilter were available for the 3L and 2L 
bioreactor, respectively. The aim of this project was to implement the highest performing 
device into a small scale bioreactor (working volume 200-400mL). The potential scalability 
of the device was also important. These two devices have been reviewed in depth [12-124] 
and an advantage of the acoustic cell retention device is the absence of a physical barrier and 
moving parts. Therefore, the acoustic device should be less prone to fouling , mechanical 
failure, and cell destruction [125].  





It was found that both devices were suitable for cell retention with retention rates over 90% 
and cell viability of 90%. However initial experiments with the BioSep found low cell 
viability (~70%). This improved once the DO set point was decreased to a level similar to 
that used for the spinfilter (20-30%). This then resulted in the addition of air at a later stage 
of  culture, after 96 hours instead of 24 hours, and in smaller volumes. Overall, the BioSep 
allowed for a higher cell density including improved cell retention, faster cell expansion, and 
higher cell viability rates (Figure 5.18) compared to the tested spinfilter (Figure 5.15).  
 
5.9.2. Optimisation of DO control 
The addition of air, to achieve and maintain a pre-set DO level, was applied via a sparger and 
when air was added, air bubbles entered the culture medium. The oxygenating bubbles can 
cause shear stress damage to the cells which has a negative effect on cell viability [126]. 
Cells adhere to the gas-liquid and are lifted to the surface where they may be damaged due to 
shear stress when bubbles penetrate the surface and burst 113-115, 127]. Another side effect 
of oxygenation via spargers is foam formation at the medium surface [126]. This is a high 
impact problem for small scale bioreactors (200-500mL) due to the smaller volume between 
medium surface and head plate to allow for foam formation. This volume available for foam 
production decreases with increasing medium volume (See appendix for foam production in 
bioreactor vessels).  
 
After the installed add-on allowed for the addition of nitrogen, tests showed the precise 
control of the DO level in PBS (Figure 5.22). As oxygenation in culture medium produces 
unwanted foam, nitrogen and air were supplied to the bioreactor above the medium but tests 
showed the lack of accuracy in DO control and this method was rejected. The preferred 
method for addition of nitrogen and air to the bioreactor was via a sparger. Based on reports 
by collaborators of Applikon Biotechnology it was hypothesised that smaller bubbles would 
have a positive impact on cell viability and reducing foam formation [126]. A range of 




spargers were tested and results showed that smaller air bubbles could be produced with a 
different design of porous sparger (Table 5.3). However, further analysis is needed to 
determine the effect on cell viability and, more importantly, foam production. 
 
During these tests and other bioreactor cultures, it was observed that the My-Control 
(responsible for adjusting the set DO level) added nitrogen and air with a high pulse. Also, 
the lack of a dead band for the DO level (as is used by pH control) resulted in continuous 
correction of the DO level (i.e. continuous addition of nitrogen and air) contributing to 
continuous foam production. Feedback was supplied to Applikon Biotechnology and 
suggestions have been made to eventually update the control system. The scarce addition of 
CO2 to influence and maintain pH did not seem to have a detrimental effect on cell viability 
and foam production was negligible during the maintenance of the pH level. 
 
5.9.3 Dynamic culture of UBMCs 
Analysis of UBMCs for culture in a 250mL MiniBioreactor was tested during bioreactor 
development process. UBMCs were used as insufficient UCB-CD34+ cells were available to 
initiate a 30mL culture. Cell viability did drop during the first few days of culture, as 
expected and similar to static cultures, but cell numbers did not increase again during the 
additional days. The pH was maintained between 7.4 and 7.5. The monitored DO level was 
high throughout the culture (>100%) and no air (or nitrogen) was added. A possible cause 
for the decrease in cell viability was a low start cell density as it was similar to cell densities 
used during static cultures. The 3D environment with cells mixed throughout the medium 
volume by the impeller resulted in spreading the cells farther apart compared to static 
cultures. Optimal cell signalling was therefore obstructed and this problem might be 
overcome by applying higher cell densities (105-106 cells/mL). It was observed during the 
experiments in Chapter 3 and 4 that HSC expansion benefits from closely packed cells. 
Another issue affecting cell viability could be the shear stress induced by the marine 
impeller, however tests with U937 cells did not indicate this. Further tests with increased 




UBMCs densities (~106 cells/mL) should be beneficial for cell expansion within the 
MiniBioreactor. 
 
The process of translating the static HSC expansion and erythroid maturation into a 3D 
environment for upscaling cell culture should be continued. Major improvements have been 
made with the MiniBioreactor to successfully culture cells and optimise the cell culture 
environment. Ongoing work is needed and should lead to the achievement of HSCs culture 
in these MiniBioreactors in the near future. 
 





Chapter 6  
General Discussion and Conclusions 
 
  





6.1 General discussion 
The three research objectives were  
1) to isolated PB-HSCs and optimise HSC culture conditions to allow for successful 
expansion beyond 7 days;  
2) the production of RBCs from PB and UCB-isolated cells including the 
improvement of erythroid expansion rate, and  
3) to use commercially-available bioreactors, by using cell line U937 as a model, for 
the development of an HSC culture system to expand and differentiate cells towards 
the erythroid lineage.  
In short, this research focussed on creating an in vitro environment for increased 
production of tissue engineered RBCs. 
 
Research groups have focussed on HSC expansion and the manufacture of artificial 
blood for many years. RBCs are responsible for oxygen transport throughout the 
human body and finding an alternative, cell-based, oxygen carrier could be 
tremendously beneficial for tackling shortages and improve safety in transfusion 
medicine. For this project we combined current progress made in this field to 
establish and improve the differentiation of HSCs into blood cell lineages to aim for 
clinically useful quantities. 
 
Isolation of HSCs from PB proved difficult, predominately due to insufficient cell 
numbers available, and therefore UCB-CD34+ cells were initially used as the main 
cell source for expansion studies. Data showed minimal expansion potential in long 
term cultures, but expansion cultures were maintained for a prolonged period by 
implementing an MSC-based stromal layer (e.g. BMSCs). 






Literature demonstrated the benefit of using the CD34- cell population of PBMCs for 
erythroid maturation [41] and during this project, the principle of using MNCs was 
transferred to analyse their potential for HSC expansion. PBMCs and UBMCs, as an 
easy accessible cells source, showed prolonged cell culture potential when supported 
by cytokines (i.e. SCF, Flt3-L, TPO) and a BMSC stromal layer. Despite successful 
expansion rates of CD34+ cells from UBMCs, the positive expression of CD34 did 
not exceed 35% for expanded PBMCs and UBMCs. With results showing the 
potential of using MNCs for CD34 expansion, more research is needed to compare 
the production rates of pre-CD34 cell isolation and HSC expansion with MNC 
expansion and subsequent isolation of CD34+ cells, and to further boost expansion 
of CD34+ cells within these MNC cultures. 
 
The isolated cell populations (e.g. CD34+ cells, UBMCs) were used to produce 
RBCs following a widely cited protocol [8]. Successful erythroid maturation was 
proven by cell analysis and red cell pellets, but more research is needed to confirm 
the characteristic biconcave shape and cell function with RBC properties. The 
erythroid maturation of UCB-CD34+ cells showed higher expansion potential 
compared to the differentiation of PB-CD34+ cells but an essential limitation was the 
isolation of sufficient PB-CD34+ cells from available PB.  
 
With the use of UBMCs, larger erythroid expansion rates were obtained, with cells 
showing positive for the RBC-associated markers CD235a and Hb-β [110]. However, 
analysis of maturated cells with hospital equipment, used for analysing patient’s 
blood samples, could not be completed to confirm successful production of artificial 





RBCs as higher cell quantities were required. Follow-up research should focus on 
full haematological analysis of cRBCs including Hb content, MCV, MCH, and 
enucleation and functionality tests. The expansion rates obtained for erythroid 
maturated UBMCs were lower than those published for differentiated UCB-CD34+ 
cells [42, 45, 52], but when expansion was obtained for CD34+ cells within the 
heterogeneous MNC population and the erythroid maturated cells, expansions of 
over 400-fold were recorded. This demonstrates the potential of UBMCs in erythroid 
maturation and further optimisation of culture protocols for these cells should be 
beneficial for increasing production of cRBCs. 
 
The development of a small scale bioreactor, aimed at expansion of HSCs and 
production of artificial RBCs, did not achieve these goals, but tremendous progress 
was made to optimise a dynamic culture environment. Cell retention devices were 
tested for their suitability in obtaining highly packed cell cultures within this 
bioreactor, with the aim of achieving RBC densities found in PB.  Tests with the 
BioSep, utilising U937 cells, achieved high cell densities (e.g. ~2x106 cells/mL) with 
potential for continuous increase as can be obtained from Figure 5.18. Medium 
refreshment and precise pH and temperature control was paramount in achieving 
high cell densities and high cell viability rates. Upon implementing erythroid 
maturation of HSCs within this bioreactor, a further increase of cell density needs to 
be further investigated. 
 
It was suggested that implementation of DO level control could aid in the 
achievement of hypoxia cultures, mimicking the HSC niche, for stimulation of 
erythropoiesis [116, 118]. Successful DO control was recorded, however, continuous 





over-correction of the set DO level (i.e. continuous addition of air and nitrogen) 
contributed to excessive foam production. Feedback was therefore provided to 
Applikon Biotechnology with suggestions to update the control system (e.g. 
implementation of a dead band). In addition to this, a range of 3D printed porous 
spargers were assessed for their bubble size, to decrease the detrimental impact on 
cell viability and to reduce foam production [126]. It is paramount that follow-up 
research has access to improved DO level control before further hypoxia cell cultures 
are performed. 
 
In this study, erythroid maturation has not yet been executed in the small scale 
bioreactors (250mL) but by analysing the 3D culture parameters progress to 
stimulate cell expansion has been made, while also studying the HSC expansion 
potential of MNCs and their ability to differentiate into RBCs in 2D cultures. Further 
research is required to optimise and combine these two areas for the increased 
production of artificial RBCs which could hypothetically be upscaled to larger 
volume bioreactors (2L). 
 
Bioreactors which are currently used in this field for the use of HSCs and the 
production of blood lineage cells are largely experimentally focussed [69, 72-75] but 
reviews have been published mapping the route for production of artificial RBCs [54, 
79, 128] and 3D tissue manufacturing [129-131] stating the complexity but also the 










• During successful isolation, approximately 3x104 CD34+ cells can be isolated 
from 30mL of fresh PB (equals ~4x107 MNCs) but for sustainable expansion 
cell culture, higher quantities of PB (>200mL) are needed to isolate sufficient 
numbers of HSCs. 
• The leukocyte cones used, provided insufficient PB-CD34+ cells for 
sustainable expansion cultures. 
• Cell densities used for expansion of UCB-CD34+ cells (104 cells/mL) were 
not applicable to PB-CD34+ cells, resulting in non-sustainable cultures. 
• Cell cultures of pre-thawed isolated UCB-CD34+ cells have better HSC 
expansion potential than post-thawed isolated UCB-CD34+ cells.  
• S-medium is a suitable basic medium for expansion of UCB-CD34+ cells but 
requires an optimised cytokine cocktail for HSC expansion whereas serum-
free I-medium is a suitable basic medium for expansion of UBMCs. 
• UCB-CD34+ cells in culture on a MSC stromal layer, using I-medium and a 
cytokine cocktail, demonstrated a prolonged round-like morphology for at 
least 14 days  
• PB-CD34+ cells cultured on a BMSC stromal layer demonstrated prolonged 
expansion potential but expression of CD34 decreased after 7 days of culture 
with I-medium proving more advantageous over a 21 day period when 
compared with P-medium and D-medium. 
• Expansion of HSCs within a PBMC culture was the most successful on an 
MSC stromal layer using I-medium containing cytokines, resulting in almost 
35% positive expression of CD34. 





• Expansion of HSCs within a UBMC culture was the most successful on a 
BMSC stromal layer using I-medium containing cytokines, resulting in 85-
fold expansion of CD34+ cells over 7 days. 
• The method published by Douay and Giarratana (2009) [86] proved 
successful for the manufacture of red cells from UCB isolated cells, with 
SCF, EPO, and IL-3 as suitable cytokines in erythroid maturation. 
• Erythroid maturation of UCB-CD34+ cells proved more successful when 
compared with PB-CD34+ cells in terms of cell expansion and the 
manufacture of red cells. 
• UCB isolated cells in erythroid maturation showed a decrease in cell 
diameter, production of a red cell pellet, indication of enucleation, and 
presence of intracellular Hb-β. 
• Erythroid maturation of UBMCs proved useful for the manufacture of RBCs, 
resulting in positive expression of RBC associated markers (e.g. CD235a and 
Hb-β), and a red cell pellet. 
• Erythroid maturation of UBMCs requires further optimisation for creating a 
larger number of RBCs 
• HSC expansion of UBMCs prior to erythroid maturation, in order to increase 
the number of CD34+ cells within the MNC population, was not 
advantageous for the production of RBCs when compared to directly-
maturated UBMCs. 
• DO, pH and temperature sensors are required to monitor the cell environment 
and link obtained data to cell viability with maintenance of pH and 
temperature levels resulting in an improved cell viability and cell expansion 
rate. 





• Active DO control can be obtained by using air and nitrogen but further 
research is needed to obtain stable DO levels in culture medium whilst 
avoiding excessive foam formation. 
• Porous spargers are useful tools for obtaining smaller sized bubbles which 
should result in minimised detrimental effects on cell viability. From the 
examples tested, bubbles produced by the 3D printed 300µm UC spargers 
were the smallest in size. 
• The BioSep is advantageous for cell retention when compared to a Spinfilter  
• Precise management of medium volume expansion relating to optimal cell 
density and medium refreshment is needed to optimise cell expansion rates 
further. 
• The MiniBioreactor is a useful tool to initiate small scale, dynamic, cultures. 
• Dynamic expansion of UBMCs, and subsequent erythroid maturation, in a 
small scale bioreactor requires further optimisation in order to produce the 
required large cell quantities. 
 
 
6.3 Suggestions for future work 
HSC expansion for a prolonged period was only achieved with UBMCs but high 
CD34+ expression was not achieved. Future research should focus on altering the 
cytokine cocktail, introducing hypoxia, and further optimisation of the culture 
medium to increase the output of HSCs [94, 118], [Tsiftsoglou et al, 2009]. These 
cells could then be evaluated for progenitor- and stem-cell frequencies within the 
haematopoietic spectrum by using a cobblestone area-forming cell (CAFC) assay 
assessing the quality of the optimised expansion method of UBMCs and PBMCs to 





demonstrate their proliferative and differentiation capacities for blood cell lineages 
[132]. One of the main challenges remains to establish continuous self-renewal of 
HSCs whilst also being directed towards erythroid maturation.  
 
Ongoing efforts should focus on the culture environment to enhance the production 
of RBCs in suspension, including feeder-free enhancement of enucleation rates. 
Recently, data has been published by Baek et al (2010) demonstrating positively 
charged culture plates to achieve efficient RBC production [133], rather than 
introducing the widely used stromal layer. This research contributes to establishing 
methods for the clinical manufacturing of RBCs whilst omitting the use of co-culture 
but attempting to mimic the stem cell niche. 
 
Ultimately, large-scale automated production of RBCs in vitro will be paramount and 
bioreactors are essential tools for this process. Achieving high cell densities (>108 
cells/mL) and expansion rates (107) have been reported [134]. Future studies should 
continue to boost these figures by focussing on creating the culture conditions that 
can be found in the stem cell niche. Also, current systems are merely focussed on 
either HSC expansion, or production of RBCs. A combined system, incorporating 
both cultures, should assist in creating a higher cell output than has currently been 
established. 
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Chapter 1 - Introduction 
   
F 1.1 Overview of artificial oxygen carriers (Li et al 2011) 
 
p.10 
F 1.2 A schematic overview of erythropoiesis (Hattangadi et al 2011) – 
Distinctive cell types in each step of erythropoiesis with corresponding 
growth factors and cell division rate in one differentiation method 
 
p.14 
T 1.1 The characteristics of cultured RBCs compared to RBCs isolated from PB. 
The characteristics of the cultured RBCs can be found in a similar range 
except for the content of the various Hb’s which is highly variable. Not all 
studies report on the blood type but a few state similar blood types as the 
donor. Important to note is that the cRBCs used in the human clinical trial 






Chapter 2 – Materials and Methods 
   
F 2.1 UI of the My-Control unit (Screen print of the control system) 
 
p.43 
F 2.2 BioXpert Lite interface for monitoring the pH, temperature (Temp), DO, 
and the stirrer speed of the bioreactor (Screen print of the interface) 
 
p.45 
F 2.3 Flow-Cytographs with the negative control (Isotype) and the antibody 
specific marker (Antigen) shown above and the subtraction (below) 
 
p.47 
T 2.1 FACS antibodies used in flow cytometric analysis 
 
p.48 
T 2.2 Primer details qRT-PCR 
 
p.49 







Chapter 3 – Results: Haematopoietic cell culture 
   
F 3.1 Magnetic Cell Separating Technique (Miltenyi Biotech) 
 
p.55 
F 3.2 Suspension Cell Culture vs. Adherent Cell Culture - The suspension culture 
with UCB isolated cells have a round morphology (left) whereas the MSCs 
in the adherent culture have a stretched, elongated morphology (right) 
 
p.57 
F 3.3 The CD34+ purity of this cell population is 82.6% which can be derived 
from the graph on the right (top). The expression of CD45 is 47.1%, 
indicating a minimum of 35.5% of the cells are HPCs 
P5.8 
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F 3.4 Isolated cell number per donated mL of blood from donors younger and 
older than 30 years. Donors aged younger than 30 years have a slightly 
higher number of CD34+ cells/mL of blood 
 
p.59 
F 3.5 Leukocyte cone with a capacity for 10mL Buffy Coat 
 
p.60 
F 3.6 In two experiments the CD34 expression after 2 days (left) and 14 days 
(right) of CD34+ isolated PBMCs from Leukocyte Cones. In the first 
experiment we harvested 1.8x104 cells after two days (88.4% CD34+). In 
the second culture we harvested 1.9x104 cells after 14 days (1.5% CD34+) 
 
p.61 
F 3.7 After 10 days of Haematopoietic Progenitor Expansion of CD34+ cells 
isolated from UCB the cells maintained their primitive phenotype with a 
positive expression of CD34 (93.2%) and also  highly positive for the 
leukocyte marker CD44 (90.9%) while negative for the oxygen carrying 
molecule Hb-β (0.5%) 
 
p.62 
F 3.8 After 9 days of culture the CD34+ expression dropped from 93.2% to below 
6% for all conditions except for  cells cultured in HSC expansion  medium 
(S-medium w/ SCF/IL-3): 24.4% 
 
p.63 
T 3.1 The cell number and cell viability decreased for cultures without cytokines. 
The cell number increased dramatically for the condition with the better 
optimised HPC expansion medium (S-medium + SCF/IL-3). Cell viability 
remained high (>95%) for culture conditioned which contain SCF and IL-3 
 
p.64 
F 3.9 CD34 expression of cells isolated from UBMCs using MACS®. The 
number of CD34+ cells was ~1500 out of a total isolated 4.2x104 (~3.6%) 
 
p.64 
F 3.10 The CD34 expression of CD34 isolated UBMCs decreases  over time 
 
p.65 
F 3.11 UCB-CD34+ cells cultured in I-medium on adipose isolated MSCs showed 
a round like morphology on the elongated stromal cells at day 7. Few cells 
were close to each other whereas other cells were more spread out on the 
stromal layer. On day 14 the cell density had increased compared to day 7. 
The cells had a round like morphology with a few cells now slightly bigger 




F 3.12 UCB-CD34+ cells cultured in I-medium on BM isolated MSCs showed a 
variation in morphologies and different sizes at day 7. Only a minority of 
the cells had a round-like morphology comparable to the healthy CD34+ 
cells from Figure 3.2. On day 14 the majority of the cells had a round-like 
morphology and an increased cell density can be observed 
 
p.68 
F 3.13 UCB-CD34+ cells cultured in I-medium without a stromal cell layer at day 
7 did not have a round like morphology for the majority of the cell 
p.69 
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population and a lot of cell debris could be found in the culture. At day 14 
the number of viable cells has decreased to below 20% and a lot of cell 
debris could be observed, similar to day 7 
 
F 3.14 Morphology of UCB-CD34+ cells in I-medium – This overview shows the 
various stromal cells and the influence on CD34+ cell morphology. After 14 
days, the cells on the supportive cell layer show a morphology similar to 
the UCB isolated suspension cells in Figure 3.2 
 
p.70 
F 3.15 The expression of the HSC phenotype marker CD34 on cells cultured with 
and without a supportive MSC stromal cell layer. Due to unexpected 
premature termination of cultures without a stromal layer and with a BMSC 
stromal layer no results could be obtained for the last data point 
 
p.71 
F 3.16 The CD34+ expression of cultured PB-CD34+ cells drops over a 21 day 
culture period. No data for I-medium on day 14 due to insufficient cell 
numbers for analysis. No data for I-medium and D-medium on day 28 due 
to unexpected premature termination of the cultures 
 
p.72 
F 3.17 Morphology of PB-CD34+ cells on a BMSC stromal layer 
 
p.73 
F 3.18 List of genes in CD34+ UCB cell-derived MNCs, which are upregulated. 
GAPDH is the housekeeping gene 
 
p.74 
T 3.2 Preliminary gene expression profile of haematopoiesis genes which are 




F 3.19 Two typical flow cytometry graphs of positive CD34 expression in PBMCs 
cultured on a BMSC stroma for 21 days (left) and without a stroma cell 
layer for 14 days (right) 
 
p.76 
F 3.20 Two typical flow cytometry graphs of negative CD34 expression in PBMCs 
cultured on an AMSC stroma for 14 days (left) and without a stroma cell 
layer for 21 days (right) 
 
p.77 
F 3.21 A complete profile overview. The results showed that PBMCs cultured 
either in I-medium or on a BMSC stromal layer contained the highest 
percentage of CD34+ cells. (I=I-Medium, P=P-Medium, D=D-Medium; 
medium contains 50ng/mL SCF/TPO/Flt3-L) 
 
p.78 
F 3.22 Percentage of CD34+ cells within their native PBMC population, cultured 




F 3.23 Percentage of CD34+ cells within their native PBMC population, cultured 
in P-Medium with SCF/Flt3-L/TPO over 21 days 
 
p.79 
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F 3.24 Percentage of CD34+ cells within their native PBMC population, cultured 
in D-Medium with SCF/Flt3-L/TPO over 21 days 
 
p.79 
F 3.25 An overview of the cell numbers for UBMCs in HSC expansion. [w/ 
stroma w/o c.k. = with a BMSC stromal layer/without cytokines] - [w/o 
stroma w/ c.k = without a stromal cell layer/with cytokines (SCF/TPO/Flt3-
L)] - [w/o stroma w/o c.k. = without a stromal cell layer/without cytokines] 
 
p.81 
F 3.26 The relative positive expression of CD34 within each culture condition for 
up to 28 days.  [w/ stroma w/o c.k. = with a BMSC stromal layer/without 
cytokines] - [w/o stroma w/ c.k = without a stromal cell layer/with 
cytokines (SCF/TPO/Flt3-L)] - [w/o stroma w/o c.k. = without a stromal 
cell layer/without cytokines] 
 
p.82 
F 3.27 The absolute number of cells expressing the CD34 marker over a 28 day 
culture period. [w/ stroma w/o c.k. = with a BMSC stromal  layer/without 
cytokines]- [w/o stroma w/ c.k = without a stromal cell layer/with cytokines 
(SCF/TPO/Flt3-L)] - [w/o stroma w/o c.k. = without a stromal cell 
layer/without cytokines] - [(CD34) = Cells expression the CD34 marker] 
 
p.83 
F 3.28 The relative positive expression of CD45 within each culture condition for 
up to 28 days. [w/ stroma w/o c.k. = with a BMSC stromal  layer/without 




F 3.29 The absolute number of cells expressing the CD45 marker in direct 
comparison with the total cell number in the culture. [w/ stroma w/o c.k. = 
with a BMSC stromal layer/without cytokines] - [w/o stroma w/ c.k = 
without a stromal cell layer/with cytokines (SCF/TPO/Flt3-L)] - [(CD45) = 
Number of CD45 positive cells in the culture] - [(Total) = Total number of 
cells in the culture] 
 
p.84 
F 3.30 An overview of UBMCs cultured without a stromal layer and without 




F 3.31 An overview of UBMCs cultured on a BMSC stromal layer - Day 1 and 3, 
Day 7 and 10, Day 15 and 28, Day 28 and 28 (left to right, top to bottom) 
 
p.87 
F 3.32 An overview of UBMCs cultured without a stroma and with cytokines - 





F 3.33 The relative positive expression of CD34 within each culture condition. 
The culture medium contained the cytokines SCF/TPO/Flt3-L. The 
UBMCs were cultured either with or without a BMSC stromal layer 
[w/ stroma w/ c.k = [with a BMSC stromal layer/with cytokines 
p.90 
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(SCF/TPO/Flt3-L)] - [w/o stroma w/ c.k = [without a stromal cell 
layer/with cytokines (SCF/TPO/Flt3-L)] 
 
T 3.3 The absolute number of total cells and CD34+ cells from the UBMCs 
culture for HSC expansion 
 
p.90 
F 3.34 Expansion of CD34+ cells within a population of UBMCs. For condition 
‘A’ the percentage of CD34+ cells rose from ~3% (day 0) to ~30%, for ‘B’ 






Chapter 4 – Results: Manufacture of Red Blood Cells 
   
F 4.1 Morphology on day 9 of erythroid maturation; a co-culture of HSCs and 
BMSCs in EPO containing D-medium 
 
p.104
F 4.2 After 10 days of erythroid maturation, day 2 of phase II, the cell population 




F 4.3 Morphology of UCB-CD34+ cells on a stromal cell layer after 12 days of 
erythroid maturation: overview (A) and higher magnification (B) 
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F 4.4 Morphology of UCB-CD34+ cells on a stromal cell layer after 20 days of 
erythroid maturation: overview (A) and higher magnification (B) 
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F 4.5 Cells stained with BCB after 24 days of erythroid maturation 
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F 4.6 Flow Cytometry graphs (A) and accompanying overview (B) of cell 
markers important in the erythroid maturation of HSCs 
 
p.112
F 4.7 Overview of viable cell numbers during initial expansion of UBMCs; day -
7 – 0 (A-C) and during erythroid maturation; day 0 – 24 (A-D). The bars 
represent data from condition D, the lines represent data from the 
conditions undergoing expansion and subsequent maturation (A-C) (n=3, 
error bars represent StDev) 
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F 4.8 Cells stained with BCB at day 9 of direct EM (Condition D) 
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F 4.9 Cells stained with Methylene Blue at day 16 of direct EM (Condition D) 
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F 4.10 UBMCs were cultured for 7 days in HSC expansion medium prior to 
erythroid maturation under different conditions: (A) = ‘with stroma/with 
cytokines’; (B) = ‘without stroma/with cytokines’; (C) = ‘with 
stroma/without cytokines’. (D) = UBMCs which have not been cultured in 
HSC expansion medium prior to erythroid maturation. The red bar 
p.119
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represents the marker profile of UBMCs after isolation whereas the other 
bars represent the conditions A-C at the day 15 (above) and day 24 (under) 
of the differentiation period. The green bar represents the marker profile for 
condition D. The horizontal axis shows the haematopoietic and erythroid 
markers (n=1 due to limited cell numbers after isolation) 
 
F 4.11 HSC expansion of UBMCs over 7 days to increase the number of CD34+ 
cells before the start of erythroid maturation (day 0). The horizontal axis 
shows the various culture conditions and the number in parentheses states 
the total cell number at day 0. All cultures started with 3x105 UBMCs at 
day -7 (n=3, error bars represent StDev) 
 
p.120
F 4.12 Morphology of cells on day 0, prior to erythroid maturation (D) and after 
the HSC expansion treatment (A, B, C) 
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F 4.13 The marker profile of cultures (A-D) after 21 days of erythroid maturation.  
UBMCs were cultured for 7 days in HSC expansion conditions, (A) = ‘with 
stroma/with cytokines’; (B) = ‘without stroma/ with cytokines’; (C) = ‘with 
stroma/ without cytokines’, prior to erythroid maturation. (D) = UBMCs 
which have not been cultured in HSC expansion medium prior to erythroid 
maturation. The red bar represents the marker profile of UBMCs after 
isolation whereas the other bars represent the conditions A-C at the end of 
the differentiation period. The green bar represents the marker profile for 
condition D at day 21. The horizontal axis shows the haematopoietic and 
erythroid markers (n=3, error bars represent StDev) 
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F 4.14 The fluctuation in cell number during 21 days of erythroid maturation. (A) 
= ‘with stroma/with cytokines’; (B) = ‘without stroma/with cytokines’; (C) 
= ‘with stroma/without cytokines’; (D) = ‘without pre-treatment’ (n=3, 
error bars represent StDev) 
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F 4.15 The cell pellets of each culture condition after approximately 2 weeks (top) 
and 3 weeks (bottom). (A) = ‘with stroma/with cytokines’; (B) = ‘without 




F 4.16 Development of cell numbers during 23 days of erythroid maturation 
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F 4.17 Relative cell numbers during 23 days of erythroid maturation 
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F 4.19 Collection of erythroid maturation cell marker profiles. Cells in 
differentiation cultures for approximately 3 weeks showed lower expression 
of CD36 and CD71 compared to cells in differentiation for 2 weeks. 
Black/grey bars show data collected at day 0. Blue bars show data 
collected after 2 weeks and brown bars show data collected after 3 weeks. 
p.129
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Data is a collection of data as shown in Figures 4.10 and 4.13. 
   
Chapter 5 – Results: Development of the bioreactor 
   
F 5.1 A schematic overview of a fed-batch bioreactor 
 
p.137
F 5.2 A schematic overview of a bioreactor with a perfusion system 
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F 5.3 Setup 2L bioreactor and BioSep 
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F 5.4 Continued testing of initial bioreactor cultures (including BioSep) 
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F 5.5 Calibration of DO sensor at maximum air influx; set point at 100% 
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F 5.6 Parameters recorded during a dynamic culture using a MiniBioreactor 
(250mL) and U937 cells. Stirrer speed was set at 75rpm, pH was set at 7.4, 
and DO was set at 50% 
 
p.142




F 5.7 The sensor registration profile (pH/DO/Temp) of the monitored 
MiniBioreactor (250mL) containing U937 cells over a 9 day culture period. 
Stirrer speed was set at 75rpm 
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F 5.8 The sensor registration profile (pH/DO/Temp) of the controlled 
MiniBioreactor (250mL) containing U937 cells over a 9 day culture period. 
Stirrer speed was set at 75rpm 
 
p.145
F 5.9 Box plot of the pH and DO values for the monitored (M1) and the 
controlled (C1) bioreactor shows the distribution of values over 9 days. 
Each box plot is divided in 4 quarters, each containing 25% of the recorded 
values with the mean as the value between Quarter 2 (black bar) and 
Quarter 3 (red bar) 
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F 5.10 An overview of bioreactors. A) Harvested cell suspension from the 
MiniBioreactor (B) next to fresh medium without any U937 cells. C) 3L 
bioreactor with a stirrer and BioSep (10L), thermo blanket open. D) My-
Control Unit and Bioreactor with pumps and medium/waste vessels 
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F 5.11 The sensor registration profile (pH/DO/Temp) of the controlled 
MiniBioreactor (250mL) containing U937 cells over a 4 day culture period 
(part 1). Stirrer speed was set at 100rpm, DO was set at 50%, and pH was 
set at 7.4 
 
p.148
F 5.12 The sensor registration profile (pH/DO/Temp) of the controlled Bioreactor 
(3L) containing U937 cells over another 4 day culture period (part 2). 
p.149
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Stirrer speed was set at 100rpm, DO was set at 50%, and pH was set at 7.4 
 




F 5.14 Sensor registration profile (pH/DO/Temp) of the controlled Bioreactor (2L) 
with a spin filter containing U937 cells over a 6 day culture period. Stirrer 
speed was set at 100rpm, DO was set at 40% (0-120 hours) and 30% (after 
120 hours), and pH was set at 7.4 
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T 5.2 Cell analysis of vessels used for the bioreactor with spinfilter 
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F 5.15 A) Cell viability graph for the Bioreactor with Spinfilter, and associated 




F 5.16 Setup of a closed system with the MiniBioreactor in progress (right) and 
connected Bioreactor (3L) with BioSep (left) for the last stage of culture 
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F 5.17 The sensor registration profile (pH/DO/Temp) of the MiniBioreactor (A) 
and the 3L Bioreactor with BioSep (B) filter containing U937 cells over 
respectively a ~2 day and 6 day culture period. Stirrer speed was set at 
75rpm, DO was set at 20%, and pH was set at 7.4 
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F 5.18 A) Cell viability graph for the 3L Bioreactor with BioSep, and associated 
Medium Waste Vessel at the end of culture. B) Cell density graph over 8 




F 5.19 Manual cell sampling system for the MiniBioreactor in an aseptic 
environment with the ‘low’ (I) and ‘high’ (II) cell sample height marked 
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F 5.20 A) Cell number and viability data as acquired by the Cell Sampling system 
in the MiniBioreactor. B) Comparison of cell numbers acquired via the 




F 5.21 The sensor registration profile (pH/DO/Temp) of the MiniBioreactor with a 
manual cell sampling system containing U937 cells over a 24hour period. 
Stirrer speed was set at 75rpm, while DO and pH were not controlled 
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F 5.22 Improved control of DO levels within PBS by addition of air and nitrogen 
into the MiniBioreactor. The setpoints were changed during testing and 
were respectively 5%, 2%, 5%, 20%, 50%, 5%, 10%, 20% and 10% 
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F 5.23 Control of dO2 levels above the medium by addition of the inert N2 and air 
into the MiniBioreactor. The setpoints have been changed during culture 
and are respectively 50% and 20% 
p.161
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F 5.24 The standard sparger produced large size bubbles (top) whereas the 
Applikon Porous Sparger produced smaller sized bubbles (bottom) 
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F 5.25 Experimental porous spargers with a 1mm Wall and with various pore 
sizes: 200µm, 300µm 400µm, 500µm (from top to bottom) 
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F 5.26 Experimental porous spargers with a 1.5mm Wall and with various pore 
sizes: 200µm, 300µm 400µm, 500µm (from top to bottom) 
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F 5.27 Experimental porous spargers with a 2mm Wall and with various pore 
sizes: 200µm, 300µm 400µm, 500µm (from top to bottom) 
 
p.165
T 5.3 Sparger analysis of bubbles output for the minibioreactor (250mL) at an air 
flowrate of 5mL/min 
 
p.166









Appendix 3 – RBC analysis with SEM 
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Appendix 3 – RBC analysis with SEM 
 
RBC analysis with SEM 
Native RBCs were processed and analysed for SEM as a method to visualise cell shape. It 
was hypothesised that native RBCs would show their characteristic biconcave shape. These 
data could then be compared to SEM images of cRBCs. Due to limited cell numbers no SEM 
data were collected for cRBCs. From Figures A3.1-4 it can be observed that the native RBCs 
show their characteristic morphology after being analysed with SEM and that this technique 





















Fig. A3.1. Overview image of PB isolated cells. RBCs are highlighted by red arrows. 
Scale bar represents 30µm 































Fig. A3.2. PB isolated RBCs are highlighted by red arrows and these cells show their 
distinctive biconcave shape. Scale bar represents 10µm 
 
Fig. A3.3. PB isolated RBC is highlighted by a red arrow and this cell has a diameter of 
~5.6µm. Scale bar represents 10µm 





























Fig. A3.4. PB isolated RBCs are highlighted by red arrows and these cells show their 
distinctive biconcave shape. Scale bar represents 10µm 
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Stromal MSC cell surface marker profile 
MSCs were either isolated from BM or adipose, as described in section 2.2.3 and 2.2.4 
respectively. Subsequently, these cells were analysed for a set of cell surface markers to 
establish their phenotype as MSCs, as described by (Dominici et al. 2006). All isolated 
MSCs did adhere to tissue culture treated plastic in standard culture conditions, but in vitro 
differentiation capacities for osteogenic, adipogenic, and chondrogenic behaviour were not 
analysed. The phenotype of these cells was established utilising the cell surface makers 
CD105, CD73, CD90, and CD29 (positive) and CD45 and CD34 (negative). Representative 
phenotypes of AMSCs and BMSCs can be found in Figures A4.1 and Figure A4.2. After 
successful confirmation of the cell properties, BMSCs and AMSCs were used as stromal 

















Fig. A4.1. Representative phenotype of AMSCs used for haematopoietic and erythroid cell cultures 
CD90 – 95.1% CD105 – 92.3% CD29 – 99.8%















Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, 
Keating A, Prockop D, and Horwitz E. 2006, Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular 





Fig. A4.2. Representative phenotype of BMSCs used for haematopoietic and erythroid cell cultures 
CD90 – 98.7% CD105 – 99.7% CD29 – 99.9% 
CD73 – 99.9% CD34 – 1.7% CD45 – 1.4% 
